: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription

Articles published in J Thorac Oncol
Retrieve available abstracts of 967 articles:
HTML format

Single Articles

August 2021

AREDO JV, Wakelee HA, Han SS
A Moving Target: Integration of Smoking Cessation Into Screening for Second Primary Lung Cancer.
J Thorac Oncol. 2021;16:e59-e60.
PubMed

PELOSI G, Pasini F
Over-Time Risk of Lung Cancer Is Largely Owing to Continuing Smoking Exposition: A Good Reason to Quit.
J Thorac Oncol. 2021;16:e57-e59.
PubMed

SINGH N, Agrawal S, Jiwnani S, Khosla D, et al
Lung Cancer in India.
J Thorac Oncol. 2021;16:1250-1266.
PubMed

July 2021

DZIADZIUSZKO R, Mok T, Peters S, Han JY, et al
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic Non-Small Cell Lung Cancer: Initial Results of the Phase 2 ALK-Positive Cohort.
J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02321.
PubMed Abstract available

PATEL SA, Herynk MH, Cascone T, Saigal B, et al
Estrogen promotes resistance to bevacizumab in murine models of non-small cell lung cancer.
J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02320.
PubMed Abstract available

SOCINSKI MA, Nishio M, Jotte RM, Cappuzzo F, et al
IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.
J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02322.
PubMed Abstract available

SMELTZER MP, Lee YS, Faris NR, Fehnel C, et al
Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected Non-small Cell Lung Cancer (NSCLC) in a High Mortality Area of the United States.
J Thorac Oncol. 2021 Jul 16. pii: S1556-0864(21)02299.
PubMed Abstract available

STEWART CA, Gay CM, Ramkumar K, Cargill KR, et al
Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.
J Thorac Oncol. 2021 Jul 15. pii: S1556-0864(21)02294.
PubMed Abstract available

JASSEM J, de Marinis F, Giaccone G, Vergnenegre A, et al
Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer.
J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02286.
PubMed Abstract available

AI X, Wang Q, Cheng Y, Liu X, et al
Safety but Limited Efficacy of Ensartinib in ROS1-Positive Non-small Cell Lung Cancer: A Single-arm, Multicenter Phase II study.
J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02290.
PubMed Abstract available

POWELL SF, Rodriguez-Abreu D, Langer CJ, Tafreshi A, et al
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407.
J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02287.
PubMed Abstract available

MYERS R, Brauer M, Dummer T, Atkar-Khattra S, et al
High Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers with Lung Cancer.
J Thorac Oncol. 2021 Jul 10. pii: S1556-0864(21)02256.
PubMed Abstract available

WANG Y, Li J, Chang S, Dong Y, et al
Risk and influencing factors for subsequent primary lung cancer after treatment of breast cancer: a systematic review and two meta-analyses based on four million cases.
J Thorac Oncol. 2021 Jul 10. pii: S1556-0864(21)02293.
PubMed Abstract available

ROLFO C, Mack P, Scagliotti GV, Aggarwal C, et al
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC).
J Thorac Oncol. 2021 Jul 8. pii: S1556-0864(21)02284.
PubMed

HANN CL, Burns TF, Dowlati A, Morgensztern D, et al
Brief Report: A Phase 1 Study Evaluating Rovalpituzumab Tesirine (Rova-T) in Frontline Treatment of Patients With Extensive-Stage Small Cell Lung Cancer.
J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02289.
PubMed Abstract available

PARK HR, Kim TM, Lee Y, Kim S, et al
Acquired resistance to third-generation EGFR tyrosine kinase inhibitors in patients with de novo EGFR(T790M)-mutant non-small cell lung cancer.
J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02254.
PubMed Abstract available

KUMAR A, Kumar S, Gilja S, Potter A, et al
Reconsidering the American Joint Committee on Cancer 8(th) Edition TNM Staging Manual Classifications for T2b/T3 Non-small-cell Lung Cancer.
J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02283.
PubMed Abstract available

MOUNTZIOS G, Gkiozos I, Stratakos G, Pissakas G, et al
Lung Cancer in Greece.
J Thorac Oncol. 2021;16:1058-1066.
PubMed

June 2021

AKAMATSU H, Murakami H, Harada H, Shimizu J, et al
Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced non-small cell lung cancer with EGFR mutation; West Japan Oncology Group 6911L.
J Thorac Oncol. 2021 Jun 8. pii: S1556-0864(21)02190.
PubMed Abstract available

SU CC, Wu JT, Neal JW, Popat RA, et al
Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis.
J Thorac Oncol. 2021 Jun 3. pii: S1556-0864(21)02181.
PubMed Abstract available

ANG YLE, Chia PL, Chua KLM, Devanand A, et al
Lung Cancer in Singapore.
J Thorac Oncol. 2021;16:906-911.
PubMed

RAMI-PORTA R, Goldstraw P, Asamura H
Commemorating the Silver Anniversary of the International Association for the Study of Lung Cancer International Workshop on Intrathoracic Staging.
J Thorac Oncol. 2021;16:902-905.
PubMed

GRASS GD, Scott JG, Sedor G, Kattan MW, et al
Response to: Noncancer Cells in Tumor Samples May Bias the Predictive Genomically Adjusted Radiation Dose.
J Thorac Oncol. 2021;16:e48-e49.
PubMed

DU Y, Hu Z, Liang J, Zhan C, et al
Noncancer Cells in Tumor Samples May Bias the Predictive Genomic-Adjusted Radiation Dose.
J Thorac Oncol. 2021;16:e47.
PubMed

RYAN BM
In Response: Using Propensity Score Matching to Balance the Baseline Characteristics.
J Thorac Oncol. 2021;16:e46.
PubMed

LIANG J, Hu Z, Zhan C, Wang Q, et al
Using Propensity Score Matching to Balance the Baseline Characteristics.
J Thorac Oncol. 2021;16:e45-e46.
PubMed

BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
Why Did the Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC Not Reveal a Difference?
J Thorac Oncol. 2021;16:e42-e45.
PubMed

BREEN WG, Brown PD, Laack NN
Hippocampal Avoidance Prophylactic Cranial Irradiation for SCLC.
J Thorac Oncol. 2021;16:e41-e42.
PubMed

DEUTSCH E, Cengel KA, Galluzzi L, Levy A, et al
Could Protons Promote Tumor Control by Avoiding Lymphopenia?
J Thorac Oncol. 2021;16:e39-e41.
PubMed

BAUMAN J, Borghaei H
To Give or Not to Give: Consolidative Durvalumab in EGFR-Mutant NSCLC.
J Thorac Oncol. 2021;16:894-896.
PubMed

WARREN GW, Evans WK, Dresler C
Critical Determinants of Cancer Treatment Outcomes: Smoking Must Be Addressed at the Highest Levels in Cancer Care.
J Thorac Oncol. 2021;16:891-893.
PubMed

CAMIDGE DR, Otterson GA, Clark JW, Ignatius Ou SH, et al
Crizotinib in Patients With MET-Amplified NSCLC.
J Thorac Oncol. 2021;16:1017-1029.
PubMed Abstract available

FINN SP, Addeo A, Dafni U, Thunnissen E, et al
Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.
J Thorac Oncol. 2021;16:990-1002.
PubMed Abstract available

STEUER CE, Jegede OA, Dahlberg SE, Wakelee HA, et al
Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial.
J Thorac Oncol. 2021;16:960-967.
PubMed Abstract available

May 2021

JAZIEH AR, Onal HC, Weng Tan DS, Soo RA, et al
Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: Results of KINDLE, a multi-country observational study.
J Thorac Oncol. 2021 May 26. pii: S1556-0864(21)02174.
PubMed Abstract available

ZHOU C, Wu L, Fan Y, Wang Z, et al
Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12).
J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02128.
PubMed Abstract available

HERBST RS, Garon EB, Kim DW, Cho BC, et al
5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer.
J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02172.
PubMed Abstract available

JOHNSON AM, Boland JM, Wrobel J, Klezcko EK, et al
Cancer cell-specific MHCII expression as a determinant of the immune infiltrate organization and function in the non-small cell lung cancer tumor microenvironment.
J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02175.
PubMed Abstract available

BARBI J, Patnaik SK, Pabla S, Zollo R, et al
Visceral Obesity Promotes Lung Cancer Progression-Toward Resolution of the Obesity Paradox in Lung Cancer.
J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02171.
PubMed Abstract available

LU S, Wang J, Yu Y, Yu X, et al
Tislelizumab Plus Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (RATIONALE 304): A Randomized Phase 3 Trial.
J Thorac Oncol. 2021 May 22. pii: S1556-0864(21)02176.
PubMed Abstract available

ZHAO H, Yao W, Min X, Gu K, et al
Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706).
J Thorac Oncol. 2021 May 22. pii: S1556-0864(21)02177.
PubMed Abstract available

LOIOLA DE ALENCAR VT, Camandaroba MPG, Pirolli R, Fogassa CAZ, et al
Immunotherapy as Single Treatment for Non-small-cell Lung Cancer Patients with Brain Metastases: a systematic review and meta-analysis - the META-L-BRAIN study.
J Thorac Oncol. 2021 May 5. pii: S1556-0864(21)02131.
PubMed Abstract available

OSAROGIAGBON RU, Ray MA, Faris NR, Smeltzer MP, et al
Response to: "Lymph Node Dissection for Non-Small-Cell Lung Cancer at Whose Discretion?"
J Thorac Oncol. 2021;16:e36-e37.
PubMed

PIRKER R, Prosch H, Popper H, Klepetko W, et al
Lung Cancer in Austria.
J Thorac Oncol. 2021;16:725-733.
PubMed

KIM CG, Cho BC, Lim SM
Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?
J Thorac Oncol. 2021;16:709-711.
PubMed

LI M, Zhan C, Wang Q
Is the Story of M Descriptors Fulfilled or Finished?
J Thorac Oncol. 2021;16:e36-e37.
PubMed

METOVIC J, Bianchi F, Barella M, Papotti M, et al
SMARCA2 Deficiency While Preserving SMARCA4 and SMARCB1 in Lung Neuroendocrine Carcinomas.
J Thorac Oncol. 2021;16:e32-e35.
PubMed

DE CARLO E, Schiappacassi M, Del Conte A, Stanzione B, et al
Combination of Chemotherapy and ALK Inhibitors in ALK-Positive NSCLC.
J Thorac Oncol. 2021;16:e31-e32.
PubMed

NISHIO M, Mendus D, Wang L, Socinski MA, et al
Response to Letter to the Editor.
J Thorac Oncol. 2021;16:e30-e31.
PubMed

DI FEDERICO A, Nuvola G, Deiana C, Donati G, et al
IMpower 132: Is the Second Exception to the Rule No Longer an Exception?
J Thorac Oncol. 2021;16:e29-e30.
PubMed

SEDOR G, Scott JG, Kattan MW, Torres-Roca JF, et al
Letter Response.
J Thorac Oncol. 2021;16:e28-e29.
PubMed

MISTRY HB
Simulating RTOG 0617 using Genomic Adjusted Radiation Dose: Comparing Apples With Oranges.
J Thorac Oncol. 2021;16:e27.
PubMed

RIMNER A, Wu AJ, Grills IS
What Is the Impact of Hippocampus Avoidance-Prophylactic Cranial Irradiation on Neurocognitive Preservation?
J Thorac Oncol. 2021;16:722-724.
PubMed

WESTEEL V
Surveillance After Curative-Intent Treatment for NSCLC: More to It Than Meets the Eye.
J Thorac Oncol. 2021;16:719-721.
PubMed

JULOORI A, Vokes EE
Beyond PACIFIC: Uncharted Waters.
J Thorac Oncol. 2021;16:715-718.
PubMed

LIU SY, Wu YL
Unmet Clinical Demand for Patients With Unresectable Stage III NSCLC Having Actionable Genetic Alterations.
J Thorac Oncol. 2021;16:712-714.
PubMed

ADJEI AA, Ignatius Ou SH, Ho C, Pujol JL, et al
Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships.
J Thorac Oncol. 2021;16:706-708.
PubMed

MATSUI S, Le-Rademacher J, Mandrekar SJ
Statistical Models in Clinical Studies.
J Thorac Oncol. 2021;16:734-739.
PubMed Abstract available

STIRLING RG, Chau C, Shareh A, Zalcberg J, et al
Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis.
J Thorac Oncol. 2021;16:784-797.
PubMed Abstract available

BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675).
J Thorac Oncol. 2021;16:840-849.
PubMed Abstract available

HELLYER JA, Aredo JV, Das M, Ramchandran K, et al
Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.
J Thorac Oncol. 2021;16:868-872.
PubMed Abstract available

FAIVRE-FINN C, Vicente D, Kurata T, Planchard D, et al
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
J Thorac Oncol. 2021;16:860-867.
PubMed Abstract available

NAGASAKA M, Zhu VW, Lim SM, Greco M, et al
Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.
J Thorac Oncol. 2021;16:740-763.
PubMed Abstract available

PASSARO A, Mok T, Peters S, Popat S, et al
Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations.
J Thorac Oncol. 2021;16:764-773.
PubMed Abstract available

April 2021

AI X, Pan Y, Shi J, Yang N, et al
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Extensive-Stage Small Cell Lung Cancer after First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.
J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02111.
PubMed Abstract available

YONESHIMA Y, Morita S, Ando M, Nakamura A, et al
Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non-small cell lung cancer.
J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02107.
PubMed Abstract available

HWANG DM, Albaqer T, Santiago RC, Weiss J, et al
Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer.
J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02108.
PubMed Abstract available

QIAO M, Jiang T, Liu X, Mao S, et al
Immune checkpoint inhibitors in EGFR-mutated non-small cell lung cancer: Dusk or Dawn?
J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02113.
PubMed Abstract available

ANDRUSKA N, Stowe HB, Crockett C, Liu W, et al
Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios.
J Thorac Oncol. 2021 Apr 23. pii: S1556-0864(21)02112.
PubMed Abstract available

SAFIRI S, Sohrabi MR, Carson-Chahhoud K, Bettampadi D, et al
Burden of tracheal, bronchus and lung cancer and its attributable risk factors in 204 countries and territories, 1990-2019.
J Thorac Oncol. 2021 Apr 15. pii: S1556-0864(21)02110.
PubMed Abstract available

PATAER A, Weissferdt A, Vaporciyan AA, Correa AM, et al
Evaluation of Pathologic Response in Lymph Nodes of Lung Cancer Patients Receiving Neoadjuvant Chemotherapy.
J Thorac Oncol. 2021 Apr 12. pii: S1556-0864(21)02109.
PubMed Abstract available

BAUMEISTER SE, Baurecht H, Nolde M, Alayash Z, et al
Cannabis use, pulmonary function, and lung cancer susceptibility: A Mendelian randomization study.
J Thorac Oncol. 2021 Apr 11. pii: S1556-0864(21)02105.
PubMed Abstract available

MEMMOTT RM, Wolfe AR, Carbone DP, Williams TM, et al
Predictors of Response, Progression Free Survival, and Overall Survival in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)02072.
PubMed Abstract available

PARK K, Ozguroglu M, Vansteenkiste J, Spigel D, et al
Avelumab vs docetaxel in patients with platinum-treated advanced non-small-cell lung cancer: 2-year follow-up from the JAVELIN Lung 200 phase 3 trial.
J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)01832.
PubMed Abstract available

ALESSI JV, Ricciuti B, Spurr LF, Gupta H, et al
SMARCA4 and other SWI/SNF family genomic alterations in non-small cell lung cancer: Clinicopathological characteristics and outcomes to immune checkpoint inhibition.
J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)02104.
PubMed Abstract available

LIU L, Bai H, Wang C, Seery S, et al
Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02071.
PubMed Abstract available

ODINTSOV I, Mattar MS, Lui AJW, Offin M, et al
Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers.
J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02068.
PubMed Abstract available

THOMAS PL, Groves SM, Zhang YK, Li J, et al
Beyond PD-L1: B7-H6 emerges as a potential immunotherapy target in small cell lung cancer.
J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02066.
PubMed Abstract available

JOHNSON ML, Zvirbule Z, Laktionov K, Helland A, et al
Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study.
J Thorac Oncol. 2021 Apr 3. pii: S1556-0864(21)02067.
PubMed Abstract available

LUO YH, Chiu CH, Scott Kuo CH, Chou TY, et al
Lung Cancer in Republic of China.
J Thorac Oncol. 2021;16:519-527.
PubMed

GOTO T
Lymph Node Dissection for NSCLC at Whose Discretion?
J Thorac Oncol. 2021;16:e25.
PubMed

PAZ-ARES L
Response to: Bintrafusp Alfa in Second-Line Treatment of Patients With NSCLC.
J Thorac Oncol. 2021;16:e24.
PubMed

XU J, Nie H, Wan H
Bintrafusp Alfa in the Second-Line Treatment of Patients With NSCLC.
J Thorac Oncol. 2021;16:e23-e24.
PubMed

QIU H, Li Q, Xiao Y, Wu D, et al
A Novel Intergenic Region Between KLHL31 and LRRC1-ALK Exon 20 Fusion Variant in Advanced Lung Adenocarcinoma and its Remarkable Response to ALK Inhibitor.
J Thorac Oncol. 2021;16:e21-e23.
PubMed

NAGASAKA M, Ou SI
Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC.
J Thorac Oncol. 2021;16:532-536.
PubMed

CAMIDGE DR
Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC.
J Thorac Oncol. 2021;16:528-531.
PubMed

GADGEEL SM
Patient-Reported Outcomes in the Era of Immunotherapy Trials.
J Thorac Oncol. 2021;16:516-518.
PubMed

FALKSON CB
Postoperative Radiation for Completely Resected Stage II/III Thymoma: What Do We Know in 2021?
J Thorac Oncol. 2021;16:515.
PubMed

PATEL SP, Kelly K
IMpower 132: Loses Power at the Finish Line.
J Thorac Oncol. 2021;16:512-514.
PubMed

PACHECO JM, Schenk EL
CD73 and Adenosine Receptor Signaling as a Potential Therapeutic Target in EGFR-Mutated NSCLC.
J Thorac Oncol. 2021;16:509-511.
PubMed

SEBASTIAN M, Stratmann JA, Eberhardt WEE
Too Good to be True?
J Thorac Oncol. 2021;16:507-508.
PubMed

LE X
Heterogeneity in MET-Aberrant NSCLC.
J Thorac Oncol. 2021;16:504-506.
PubMed

OU FS, Michiels S, Shyr Y, Adjei AA, et al
Biomarker Discovery and Validation: Statistical Considerations.
J Thorac Oncol. 2021;16:537-545.
PubMed Abstract available

TATEISHI Y, Horita N, Namkoong H, Enomoto T, et al
Postoperative Radiotherapy for Completely Resected Masaoka/Masaoka-Koga Stage II/III Thymoma Improves Overall Survival: An Updated Meta-Analysis of 4746 Patients.
J Thorac Oncol. 2021;16:677-685.
PubMed Abstract available

LE X, Negrao MV, Reuben A, Federico L, et al
Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.
J Thorac Oncol. 2021;16:583-600.
PubMed Abstract available

LAM VK, Zhang J, Wu CC, Tran HT, et al
Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC.
J Thorac Oncol. 2021;16:601-609.
PubMed Abstract available

VILLALBA JA, Shih AR, Sayo TMS, Kunitoki K, et al
Accuracy and Reproducibility of Intraoperative Assessment on Tumor Spread Through Air Spaces in Stage 1 Lung Adenocarcinomas.
J Thorac Oncol. 2021;16:619-629.
PubMed Abstract available

MOONEN L, Derks JL, Hermans BCM, Bunnik IM, et al
Preoperative Biopsy Diagnosis in Pulmonary Carcinoids, a Shot in the Dark.
J Thorac Oncol. 2021;16:610-618.
PubMed Abstract available

March 2021

SCARFONE G, Fumagalli M, Imbimbo M, Ceruti T, et al
First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report.
J Thorac Oncol. 2021 Mar 29. pii: S1556-0864(21)01705.
PubMed Abstract available

OSAROGIAGBON RU, Rami-Porta R, Tsao MS, Montuenga LM, et al
The International Association for the Study of Lung Cancer (IASLC) Molecular Database Project: Objectives, Challenges and Opportunities.
J Thorac Oncol. 2021 Mar 23. pii: S1556-0864(21)01781.
PubMed

AREDO JV, Luo SJ, Gardner RM, Sanyal N, et al
Tobacco Smoking and Risk of Second Primary Lung Cancer.
J Thorac Oncol. 2021 Mar 12. pii: S1556-0864(21)01747.
PubMed Abstract available

TANG WF, Wu M, Bao H, Xu Y, et al
Timing and origins of local and distant metastases in lung cancer.
J Thorac Oncol. 2021 Mar 12. pii: S1556-0864(21)01746.
PubMed Abstract available

MINO-KENUDSON M, Le Stang N, Daigneault JB, Nicholson AG, et al
IASLC Global Survey on PD-L1 Testing for Non-Small Cell Lung Cancer.
J Thorac Oncol. 2021 Mar 1. pii: S1556-0864(21)01732.
PubMed Abstract available

HENDRIKS LEL, Dingemans AC, De Ruysscher DKM, Aarts MJ, et al
Lung Cancer in the Netherlands.
J Thorac Oncol. 2021;16:355-365.
PubMed

DY GK, Prasad D, Kumar P, Attwood K, et al
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy.
J Thorac Oncol. 2021;16:e19-e20.
PubMed

YANG X, Li Y, Duan Q, Zhang Q, et al
Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment.
J Thorac Oncol. 2021;16:e17-e19.
PubMed

SHIELDS MD, Hicks JK, Boyle TA, Haura EB, et al
Selpercatinib Overcomes CCDC6-RET-Mediated Resistance to Osimertinib.
J Thorac Oncol. 2021;16:e15-e17.
PubMed

UPRETY D
Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting.
J Thorac Oncol. 2021;16:371-374.
PubMed

REMON J, Hendriks LEL
Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC.
J Thorac Oncol. 2021;16:368-370.
PubMed

ADJEI AA
Controversies in Thoracic Oncology.
J Thorac Oncol. 2021;16:366-367.
PubMed

RAJAN A
Immunotherapy for Thymic Cancers: A Convoluted Path Toward a Cherished Goal.
J Thorac Oncol. 2021;16:352-354.
PubMed

SONG L, Xu Q, Lizaso A, Zhang Y, et al
Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC.
J Thorac Oncol. 2021;16:349-351.
PubMed

SONG Z, Lu C, Xu CW, Zheng Z, et al
Noncanonical Gene Fusions Detected at the DNA Level Necessitate Orthogonal Diagnosis Methods Before Targeted Therapy.
J Thorac Oncol. 2021;16:344-348.
PubMed

WANG X, Piantadosi S, Le-Rademacher J, Mandrekar SJ, et al
Statistical Considerations for Subgroup Analyses.
J Thorac Oncol. 2021;16:375-380.
PubMed

NILSSON MB, Robichaux J, Herynk MH, Cascone T, et al
Altered Regulation of HIF-1alpha in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype.
J Thorac Oncol. 2021;16:439-451.
PubMed Abstract available

NG TL, Johnson A, Nemenoff RA, Hsieh E, et al
Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation.
J Thorac Oncol. 2021;16:486-491.
PubMed Abstract available

LI W, Guo L, Liu Y, Dong L, et al
Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
J Thorac Oncol. 2021;16:404-418.
PubMed Abstract available

GIACCONE G, Kim C
Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up.
J Thorac Oncol. 2021;16:483-485.
PubMed Abstract available

SECHI E, Zekeridou A
Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies.
J Thorac Oncol. 2021;16:381-394.
PubMed Abstract available

February 2021

MALHOTRA J, Nikolinakos P, Leal T, Lehman J, et al
A Phase I/II Study of Rovalpituzumab Tesirine in Combination With Nivolumab +/- Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer.
J Thorac Oncol. 2021 Feb 27. pii: S1556-0864(21)01745.
PubMed Abstract available

YAMADA Y, Simon-Keller K, Belharazem-Vitacolonnna D, Bohnenberger H, et al
A tuft cell-like signature is highly prevalent in thymic squamous cell carcinoma and delineates new molecular subsets among the major lung cancer histotypes.
J Thorac Oncol. 2021 Feb 17. pii: S1556-0864(21)01708.
PubMed Abstract available

BLACKHALL F, Jao K, Greillier L, Cho BC, et al
Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study.
J Thorac Oncol. 2021 Feb 16. pii: S1556-0864(21)01709.
PubMed Abstract available

OSAROGIAGBON RU, Smeltzer MP, Faris NR, Ray MA, et al
Outcomes Following Use of a Lymph Node Collection Kit for Lung Cancer Surgery: A Pragmatic, Population-Based, Multi-Institutional, Staggered Implementation Study.
J Thorac Oncol. 2021 Feb 16. pii: S1556-0864(21)01658.
PubMed Abstract available

YUN JK, Lee GD, Choi S, Kim YH, et al
A Validation Study on the Recommended Change in Residual Tumor Descriptors Proposed by the International Association for the Study of Lung Cancer for Patients with pN2 Non-small Cell Lung Cancer.
J Thorac Oncol. 2021 Feb 16. pii: S1556-0864(21)01668.
PubMed Abstract available

ZHANG Y, Luo G, Etxeberria J, Hao Y, et al
Global patterns and trends in lung cancer incidence: a population-based study.
J Thorac Oncol. 2021 Feb 16. pii: S1556-0864(21)01700.
PubMed Abstract available

YANG Y, Huang J, Wang T, Zhou J, et al
Decoding the Evolutionary Response to Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer Patients by Dynamic Circulating Tumor DNA Sequencing.
J Thorac Oncol. 2021 Feb 12. pii: S1556-0864(21)01662.
PubMed Abstract available

RAY MA, Fehnel C, Akinbobola O, Faris NR, et al
Comparative Effectiveness of a Lymph Node Collection kit Versus 'Heightened Awareness' on Lung Cancer Surgery Quality and Outcomes.
J Thorac Oncol. 2021 Feb 12. pii: S1556-0864(21)01665.
PubMed Abstract available

RADONIC T, Geurts-Giele WRR, Samsom KG, Roemen GMJM, et al
RET FISH analysis is a sensitive but highly unspecific screening method for RET fusions in lung cancer.
J Thorac Oncol. 2021 Feb 12. pii: S1556-0864(21)01666.
PubMed Abstract available

AREDO JV, Mambetsariev I, Hellyer JA, Amini A, et al
Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy.
J Thorac Oncol. 2021 Feb 12. pii: S1556-0864(21)01702.
PubMed Abstract available

HENDERSON LM, Durham DD, Tammemagi MC, Benefield T, et al
Lung Cancer Screening with Low Dose Computed Tomography in Patients With and Without Prior History of Cancer in the National Lung Screening Trial.
J Thorac Oncol. 2021 Feb 10. pii: S1556-0864(21)01703.
PubMed Abstract available

YE L, Creaney J, Redwood A, Robinson B, et al
The current lung cancer neoantigen landscape and implications for therapy.
J Thorac Oncol. 2021 Feb 10. pii: S1556-0864(21)01698.
PubMed Abstract available

ILIE M, MaziEres J, Chamorey E, Heeke S, et al
Prospective multi-center validation of the detection of ALK rearrangements of circulating tumor cells for non-invasive longitudinal management of patients with advanced non-small cell lung cancer.
J Thorac Oncol. 2021 Feb 3. pii: S1556-0864(21)01664.
PubMed Abstract available

DAGOGO-JACK I, Moonsamy P, Gainor JF, Lennerz JK, et al
A Phase II Study of Capmatinib in Patients with MET-Altered Lung Cancer Previously Treated with a MET Inhibitor.
J Thorac Oncol. 2021 Feb 2. pii: S1556-0864(21)01650.
PubMed Abstract available

BARTLETT EC, Silva M, Callister ME, Devaraj A, et al
False negative results in lung cancer screening - Evidence and Controversies.
J Thorac Oncol. 2021 Feb 2. pii: S1556-0864(21)01652.
PubMed Abstract available

JOSEPH N, Choudhury A
Dosimetric Predictors of Radiotherapy-Induced Lymphocytopenia in Lung Cancer.
J Thorac Oncol. 2021;16:e11-e12.
PubMed

LEIGHL NB
Meeting Immunotherapy Resistance in Lung Cancer.
J Thorac Oncol. 2021;16:187-190.
PubMed

LEE J, Ahn MJ
A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.
J Thorac Oncol. 2021;16:e14.
PubMed

ZHENG MM, Li YS, Sun H, Wu YL, et al
Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.
J Thorac Oncol. 2021;16:e12-e14.
PubMed

TSUI DCC, Camidge DR
Molecular Profiling of the Cerebrospinal Fluid in Leptomeningeal NSCLC: The Shape of Things to Come?
J Thorac Oncol. 2021;16:194-196.
PubMed

SEQUIST LV, Skates SJ, Haas W
A New Era of Protein-Based Assays for Cancer Early Detection.
J Thorac Oncol. 2021;16:191-193.
PubMed

FERRARA R, Campochiaro C, Garassino MC
Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events.
J Thorac Oncol. 2021;16:183-186.
PubMed

PADDA SK, Reckamp KL
Combination of Immunotherapy and Antiangiogenic Therapy in Cancer-a Rational Approach.
J Thorac Oncol. 2021;16:178-182.
PubMed

MOK T, Peters S, Camidge DR, Noe J, et al
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.
J Thorac Oncol. 2021;16:259-268.
PubMed Abstract available

LI B, Zhang Y, Miao L, Ma L, et al
Esophagectomy With Three-Field Versus Two-Field Lymphadenectomy for Middle and Lower Thoracic Esophageal Cancer: Long-Term Outcomes of a Randomized Clinical Trial.
J Thorac Oncol. 2021;16:310-317.
PubMed Abstract available

BANFILL K, Giuliani M, Aznar M, Franks K, et al
Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions.
J Thorac Oncol. 2021;16:216-227.
PubMed Abstract available

GJYSHI O, Xu T, Elhammali A, Boyce-Fappiano D, et al
Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC.
J Thorac Oncol. 2021;16:269-277.
PubMed Abstract available

PETERS S, Felip E, Dafni U, Tufman A, et al
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology P
J Thorac Oncol. 2021;16:278-288.
PubMed Abstract available

JIANG T, Fang Z, Tang S, Cheng R, et al
Mutational Landscape and Evolutionary Pattern of Liver and Brain Metastasis in Lung Adenocarcinoma.
J Thorac Oncol. 2021;16:237-249.
PubMed Abstract available

OSTRIN EJ, Bantis LE, Wilson DO, Patel N, et al
Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules.
J Thorac Oncol. 2021;16:228-236.
PubMed Abstract available

LE X, Nilsson M, Goldman J, Reck M, et al
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.
J Thorac Oncol. 2021;16:205-215.
PubMed Abstract available

MOI L, Bouchaab H, Mederos N, Nguyen-Ngoc T, et al
Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis.
J Thorac Oncol. 2021;16:318-326.
PubMed Abstract available

January 2021

RECK M, Ciuleanu TE, Lee JS, Schenker M, et al
First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced Non-Small Cell Lung Cancer With Tumor PD-L1 >/= 1%: Patient-Reported Outcomes From CheckMate 227 Part 1.
J Thorac Oncol. 2021 Jan 21. pii: S1556-0864(21)00041.
PubMed Abstract available

CARBONE M, Lednicky J, Xiao SY, Venditti M, et al
Coronavirus Infectious Disease Epidemic (COVID-19): where we are, what can be done and hope for.
J Thorac Oncol. 2021 Jan 7. pii: S1556-0864(20)31140.
PubMed Abstract available

LI L, Ling Y, Guo C, Guo L, et al
Necrosis Is Not the Main Part of Immune-Related Pathologic Response to Neoadjuvant Immunotherapy in Squamous Cell Lung Cancer.
J Thorac Oncol. 2021;16:e7-e9.
PubMed

PUJOL JL, Thomas PA, Giraud P, Denis MG, et al
Lung Cancer in France.
J Thorac Oncol. 2021;16:21-29.
PubMed

HAMANN HA, Williamson TJ, Studts JL, Ostroff JS, et al
Lung Cancer Stigma Then and Now: Continued Challenges Amid a Landscape of Progress.
J Thorac Oncol. 2021;16:17-20.
PubMed

SHOJAEE S, Nana-Sinkam P
One Metformin a Day, Keeps Lung Cancer Away! Or Does It?
J Thorac Oncol. 2021;16:11-13.
PubMed

TRAVIS WD, Dacic S, Sholl LM, Wistuba II, et al
Pathologic Assessment of Lung Squamous Cell Carcinoma After Neoadjuvant Immunotherapy.
J Thorac Oncol. 2021;16:e9-e10.
PubMed

CALLSTROM MR, de Baere T
Response to Is Cryoablation Really Safe and Efficacious: Analyzing Results Within SOLSTICE Trial.
J Thorac Oncol. 2021;16:e6-e7.
PubMed

SHARMA A, Kamal VK
Is Cryoablation Really Safe and Efficacious? Analyzing Results From the SOLSTICE Trial.
J Thorac Oncol. 2021;16:e5.
PubMed

BAIRD AM, Finn SP, Gray SG, Sheils O, et al
Epigenetic Modifier UHRF1 May Be a Potential Target in Malignant Pleural Mesothelioma.
J Thorac Oncol. 2021;16:14-16.
PubMed

LEE JJ, Yin G
Principles and Reporting of Bayesian Trials.
J Thorac Oncol. 2021;16:30-36.
PubMed Abstract available

SANDS J, Tammemagi MC, Couraud S, Baldwin DR, et al
Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation.
J Thorac Oncol. 2021;16:37-53.
PubMed Abstract available

SATO H, Offin M, Kubota D, Yu HA, et al
Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers.
J Thorac Oncol. 2021;16:113-126.
PubMed Abstract available

DIMOU A, Grewe P, Sidney J, Sette A, et al
HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival.
J Thorac Oncol. 2021;16:104-112.
PubMed Abstract available

REARDON ES, Shukla V, Xi S, Gara SK, et al
UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.
J Thorac Oncol. 2021;16:89-103.
PubMed Abstract available

December 2020

NISHIO M, Barlesi F, West H, Ball S, et al
Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial.
J Thorac Oncol. 2020 Dec 14. pii: S1556-0864(20)31100.
PubMed Abstract available

CHU T, Zhong R, Zhong H, Zhang B, et al
Phase Ib Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients with Advanced Non-small Cell Lung Cancer.
J Thorac Oncol. 2020 Dec 14. pii: S1556-0864(20)31101.
PubMed Abstract available

KRON A, Scheffler M, Heydt C, Ruge L, et al
Genetic Heterogeneity of MET-aberrant Non-Small Cell Lung Cancer and its Impact on the Outcome of Immunotherapy.
J Thorac Oncol. 2020 Dec 9. pii: S1556-0864(20)31091.
PubMed Abstract available

PAN D, Hu AY, Antonia SJ, Li CY, et al
A Gene Mutation Signature Predicting Immunotherapy Benefits in Non-Small Cell Lung Cancer Patients.
J Thorac Oncol. 2020 Dec 8. pii: S1556-0864(20)31096.
PubMed Abstract available

HELLYER JA, Padda SK, Diehn M, Wakelee HA, et al
Clinical implications of KEAP1-NFE2L2 mutations in non-small cell lung cancer.
J Thorac Oncol. 2020 Dec 8. pii: S1556-0864(20)31089.
PubMed Abstract available

SCOTT JG, Sedor G, Scarborough JA, Kattan MW, et al
Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2020 Dec 7. pii: S1556-0864(20)31046.
PubMed Abstract available

JOHN T, Cooper WA, Wright G, Siva S, et al
Lung Cancer in Australia.
J Thorac Oncol. 2020;15:1809-1814.
PubMed

ROSSI G, Caruso D, Stella F, Davoli F, et al
Histologic Confounding Findings in Coronavirus disease 2019 (COVID-19) Pathology.
J Thorac Oncol. 2020;15:e192-e193.
PubMed

CAI Y, Kuang D, Zhang N
Response to Letter to the Editor.
J Thorac Oncol. 2020;15:e193-e194.
PubMed

YANG Y, Zhou H, Zhang L
Response to Letter to the Editor: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (ORIENT-11).
J Thorac Oncol. 2020;15:e191-e192.
PubMed

CUI L, Zhao N, Zhang Z, Jiao X, et al
Comparing Immunotherapies in Combination With Chemotherapy for Previously Untreated Advanced Nonsquamous NSCLC.
J Thorac Oncol. 2020;15:e189-e191.
PubMed

CASO R, Jones DR
Response to the Letter to the Editor: Clinical and Pathologic Implications of Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.
J Thorac Oncol. 2020;15:e188-e189.
PubMed

XU X, Mao Y, Ding Q, Chen Y, et al
Clinical and Pathologic Implications of Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.
J Thorac Oncol. 2020;15:e187-e188.
PubMed

YATABE Y
Reassessing the SCLC Subtypes.
J Thorac Oncol. 2020;15:1819-1822.
PubMed

PUNEKAR SR, Shum E
Expanding the Role of Immunotherapy to Limited-Stage SCLC.
J Thorac Oncol. 2020;15:1806-1808.
PubMed

AHN BC, Zhu VW, Lim SM
The Next Target for NSCLC: Let It Be "RET".
J Thorac Oncol. 2020;15:1803-1805.
PubMed

MAMDANI H, Schwartz AG
Genomic Characterization of NSCLC in African Americans: A Step Toward "Race-Aware" Precision Medicine.
J Thorac Oncol. 2020;15:1800-1802.
PubMed

ARAUZ RF, Byun JS, Tandon M, Sinha S, et al
Whole-Exome Profiling of NSCLC Among African Americans.
J Thorac Oncol. 2020;15:1880-1892.
PubMed Abstract available

YANG JC, Camidge DR, Yang CT, Zhou J, et al
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
J Thorac Oncol. 2020;15:1907-1918.
PubMed Abstract available

DUAN J, Xu J, Wang Z, Bai H, et al
Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment.
J Thorac Oncol. 2020;15:1857-1870.
PubMed Abstract available

ESAI SELVAN M, Zauderer MG, Rudin CM, Jones S, et al
Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk.
J Thorac Oncol. 2020;15:1871-1879.
PubMed Abstract available

CASO R, Sanchez-Vega F, Tan KS, Mastrogiacomo B, et al
The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.
J Thorac Oncol. 2020;15:1844-1856.
PubMed Abstract available

November 2020

OWONIKOKO TK, Dwivedi B, Chen Z, Zhang C, et al
YAP1 Expression in Small Cell Lung Cancer Defines a Distinct Subtype with T-cell Inflamed Phenotype.
J Thorac Oncol. 2020 Nov 25. pii: S1556-0864(20)31028.
PubMed Abstract available

NISHIO M, Yoshida T, Kumagai T, Hida T, et al
Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
J Thorac Oncol. 2020 Nov 25. pii: S1556-0864(20)31026.
PubMed Abstract available

SPIGEL D, Jotte R, Nemunaitis J, Shum M, et al
Brief Report: Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination with Pegilodecakin in Patients with Metastatic Non-Small-Cell Lung Cancer (CYPRESS-1 and CYPRESS-2).
J Thorac Oncol. 2020 Nov 6. pii: S1556-0864(20)30805.
PubMed Abstract available

FURUTA H, Araki M, Masago K, Sagae Y, et al
Novel resistance mechanisms including L1196Q, P1094H, and R1248_D1249insertion in three patients with non-small-cell lung cancer following ALK tyrosine kinase inhibitor treatment.
J Thorac Oncol. 2020 Nov 6. pii: S1556-0864(20)30803.
PubMed Abstract available

CHUN SG, Simone CB 2nd, Amini A, Chetty IJ, et al
American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-stage Small Cell Lung Cancer 2020.
J Thorac Oncol. 2020 Nov 6. pii: S1556-0864(20)30846.
PubMed Abstract available

FAN Y, Zhao J, Wang Q, Huang D, et al
Camrelizumab Plus Apatinib in Extensive-Stage Small-Cell Lung Cancer (PASSION): A Multicenter, Two-Stage, Phase 2 Trial.
J Thorac Oncol. 2020 Nov 6. pii: S1556-0864(20)30806.
PubMed Abstract available

MAZIERES J, Rittmeyer A, Gadgeel S, Hida T, et al
Atezolizumab vs Docetaxel in Pretreated Patients with Non-Small Cell Lung Cancer: Final Results From the Randomized Phase II POPLAR and Phase III OAK Clinical Trials.
J Thorac Oncol. 2020 Nov 6. pii: S1556-0864(20)30802.
PubMed Abstract available

OSAROGIAGBON RU, Ray MA, Faris NR, Smeltzer MP, et al
Response to Clinical Thoughts on Mediastinal Node Management in Early-Stage Lung Cancer.
J Thorac Oncol. 2020;15:e185-e186.
PubMed

CHEN D, Mao Y, Chen Y, Chen C, et al
Clinical Thoughts on Mediastinal Node Management in Early-Stage Lung Cancer.
J Thorac Oncol. 2020;15:e183-e184.
PubMed

REUNGWETWATTANA T, Oranratnachai S, Puataweepong P, Tangsujaritvijit V, et al
Lung Cancer in Thailand.
J Thorac Oncol. 2020;15:1714-1721.
PubMed

TANNER NT, Rivera MP
Improving Inequities in Lung Cancer Screening: Risk Prediction Models and the Potential to Achieve a Great Equalizer Effect.
J Thorac Oncol. 2020;15:1711-1713.
PubMed

ADJEI AA
A Call to Arms: Reducing Disparities in Lung Cancer Care Worldwide.
J Thorac Oncol. 2020;15:1700-1702.
PubMed

BAKHRIBAH H, Alfayea T
Immunotherapy and Coronavirus Disease 2019: Challenges and Possibilities.
J Thorac Oncol. 2020;15:1709-1710.
PubMed

LU S, Li Z
Adverse Effects of Combined Tyrosine Kinase Inhibitors.
J Thorac Oncol. 2020;15:e182-e183.
PubMed

LI Z, Deng J, Yan F, Ma Y, et al
Letter to the Editor About the Adverse Effect of Combined Tyrosine Kinase Inhibitors.
J Thorac Oncol. 2020;15:e181-e182.
PubMed

HEGDE A, Velcheti V
Osimertinib for Leptomeningeal Disease in EGFR-Mutated NSCLC.
J Thorac Oncol. 2020;15:1705-1708.
PubMed

ALEXANDER M, Wrangle J
Can We MIRror the Efficacy of Immune Checkpoints With miRNAs?
J Thorac Oncol. 2020;15:1703-1704.
PubMed

RICE SJ, Hyland V, Behera M, Ramalingam SS, et al
Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury.
J Thorac Oncol. 2020;15:1727-1737.
PubMed Abstract available

OU FS, Le-Rademacher JG, Ballman KV, Adjei AA, et al
Guidelines for Statistical Reporting in Medical Journals.
J Thorac Oncol. 2020;15:1722-1726.
PubMed Abstract available

October 2020

ZHENG MM, Li YS, Tu HY, Jiang BY, et al
Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated non-small cell lung cancer.
J Thorac Oncol. 2020 Oct 26. pii: S1556-0864(20)30816.
PubMed Abstract available

REMON J, Reguart N, Garcia-Campelo R, Conde E, et al
Lung Cancer in Spain.
J Thorac Oncol. 2020 Oct 24. pii: S1556-0864(20)30812.
PubMed

GAUDREAU PO, Negrao MV, Mitchell KG, Reuben A, et al
Neoadjuvant Chemotherapy Increases Cytotoxic T cell, Tissue Resident Memory T cell and B Cell Infiltration in Resectable Non-Small Cell Lung Cancer.
J Thorac Oncol. 2020 Oct 20. pii: S1556-0864(20)30813.
PubMed Abstract available

HERBST RS, Arkenau HT, Bendell J, Arrowsmith E, et al
Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive Non-Small Cell Lung Cancer.
J Thorac Oncol. 2020 Oct 14. pii: S1556-0864(20)30809.
PubMed Abstract available

RAMI-PORTA R, Wittekind C, Goldstraw P
Complete Resection in Lung Cancer Surgery: From Definition to Validation and Beyond.
J Thorac Oncol. 2020 Oct 13. pii: S1556-0864(20)30727.
PubMed

STINCHCOMBE TE, Doebele RC, Wang X, Gerber DE, et al
Brief report: Preliminary clinical and molecular analysis results from a single arm phase 2 trial of brigatinib in patients with disease progression after next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in advanced ALK + no
J Thorac Oncol. 2020 Oct 8. pii: S1556-0864(20)30764.
PubMed Abstract available

KIDANE B, Levin DP
Identification and Resolution of Asymptomatic COVID-19 Pneumonitis and Colitis: Serial Assessment of Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Evaluation of Lung Cancer.
J Thorac Oncol. 2020 Oct 5. pii: S1556-0864(20)30725.
PubMed

SEITLINGER J, Banga Nkomo D, Streit A, Stasiak F, et al
Letter to the Editor Concerning the Article From Cai et al. Focusing on Coronavirus Disease 2019 Impact on Lung Cancer Resection, Published in June 2020.
J Thorac Oncol. 2020;15:e172-e173.
PubMed

GAO S, Li N, Wang S, Zhang F, et al
Lung Cancer in People's Republic of China.
J Thorac Oncol. 2020;15:1567-1576.
PubMed

LIM E
What Is the Optimum Lymph Node Management in Patients Undergoing Surgery for Lung Cancer?
J Thorac Oncol. 2020;15:1565-1566.
PubMed

SCHILD SE
Optimizing the Radiotherapy of Lung Cancer.
J Thorac Oncol. 2020;15:1559-1560.
PubMed

LAM VK, Forde PM
Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer.
J Thorac Oncol. 2020;15:1556-1558.
PubMed

RIGNEY M, Rapsomaniki E, Carter-Harris L, King JC, et al
Brief Report: Ten Year Cross-sectional Analysis of Public, Oncologist, and Patient Attitudes About Lung Cancer and Associated Stigma.
J Thorac Oncol. 2020 Oct 1. pii: S1556-0864(20)30757.
PubMed Abstract available

HIGGINS KA, Simone CB 2nd, Amini A, Chetty IJ, et al
American Radium Society , Appropriate Use Criteria on Radiation Therapy for Extensive-stage Small Cell Lung Cancer.
J Thorac Oncol. 2020 Oct 1. pii: S1556-0864(20)30759.
PubMed Abstract available

BAINE MK, Hsieh MS, Lai WV, Egger JV, et al
Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization.
J Thorac Oncol. 2020 Oct 1. pii: S1556-0864(20)30755.
PubMed Abstract available

KUNIMASA K, Honma K, Matsumoto M, Nishino K, et al
Dermatopathic Lymphadenopathy Mimicking Disease Progression During Osimertinib Treatment.
J Thorac Oncol. 2020;15:e178-e180.
PubMed

MATSUDA K, Kashima J, Yatabe Y
The Isoform Matters in NUT Carcinoma: A Diagnostic Pitfall of p40 Immunohistochemistry.
J Thorac Oncol. 2020;15:e176-e178.
PubMed

DAGOGO-JACK I
Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation.
J Thorac Oncol. 2020;15:e174-e176.
PubMed

CAI Y, Gao Y, Zhang N
Response to Letter to the Editor.
J Thorac Oncol. 2020;15:e173-e174.
PubMed

PIGNATARO D, Bertaglia V, Bironzo P, Olmetto E, et al
Oligoprogressive Disease With SCLC Transformation in EGFR-Mutated NSCLC: How Biology Knowledge Can Change the Game Rules.
J Thorac Oncol. 2020;15:e170-e172.
PubMed

HASSAN R, Miettinen M
Response to Letter to Editor by Cornelissen et al.
J Thorac Oncol. 2020;15:e169-e170.
PubMed

CORNELISSEN R, Dubbink HJ, von der Thusen JH
ALK in Mesothelioma: To FISH or Not to FISH?
J Thorac Oncol. 2020;15:e168-e169.
PubMed

MORENO AC, Lin SH
Authors' Reply to Yajing Du's Letter to the Editor on "Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC".
J Thorac Oncol. 2020;15:e166-e168.
PubMed

DU Y, Zhan C, Li M, Qiao T, et al
Promising Stereotactic Body Radiotherapy in NSCLC.
J Thorac Oncol. 2020;15:e165-e166.
PubMed

COLEMAN N, Woolf D, Welsh L, McDonald F, et al
EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib.
J Thorac Oncol. 2020;15:e162-e165.
PubMed

WANG YY, Tian XC, Zhu L, Bai XH, et al
Concomitant Radiation Recall Dermatitis and Radiation Recall Pneumonitis Induced by Pembrolizumab.
J Thorac Oncol. 2020;15:e160-e162.
PubMed

LI M, Xu Z, Zhan C, Wang Q, et al
A Few Clouds Over the Eighth Edition T Categorization System.
J Thorac Oncol. 2020;15:e159-e160.
PubMed

CHU QSC
How Is Receptor Activator of Nuclear Factor-kappabeta/Receptor Activator of Nuclear Factor-kappabeta Ligand Targeting Ranked as an Immuno-Oncology Target for NSCLC: a Pathway Unclear as yet?
J Thorac Oncol. 2020;15:1561-1564.
PubMed

SINGH S, Bergsland EK, Card CM, Hope TA, et al
Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Updat
J Thorac Oncol. 2020;15:1577-1598.
PubMed Abstract available

WANG X, Palaskas NL, Yusuf SW, Abe JI, et al
Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer.
J Thorac Oncol. 2020;15:1682-1690.
PubMed Abstract available

PETERS S, Danson S, Hasan B, Dafni U, et al
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLE
J Thorac Oncol. 2020;15:1647-1656.
PubMed Abstract available

MOREIRA AL, Ocampo PSS, Xia Y, Zhong H, et al
A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee.
J Thorac Oncol. 2020;15:1599-1610.
PubMed Abstract available

NEGRAO MV, Raymond VM, Lanman RB, Robichaux JP, et al
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.
J Thorac Oncol. 2020;15:1611-1623.
PubMed Abstract available

September 2020

AWAD MM, Gadgeel SM, Borghaei H, Patnaik A, et al
Brief Report: Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
J Thorac Oncol. 2020 Sep 28. pii: S1556-0864(20)30761.
PubMed Abstract available

KANG J, Jeong SM, Shin DW, Cho M, et al
Associations of aspirin, statins, and metformin with lung cancer risk and related mortality: time-dependent analysis of population-based nationally representative data.
J Thorac Oncol. 2020 Sep 12. pii: S1556-0864(20)30712.
PubMed Abstract available

GEMMA A, Kusumoto M, Sakai F, Endo M, et al
Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with epidermal growth factor receptor T790M-positive non-small cell lung cancer treated with osimertinib in Japan.
J Thorac Oncol. 2020 Sep 11. pii: S1556-0864(20)30717.
PubMed Abstract available

WELSH JW, Heymach JV, Guo C, Menon H, et al
Phase I/II Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage Small Cell Lung Cancer.
J Thorac Oncol. 2020 Sep 8. pii: S1556-0864(20)30713.
PubMed Abstract available

BRAUN M, Fuchs V, Kian W, Roisman L, et al
Nivolumab Induced Hepatocanalicular Cholestasis and Liver Rejection in a Patient With Lung Cancer and Liver Transplant.
J Thorac Oncol. 2020;15:e149-e150.
PubMed

GEDVILAITE V, Danila E, Cicenas S, Smailyte G, et al
Lung Cancer in Lithuania.
J Thorac Oncol. 2020;15:1401-1405.
PubMed

AHN MJ
Molecular Testing in Lung Cancer: Still Big Gap in Implementation for Real-World Use.
J Thorac Oncol. 2020;15:1399-1400.
PubMed

ZHOU F, Zhou C
Treatment Algorithm for Advanced ALK-Rearranged NSCLC: Reply.
J Thorac Oncol. 2020;15:e157-e158.
PubMed

URBANSKA EM, Sorensen JB, Santoni-Rugiu E
Treatment Algorithm for Advanced ALK-Rearranged NSCLC.
J Thorac Oncol. 2020;15:e156-e157.
PubMed

HAURA EB, Hicks JK, Boyle TA
Erdafitinib Overcomes FGFR3-TACC3-Mediated Resistance to Osimertinib.
J Thorac Oncol. 2020;15:e154-e156.
PubMed

ZHENG J, Sun W, Chen W, Zhou J, et al
Sustained Response to Crizotinib After Resistance to First-Line Alectinib Treatment in Two Patients With ALK-Rearranged NSCLC.
J Thorac Oncol. 2020;15:e150-e153.
PubMed

OKUDA K, Nakanishi R
Circulating Cancer-Associated Cells for the Early Detection and Decision-Making Concerning Effective Therapeutic Strategies for NSCLC.
J Thorac Oncol. 2020;15:1397-1398.
PubMed

LYCAN TW JR, Petty WJ
Adverse Event Reporting at Professional Conferences: We Need Better Standards and Bigger Posters.
J Thorac Oncol. 2020;15:1394-1396.
PubMed

GOTO Y
Current Understanding and Biomarker Application of Programmed Death-Ligand 1 Expression in Tumors.
J Thorac Oncol. 2020;15:1392-1393.
PubMed

ADDEO A, Banna LG, Friedlaender A
Filtering Data About Treatment-Induced Renal Injury: From Biology to Practice.
J Thorac Oncol. 2020;15:1389-1391.
PubMed

KERN JA, Kim J, Foster DG, Mishra R, et al
Role of mTOR As an Essential Kinase in SCLC.
J Thorac Oncol. 2020;15:1522-1534.
PubMed Abstract available

DAHLBERG SE, Korn EL, Le-Rademacher J, Mandrekar SJ, et al
Clinical Versus Statistical Significance in Studies of Thoracic Malignancies.
J Thorac Oncol. 2020;15:1406-1408.
PubMed

OYAMA T, Goto T, Amemiya K, Hirotsu Y, et al
Squamous Cell Carcinoma of the Lung With Micropapillary Pattern.
J Thorac Oncol. 2020;15:1541-1544.
PubMed

SHOLL LM, Hirsch FR, Hwang D, Botling J, et al
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.
J Thorac Oncol. 2020;15:1409-1424.
PubMed Abstract available

DUMOULIN DW, Visser S, Cornelissen R, van Gelder T, et al
Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC.
J Thorac Oncol. 2020;15:1472-1483.
PubMed Abstract available

ZHU VW, Lin YT, Kim DW, Loong HH, et al
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC.
J Thorac Oncol. 2020;15:1484-1496.
PubMed Abstract available

August 2020

TAN AC, Seet AOL, Lai GGY, Lim TH, et al
Molecular characterisation and clinical outcomes in RET rearranged non-small cell lung cancer (NSCLC).
J Thorac Oncol. 2020 Aug 28. pii: S1556-0864(20)30671.
PubMed Abstract available

CALABRESE F, Fortarezza F, Giraudo C, Pezzuto F, et al
Two sorts of microthrombi in a COVID-19 patient with lung cancer.
J Thorac Oncol. 2020 Aug 28. pii: S1556-0864(20)30668.
PubMed

IKEDA S, Kato T, Kenmotsu H, Ogura T, et al
A phase II study of atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonias.
J Thorac Oncol. 2020 Aug 25. pii: S1556-0864(20)30678.
PubMed Abstract available

PASQUINELLI MM, Tammemagi MC, Kovitz KL, Durham ML, et al
Risk Prediction Model versus United States Preventive Services Task Force Lung Cancer Screening Eligibility Criteria - Reducing Race Disparities.
J Thorac Oncol. 2020 Aug 17. pii: S1556-0864(20)30638.
PubMed Abstract available

ADAMEK M, Biernat W, Chorostowska-Wynimko J, Didkowska JA, et al
Lung Cancer in Poland.
J Thorac Oncol. 2020;15:1271-1276.
PubMed

GU Z, Liu Y, Qiu B, Liu H, et al
Risk Stratification Is Helpful in Designing Follow-Up Strategy and Future Studies on Adjuvant Therapies: Response to the External Validation on the Chinese Alliance for Research in Thymomas Predictive Model of Recurrence.
J Thorac Oncol. 2020;15:e139-e141.
PubMed

CHIAPPETTA M, Sperduti I, Lococo F, Margaritora S, et al
Does Follow-Up Duration Affect the Effectiveness of a Predictive Nomogram Model for Thymic Malignancy Recurrences? Results From an External Validation.
J Thorac Oncol. 2020;15:e137-e139.
PubMed

DAGOGO-JACK I, Mino-Kenudson M
Reply to the Letter to the Editor From Zhou et al.
J Thorac Oncol. 2020;15:e136-e137.
PubMed

ZHOU H, Shen J, Liu J, Fang W, et al
Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Mutant NSCLC.
J Thorac Oncol. 2020;15:e133-e136.
PubMed

GENDARME S, Chouaid C
Monitoring Subsolid Pulmonary Nodules in High-Risk Patients Is Even More Cost-Effective When Combined With a Stop-Smoking Program.
J Thorac Oncol. 2020;15:1268-1270.
PubMed

URUGA H, Mino-Kenudson M
Is the Programmed Death-Ligand 1 73-10 Immunohistochemistry Assay Compatible With the 22C3 Assay?
J Thorac Oncol. 2020;15:1265-1267.
PubMed

PEROL M
Multidisciplinary Approach of Immune Checkpoint Inhibitor-Related Pneumonitis: A Key to Address Knowledge and Management Gaps.
J Thorac Oncol. 2020;15:1261-1264.
PubMed

STINCHCOMBE TE
IMpower 131: The Exception to the Rule.
J Thorac Oncol. 2020;15:1258-1260.
PubMed

KOKORIAN R, Grainville T, Robert L, Corre R, et al
Coeliac-Like Disease Is a Rare Immune-Related Complication Induced by Nivolumab in NSCLC.
J Thorac Oncol. 2020;15:e147-e148.
PubMed

ARAKAWA S, Yoshida T, Nakayama Y, Motoi N, et al
Small Cell Cancer Transformation of Lung Adenocarcinoma During Durvalumab Treatment After Chemoradiotherapy.
J Thorac Oncol. 2020;15:e145-e146.
PubMed

COLEMAN N, Yousaf N, Arkenau HT, Welsh L, et al
Lorlatinib Salvages Central Nervous System-Only Relapse on Entrectinib in ROS1-Positive NSCLC.
J Thorac Oncol. 2020;15:e142-e144.
PubMed

ZHENG Q, Fang W, Huang Y, Gan J, et al
Identification of a Novel KIF5B-RET, ABHD17C-RET Double-Fusion Variant in Lung Adenocarcinoma and Response to Cabozantinib.
J Thorac Oncol. 2020;15:e132-e133.
PubMed

MANDREKAR SJ, Le-Rademacher J, Adjei AA
Introducing the Journal of Thoracic Oncology Statistical Series.
J Thorac Oncol. 2020;15:1257.
PubMed

AN MW, Duong Q, Le-Rademacher J, Mandrekar SJ, et al
Principles of Good Clinical Trial Design.
J Thorac Oncol. 2020;15:1277-1280.
PubMed Abstract available

JEENE PM, Vermeulen BD, Rozema T, Braam PM, et al
Short-Course External Beam Radiotherapy Versus Brachytherapy for Palliation of Dysphagia in Esophageal Cancer: A Matched Comparison of Two Prospective Trials.
J Thorac Oncol. 2020;15:1361-1368.
PubMed Abstract available

WANG Y, Yang N, Zhang Y, Li Li, et al
Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.
J Thorac Oncol. 2020;15:1369-1375.
PubMed Abstract available

KIM-WANNER SZ, Assenov Y, Nair MB, Weichenhan D, et al
Genome-Wide DNA Methylation Profiling in Early Stage I Lung Adenocarcinoma Reveals Predictive Aberrant Methylation in the Promoter Region of the Long Noncoding RNA PLUT: An Exploratory Study.
J Thorac Oncol. 2020;15:1338-1350.
PubMed Abstract available

HAMMER MM, Palazzo LL, Paquette A, Eckel AL, et al
Cost-Effectiveness of Follow-Up for Subsolid Pulmonary Nodules in High-Risk Patients.
J Thorac Oncol. 2020;15:1298-1305.
PubMed Abstract available

July 2020

YANG Y, Wang Z, Fang J, Yu Q, et al
Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11).
J Thorac Oncol. 2020 Jul 31. pii: S1556-0864(20)30595.
PubMed Abstract available

PEARSALL SM, Humphrey S, Revill M, Morgan D, et al
The rare YAP1 subtype of Small Cell Lung Cancer revisited in a biobank of 39 Circulating Tumour Cell Patient Derived eXplant models (CDX): A brief report.
J Thorac Oncol. 2020 Jul 25. pii: S1556-0864(20)30588.
PubMed Abstract available

BUENO R, Richards WG, Harpole DH, Ballman KV, et al
Multi-institutional prospective validation of prognostic mRNA signatures in early stage squamous lung cancer (Alliance).
J Thorac Oncol. 2020 Jul 24. pii: S1556-0864(20)30558.
PubMed Abstract available

ROLFO C, Cardona AF, Ruiz-Patino A, Ariza S, et al
Atypical skin manifestations during immune checkpoint blockage in COVID19-infected lung cancer patients.
J Thorac Oncol. 2020 Jul 9. pii: S1556-0864(20)30543.
PubMed Abstract available

LEE J, La Choi Y, Han J, Park S, et al
Osimertinib improves overall survival in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status.
J Thorac Oncol. 2020 Jul 8. pii: S1556-0864(20)30505.
PubMed Abstract available

KILADZE I, Mariamidze E, Jeremic B
Lung Cancer in Georgia.
J Thorac Oncol. 2020;15:1113-1118.
PubMed

SMELTZER MP, Osarogiagbon RU
Out of the Darkness, Into Light: The Scientific Rigor of Lung Cancer Clinical Trials in the Age of Enlightenment.
J Thorac Oncol. 2020;15:1110-1112.
PubMed

LIN JJ, Solomon BJ
Reply to "Emergence of High Level of MET Amplification During Treatment With Selpercatinib in KIF5B-RET NSCLC".
J Thorac Oncol. 2020;15:e127-e128.
PubMed

ZHU VW, Madison R, Schrock AB, Ou SI, et al
Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC.
J Thorac Oncol. 2020;15:e124-e127.
PubMed

EMOTO K, Tan KS, Rekhtman N, Adusumilli PS, et al
The Newly Described Filigree Pattern Is an Expansion of the Micropapillary Adenocarcinoma Concept Rather Than a Proposed New Subtype.
J Thorac Oncol. 2020;15:e121-e124.
PubMed

THUNNISSEN E, Flieder D
Morphologic Logic: "Filigree" and "Classical" Micropapillary Pattern Are Orientation-Dependent Views of the Same Lesion.
J Thorac Oncol. 2020;15:e120-e121.
PubMed

TRAVIS WD, Aly RG, Rekhtman N, Tan KS, et al
Spread Through Air Spaces Is Prognostic in Neuroendocrine Lung Tumors and Can Be Distinguished From Artifacts.
J Thorac Oncol. 2020;15:e118-e120.
PubMed

THUNNISSEN E, Marchevsky A, Rossi G, Russell PA, et al
RE: Spread Through Air Spaces (STAS) is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung.
J Thorac Oncol. 2020;15:e116-e117.
PubMed

JEAN D, Delaunay T, Meiller C, Boisgerault N, et al
Reply to: Oncolytic Viral Therapy for Malignant Pleural Mesothelioma.
J Thorac Oncol. 2020;15:e113-e116.
PubMed

YANG H, Xu D, Gao Y, Schmid RA, et al
Oncolytic Viral Therapy for Malignant Pleural Mesothelioma.
J Thorac Oncol. 2020;15:e111-e113.
PubMed

GAUTSCHI O, Bubendorf L, Leyvraz S, Menon R, et al
Challenges in the Diagnosis of NTRK Fusion-Positive Cancers.
J Thorac Oncol. 2020;15:e108-e110.
PubMed

SUTHERLAND KD, Vissers JHA
Balancing the Count: Harmonizing Panel-Based Tumor Mutational Burden Assessment.
J Thorac Oncol. 2020;15:1106-1109.
PubMed

HSIAO SJ, Ou SI
Is Retention of the 5' Nononcogenic ALK Fusion Variant a Novel Poor Prognostic Factor in ALK-Positive NSCLC?
J Thorac Oncol. 2020;15:1103-1105.
PubMed

LOONG HH, Li MSC, Tang GCH, Lau YM, et al
Have We Revealed the Achilles' Heel of Brigatinib? Implications on Clinical Practice.
J Thorac Oncol. 2020;15:1100-1102.
PubMed

JETT JR, Kim ES
Response to Letter to the Editor.
J Thorac Oncol. 2020;15:e110-e111.
PubMed

BARSKY AR, Kim MM, Williams GR, Lally BE, et al
Proton-Beam Therapy: At the Heart of Cardiac Dose-Sparing in Mediastinal Radiotherapy for Thymic Carcinoma.
J Thorac Oncol. 2020;15:1240-1242.
PubMed

CALLSTROM MR, Woodrum DA, Nichols FC, Palussiere J, et al
Multicenter Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE).
J Thorac Oncol. 2020;15:1200-1209.
PubMed Abstract available

STENZINGER A, Endris V, Budczies J, Merkelbach-Bruse S, et al
Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.
J Thorac Oncol. 2020;15:1177-1189.
PubMed Abstract available

June 2020

PAZ-ARES L, Vicente D, Tafreshi A, Robinson A, et al
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407.
J Thorac Oncol. 2020 Jun 26. pii: S1556-0864(20)30500.
PubMed Abstract available

RAY MA, Smeltzer MP, Faris N, Osarogiagbon RU, et al
Survival after mediastinal node dissection, systematic sampling or neither for early-stage non-small-cell lung cancer.
J Thorac Oncol. 2020 Jun 20. pii: S1556-0864(20)30479.
PubMed Abstract available

SHUKUYA T, Ghai V, Amann JM, Okimoto T, et al
Circulating miRNAs and extracellular vesicle containing miRNAs as response biomarkers of anti PD-1/PD-L1 therapy in non-small-cell lung cancer.
J Thorac Oncol. 2020 Jun 18. pii: S1556-0864(20)30467.
PubMed Abstract available

ABRAVAN A, Faivre-Finn C, Kennedy J, McWilliam A, et al
Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer.
J Thorac Oncol. 2020 Jun 14. pii: S1556-0864(20)30478.
PubMed Abstract available

UPRETY D, Mandrekar SJ, Wigle D, Roden AC, et al
Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer - Current Concepts and Future Approaches.
J Thorac Oncol. 2020 Jun 6. pii: S1556-0864(20)30425.
PubMed Abstract available

RUIZ R, Galvez-Nino M, Poquioma E, Limache-Garcia A, et al
Lung Cancer in Peru.
J Thorac Oncol. 2020;15:891-898.
PubMed

WANG F, Adjei AA
Does the Lung Cancer Field Need Another Third-Generation EGFR Tyrosine Kinase Inhibitor?
J Thorac Oncol. 2020;15:881-883.
PubMed

MCGINNIS GJ, Ning MS, Nitsch PL, O'Reilly MS, et al
Rapid Detection of Asymptomatic Coronavirus Disease 2019 by Computed Tomography Image Guidance for Stereotactic Ablative Radiotherapy.
J Thorac Oncol. 2020;15:1085-1087.
PubMed

NICHOLSON AG, Sauter JL, Galateau-Salle F
In Reply.
J Thorac Oncol. 2020;15:e94-e95.
PubMed

AUJAYEB A, Taylor L
Is the Deciduoid Variant of Pleural Mesothelioma Significant?
J Thorac Oncol. 2020;15:e94.
PubMed

ARAI S, Yano S
In Reply.
J Thorac Oncol. 2020;15:e93.
PubMed

CORTINOVIS D, Gemelli M, Cappuzzo F
Alectinib Resistance Through Amphiregulin Overexpression: Is Osimertinib the Best Candidate?
J Thorac Oncol. 2020;15:e92-e93.
PubMed

HASSAN R, Sengupta M, Murai J, Pommier Y, et al
Response to Letter to the Editor by Yang et al.
J Thorac Oncol. 2020;15:e91.
PubMed

YANG H, Xu D, Gao Y, Schmid RA, et al
The Association of BAP1 Loss-of-Function With the Defect in Homologous Recombination Repair and Sensitivity to PARP-Targeted Therapy.
J Thorac Oncol. 2020;15:e88-e90.
PubMed

MAZZOTTA M, Marinelli D, Maugeri-Sacca M
KEAP1-NFE2L2 Mutations in NSCLC: Increased Awareness Needed. Reply to "KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis".
J Thorac Oncol. 2020;15:e87-e88.
PubMed

ZHANG C, Zhang C, Li J, Wang H, et al
KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis.
J Thorac Oncol. 2020;15:e85-e86.
PubMed

DAGOGO-JACK I, Lennerz JK
Personalized Diagnostic Workflows: The Next Wave of Precision Medicine in NSCLC.
J Thorac Oncol. 2020;15:888-890.
PubMed

CARBONE M
Transitional Mesothelioma and Artificial Intelligence: Do We Need One More Subtype? and Do We Need Computers to Identify Them?
J Thorac Oncol. 2020;15:884-887.
PubMed

NAGASAKA M, Ou SI
Is NRG2alpha Fusion a "Doppelganger" to NRG1alpha/beta Fusions in Oncology?
J Thorac Oncol. 2020;15:878-880.
PubMed

ZHANG C, Yan LX, Jiang BY, Wu YL, et al
Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC.
J Thorac Oncol. 2020;15:e95-e99.
PubMed

CHURG A, Dacic S, Galateau-Salle F, Attanoos R, et al
Malignant Mesothelioma In Situ: Clinical and Pathologic Implications.
J Thorac Oncol. 2020;15:899-901.
PubMed

ZHANG J, Zou C, Zhou C, Luo Y, et al
A Novel Linc00308/D21S2088E Intergenic Region ALK Fusion and Its Enduring Clinical Responses to Crizotinib.
J Thorac Oncol. 2020;15:1073-1077.
PubMed

REMON J, Passiglia F, Ahn MJ, Barlesi F, et al
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
J Thorac Oncol. 2020;15:914-947.
PubMed Abstract available

GALATEAU SALLE F, Le Stang N, Tirode F, Courtiol P, et al
Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center.
J Thorac Oncol. 2020;15:1037-1053.
PubMed Abstract available

DECESARIS CM, McCarroll R, Mishra MV, Glass E, et al
Assessing Outcomes of Patients Treated With Re-Irradiation Utilizing Proton Pencil-Beam Scanning for Primary or Recurrent Malignancies of the Esophagus and Gastroesophageal Junction.
J Thorac Oncol. 2020;15:1054-1064.
PubMed Abstract available

GOODMAN CD, Nijman SFM, Senan S, Nossent EJ, et al
A Primer on Interstitial Lung Disease and Thoracic Radiation.
J Thorac Oncol. 2020;15:902-913.
PubMed Abstract available

KOHSAKA S, Hayashi T, Nagano M, Ueno T, et al
Identification of Novel CD74-NRG2alpha Fusion From Comprehensive Profiling of Lung Adenocarcinoma in Japanese Never or Light Smokers.
J Thorac Oncol. 2020;15:948-961.
PubMed Abstract available

ZHAO S, Fang W, Pan H, Yang Y, et al
Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma.
J Thorac Oncol. 2020;15:962-972.
PubMed Abstract available

LOTSBERG ML, Wnuk-Lipinska K, Terry S, Tan TZ, et al
AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells.
J Thorac Oncol. 2020;15:973-999.
PubMed Abstract available

SHI Y, Zhang S, Hu X, Feng J, et al
Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation.
J Thorac Oncol. 2020;15:1015-1026.
PubMed Abstract available

May 2020

BEST SA, Hess J, Souza-Fonseca-Guimaraes F, Cursons J, et al
Harnessing natural killer immunity in metastatic small cell lung cancer.
J Thorac Oncol. 2020 May 26. pii: S1556-0864(20)30394.
PubMed Abstract available

OUYANG W, Hu J, Zhang H, Xie C, et al
The Management of Patients With Lung Cancer During the Outbreak of Coronavirus Disease 2019.
J Thorac Oncol. 2020 May 23. pii: S1556-0864(20)30385.
PubMed

HEEKE S, Benzaquen J, Hofman V, Long-Mira E, et al
Brief Report: Comparison of three sequencing panels used for the assessment of tumor mutational burden in non-small cell lung cancer demonstrates low comparability.
J Thorac Oncol. 2020 May 22. pii: S1556-0864(20)30417.
PubMed Abstract available

SMELTZER MP, Wynes MW, Lantuejoul S, Soo R, et al
The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer.
J Thorac Oncol. 2020 May 14. pii: S1556-0864(20)30383.
PubMed Abstract available

DINGEMANS AC, Soo RA, Jazieh AR, Rice SJ, et al
Treatment guidance for lung cancer patients during the COVID-19 pandemic.
J Thorac Oncol. 2020 May 13. pii: S1556-0864(20)30382.
PubMed Abstract available

MANJUNATH Y, Mitchem JB, Suvilesh KN, Avella DM, et al
Circulating giant tumor-macrophage fusion cells are independent prognosticators in non-small cell lung cancer patients.
J Thorac Oncol. 2020 May 13. pii: S1556-0864(20)30381.
PubMed Abstract available

AL-SAMKARI H, Leiva O, Dagogo-Jack I, Shaw A, et al
Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2020 May 10. pii: S1556-0864(20)30380.
PubMed Abstract available

HONG L, Negrao MV, Dibaj SS, Chen R, et al
Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer.
J Thorac Oncol. 2020 May 7. pii: S1556-0864(20)30373.
PubMed Abstract available

ZHU J, Zhang Y, Gao XH, Xi EP, et al
COVID-19 or Lung Cancer: A differential diagnostic experience and management model from Wuhan.
J Thorac Oncol. 2020 May 6. pii: S1556-0864(20)30377.
PubMed

LEE JC, Blazak JK
The Use of Positron Emission Tomography in Coronavirus Disease 2019 Cases.
J Thorac Oncol. 2020 May 5. pii: S1556-0864(20)30374.
PubMed

CHANG HL, Chen YH, Yang CJ
Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)-Associated Interstitial Lung Disease During the COVID-19 Pandemic.
J Thorac Oncol. 2020 May 5. pii: S1556-0864(20)30376.
PubMed

DAI J, Sun L, Jin K, Jiang G, et al
Identifiable and Unidentifiable Factors Influencing Lymph Node Examination and Adjuvant Chemotherapy in Stage I Lung Cancer.
J Thorac Oncol. 2020;15:e78-e79.
PubMed

TIAN S, Xiao SY
Pathology of 2019 Novel Coronavirus Pneumonia: A Dynamic Disease Process.
J Thorac Oncol. 2020;15:e67-e68.
PubMed

BOGOS K, Kiss Z, Galffy G, Tamasi L, et al
Lung Cancer in Hungary.
J Thorac Oncol. 2020;15:692-699.
PubMed

JOOB B, Wiwanitkit V
Pulmonary Pathology of Early Phase 2019 Novel Coronavirus Pneumonia.
J Thorac Oncol. 2020;15:e67.
PubMed

WO Y, Wang Y, Lu T, Sun D, et al
Evaluated Lymph Node Number in Population-Based Analyses: Significant Prognostic Factor, but Assess With Caution.
J Thorac Oncol. 2020;15:e77-e78.
PubMed

FRIEDBERG JS, Culligan MJ, Tsao AS, Rusch V, et al
Reply to Waller et al. Standardizing Surgical Treatment for Mesothelioma.
J Thorac Oncol. 2020;15:e75-e77.
PubMed

WALLER DA, Bilancia R, Bille A, Tenconi S, et al
Standardizing Surgical Treatment of Malignant Pleural Mesothelioma.
J Thorac Oncol. 2020;15:e73-e74.
PubMed

WANG Z, Duan J, Wang J, Wang G, et al
In Reply: A Modified Algorithm Adjusting Both High and Minor Allele-Frequency to Redefine Blood-Based Tumor Mutational Burden for Optimal Prediction of Clinical Benefits From Programmed Cell Death-Protein 1 Immunotherapy.
J Thorac Oncol. 2020;15:e72-e73.
PubMed

LIU Z, Xie Z, Cai X, He J, et al
A Modified Algorithm Adjusting Both High and Minor Allele Frequency Mutation to Redefine Blood-Based Tumor Mutational Burden (bTMB) for Optimal Prediction of Clinical Benefits From Immune Checkpoint Inhibitor Therapy.
J Thorac Oncol. 2020;15:e69-e72.
PubMed

PEIKERT T
Personalized Oncolytic Therapy: The Next Step Toward the Successful Clinical Application of Vaccine-Strain Measles Viruses for Cancer Therapy?
J Thorac Oncol. 2020;15:689-691.
PubMed

DE MIGUEL FJ
An Elaborate STING Operation to Take Down NSCLC: Combination of Immunotherapies and Chemotherapies.
J Thorac Oncol. 2020;15:686-688.
PubMed

DENG L, Cheng H
Uncommon as an Individual, Not That Uncommon as a Whole.
J Thorac Oncol. 2020;15:681-685.
PubMed

YASUDA H
Targeting Co-Occurring Genomic Alterations in MET Exon 14 Skipping Mutation-Positive NSCLC.
J Thorac Oncol. 2020;15:679-680.
PubMed

CARBONE M, Green JB, Bucci EM, Lednicky JA, et al
Coronaviruses: Facts, Myths, and Hypotheses.
J Thorac Oncol. 2020;15:675-678.
PubMed

WARREN GW, Alberg AJ, Cummings KM, Dresler C, et al
Smoking Cessation After a Cancer Diagnosis Is Associated With Improved Survival.
J Thorac Oncol. 2020;15:705-708.
PubMed

JAMME P, Fernandes M, Copin MC, Descarpentries C, et al
Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations.
J Thorac Oncol. 2020;15:741-751.
PubMed Abstract available

DELLA CORTE CM, Sen T, Gay CM, Ramkumar K, et al
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
J Thorac Oncol. 2020;15:777-791.
PubMed Abstract available

VAGHJIANI RG, Takahashi Y, Eguchi T, Lu S, et al
Tumor Spread Through Air Spaces Is a Predictor of Occult Lymph Node Metastasis in Clinical Stage IA Lung Adenocarcinoma.
J Thorac Oncol. 2020;15:792-802.
PubMed Abstract available

RATHKEY D, Khanal M, Murai J, Zhang J, et al
Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression.
J Thorac Oncol. 2020;15:843-859.
PubMed Abstract available

DOMBLIDES C, Leroy K, Monnet I, Mazieres J, et al
Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.
J Thorac Oncol. 2020;15:860-866.
PubMed Abstract available

DELAUNAY T, Achard C, Boisgerault N, Grard M, et al
Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus.
J Thorac Oncol. 2020;15:827-842.
PubMed Abstract available

April 2020

KUMAR S, Chmura S, Robinson C, Lin SH, et al
Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic.
J Thorac Oncol. 2020 Apr 28. pii: S1556-0864(20)30331.
PubMed Abstract available

GROTE HJ, Feng Z, Schlichting M, Helwig C, et al
PD-L1 Immunohistochemistry Assay Comparison Studies in Non-Small Cell Lung Cancer: Characterization of the 73-10 Assay.
J Thorac Oncol. 2020 Apr 27. pii: S1556-0864(20)30327.
PubMed Abstract available

SIMONS EA, Smith DE, Gao D, Camidge DR, et al
Variation in toxicity reporting methods for early phase lung cancer treatment trials at oncology conferences.
J Thorac Oncol. 2020 Apr 27. pii: S1556-0864(20)30335.
PubMed Abstract available

CAFAROTTI S
SARS-COV2 INFECTION AND LUNG CANCER PATIENTS: the potential role of IL17 target therapy.
J Thorac Oncol. 2020 Apr 27. pii: S1556-0864(20)30330.
PubMed Abstract available

SANZ-SANTOS J, Rami-Porta R, Call S
Lessons already learnt from the Covid-19 pandemic.
J Thorac Oncol. 2020 Apr 22. pii: S1556-0864(20)30326.
PubMed

WARREN G, Adjei AA
A CALL FOR RAPID SUBMISSION OF DATA FOR AGGREGATE REVIEW: Can daily radiotherapy imaging be used as a potential screen for COVID-19?
J Thorac Oncol. 2020 Apr 21. pii: S1556-0864(20)30318.
PubMed

OUYANG W, Yu J, Zhang J, Xie C, et al
Alert to Potential Contagiousness: A Case of Lung Cancer with Asymptomatic SARS-CoV-2 Infection.
J Thorac Oncol. 2020 Apr 16. pii: S1556-0864(20)30300.
PubMed

TORLAKOVIC E, Albadine R, Bigras G, Boag A, et al
Canadian Multicentre Project on Standardization of PD-L1 22C3 Immunohistochemistry Laboratory Developed Tests for Pembrolizumab Therapy in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2020 Apr 15. pii: S1556-0864(20)30293.
PubMed Abstract available

CAFAROTTI S, Patella M
LUNG CANCER SURGICAL MANAGEMENT DURING THE OUTBREAK OF COVID-19.
J Thorac Oncol. 2020 Apr 11. pii: S1556-0864(20)30291.
PubMed

SUZUKI Y, Karayama M, Uto T, Fujii M, et al
Assessment of Immune-Related Interstitial Lung Disease in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Multi-Center Prospective Study.
J Thorac Oncol. 2020 Apr 11. pii: S1556-0864(20)30297.
PubMed Abstract available

CAI Y, Hao Z, Gao Y, Ping W, et al
COVID-19 in the perioperative period of lung resection: a brief report from a single thoracic surgery department in Wuhan, China.
J Thorac Oncol. 2020 Apr 11. pii: S1556-0864(20)30298.
PubMed Abstract available

SUPPLI MH, Riisgaard de Blanck S, Elgaard T, Josipovic M, et al
Early appearance of COVID-19 associated pulmonary infiltrates during daily radiotherapy imaging for lung cancer.
J Thorac Oncol. 2020 Apr 10. pii: S1556-0864(20)30299.
PubMed

RUSSANO M, Citarella F, Vincenzi B, Tonini G, et al
COVID-19 or Lung Cancer: what should we treat?
J Thorac Oncol. 2020 Apr 10. pii: S1556-0864(20)30294.
PubMed

JOTTE R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, et al
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized Phase III Trial.
J Thorac Oncol. 2020 Apr 7. pii: S1556-0864(20)30292.
PubMed Abstract available

YANG H
Co-Occurring LKB1 Deficiency Determinates the Susceptibility to ERK-Targeted Therapy in RAS-Mutant Lung Cancer.
J Thorac Oncol. 2020;15:e58-59.
PubMed

KAIRA K, Ogiwara Y, Naruse I
Occurrence of Ventricular Fibrillation in a Patient With Lung Cancer Receiving Osimertinib.
J Thorac Oncol. 2020;15:e54-e55.
PubMed

GRINBERG RD, Refaely Y, Cohen LB, Shaham D, et al
Lung Cancer in Israel.
J Thorac Oncol. 2020;15:493-498.
PubMed

TREMBLAY A
Reply and Commentary to "Smoking Cessation Interventions in the Setting of Low-Dose Computed Tomography: Are They Effective?"
J Thorac Oncol. 2020;15:e61-e62.
PubMed

SANGUANKEO A
Smoking Cessation Interventions in the Setting of Low-Dose Computed Tomography: Are They Effective?
J Thorac Oncol. 2020;15:e60.
PubMed

CAIOLA E, Broggini M, Marabese M
LKB1ness Dictates ERK Inhibitors Response in NSCLC.
J Thorac Oncol. 2020;15:e59.
PubMed

EGUREN-SANTAMARIA I, Sanmamed MF, Gil-Bazo I
Are Immune Checkpoint Inhibitors Effective Against Uncommon Oncogene-Driven NSCLC Subtypes?
J Thorac Oncol. 2020;15:489-492.
PubMed

ZHOU F, Zhou C
Treatment Algorithm for Advanced ALK-Rearranged NSCLC: A Marathon Rather Than a Sprint.
J Thorac Oncol. 2020;15:485-488.
PubMed

SOLOMON B
Identifying Mechanisms of Resistance to ALK Tyrosine Kinase Inhibitors Using Analysis of Circulating Tumor DNA.
J Thorac Oncol. 2020;15:482-484.
PubMed

XIA B, Ou SI
Simultaneous RET Solvent-Front and Gatekeeper Resistance Mutations In Trans: A Rare TKI-Specific Therapeutic Challenge?
J Thorac Oncol. 2020;15:479-481.
PubMed

BU K, Lu Y, Liu X, Cheng C, et al
Lysocardiolipin Acyltransferase 1-Anaplastic Lymphoma Receptor Tyrosine Kinase: A Novel Crizotinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
J Thorac Oncol. 2020;15:e55-e57.
PubMed

LV Y, Ling F, Zhang J, Xiao M, et al
A Novel Intergenic LSM14A-RET Fusion Variant in a Patient With Lung Adenocarcinoma.
J Thorac Oncol. 2020;15:e52-e53.
PubMed

XU J, Jiang Q, Xu H, Liu A, et al
Two Patients Having NSCLC With Novel Duplication Mutation in Their EGFR Gene (p.I740_K745dupIPVAIK) and Their Response to Osimertinib.
J Thorac Oncol. 2020;15:e49-e51.
PubMed

SOLOMON BJ, Tan L, Lin JJ, Wong SQ, et al
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
J Thorac Oncol. 2020;15:541-549.
PubMed Abstract available

AHN MJ, Chiu CH, Cheng Y, Han JY, et al
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis.
J Thorac Oncol. 2020;15:637-648.
PubMed Abstract available

YAGI Y, Aly RG, Tabata K, Barlas A, et al
Three-Dimensional Histologic, Immunohistochemical, and Multiplex Immunofluorescence Analyses of Dynamic Vessel Co-Option of Spread Through Air Spaces in Lung Adenocarcinoma.
J Thorac Oncol. 2020;15:589-600.
PubMed Abstract available

GUO R, DuBoff M, Jayakumaran G, Kris MG, et al
Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas.
J Thorac Oncol. 2020;15:655-660.
PubMed Abstract available

KIM H, Goo JM, Kim YT, Park CM, et al
Validation of the Eighth Edition Clinical T Categorization System for Clinical Stage IA, Resected Lung Adenocarcinomas: Prognostic Implications of the Ground-Glass Opacity Component.
J Thorac Oncol. 2020;15:580-588.
PubMed Abstract available

RODEN AC, Fang W, Shen Y, Carter BW, et al
Distribution of Mediastinal Lesions Across Multi-Institutional, International, Radiology Databases.
J Thorac Oncol. 2020;15:568-579.
PubMed Abstract available

NOE J, Lovejoy A, Ou SI, Yaung SJ, et al
ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials.
J Thorac Oncol. 2020;15:601-608.
PubMed Abstract available

March 2020

POLVERARI G, Arena V, Ceci F, Pelosi E, et al
(18)F-FDG uptake in Asymptomatic SARS-CoV-2 (COVID-19) patient, referred to PET/CT for Non-Small Cells Lung Cancer restaging.
J Thorac Oncol. 2020 Mar 31. pii: S1556-0864(20)30286.
PubMed

BONOMI L, Ghilardi L, Arnoldi E, Tondini CA, et al
A rapid fatal evolution of Coronavirus Disease-19 (COVID-19) in an advanced lung cancer patient with a long time response to nivolumab.
J Thorac Oncol. 2020 Mar 31. pii: S1556-0864(20)30285.
PubMed

DE SOUZA GUTIERRES B, Aguiar PN Jr, Dourado BB, Alves AL, et al
Evidence Strength of Pharmaceutical Industry Funded Clinical Trials in Metastatic Non-Small Cell Lung Cancer: A Comparison with Other Sources of Funding.
J Thorac Oncol. 2020 Mar 23. pii: S1556-0864(20)30196.
PubMed Abstract available

MEZQUITA L, Jove M, Nadal E, Kfoury M, et al
Brief report: High prevalence of somatic oncogenic driver alterations in non-small cell lung cancer patients with Li-Fraumeni Syndrome.
J Thorac Oncol. 2020 Mar 13. pii: S1556-0864(20)30197.
PubMed Abstract available

PAZ-ARES L, Kim TM, Vicente D, Felip E, et al
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in second-line treatment of patients with non-small cell lung cancer: results from an expansion cohort of a phase 1 trial.
J Thorac Oncol. 2020 Mar 12. pii: S1556-0864(20)30195.
PubMed Abstract available

LURIENNE L, Cervesi J, Duhalde L, de Gunzburg J, et al
Non-small-cell lung cancer immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis.
J Thorac Oncol. 2020 Mar 12. pii: S1556-0864(20)30194.
PubMed Abstract available

LI W, Liu Y, Li W, Chen L, et al
Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in non-small cell lung cancer.
J Thorac Oncol. 2020 Mar 6. pii: S1556-0864(20)30189.
PubMed Abstract available

ZHANG H, Huang Y, Xie C
The Treatment and Outcome of a Lung Cancer Patient Infected with SARS-CoV-2.
J Thorac Oncol. 2020 Mar 5. pii: S1556-0864(20)30191.
PubMed

NG TL, Narasimhan N, Gupta N, Venkatakrishnan K, et al
Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced Non-Small Cell Lung Cancer.
J Thorac Oncol. 2020 Mar 2. pii: S1556-0864(20)30133.
PubMed Abstract available

RAJADURAI P, How SH, Liam CK, Sachithanandan A, et al
Lung Cancer in Malaysia.
J Thorac Oncol. 2020;15:317-323.
PubMed

LI T
Managing the Isolated Central Nervous System Progression in Patients With Oncogene-Driven Metastatic NSCLC: Does Circulating Tumor DNA Add to Management?
J Thorac Oncol. 2020;15:314-316.
PubMed

MACAYA I, Entrialgo-Cadierno R, Valencia K, Vicent S, et al
Liver Kinase B1 (LKB1) Loss Has its p-ERKs: ERK Inactivation as a Vulnerability in NSCLC With LKB1 Mutations.
J Thorac Oncol. 2020;15:311-313.
PubMed

MENIS J, Reck M
Checkpoint Inhibitors in SCLC: How Much Can We Trust in Randomized Cohorts of Phase I/II Trials?
J Thorac Oncol. 2020;15:308-310.
PubMed

DE-RUI HUANG D, Chih-Hsin Yang J
Checkpoint Inhibitor Combined With Tyrosine Kinase Inhibitor-the End or Beginning?
J Thorac Oncol. 2020;15:305-307.
PubMed

ZHANG Q, Jiang T, Xiao M, Zhang J, et al
Identification of a Novel Osimertinib-Sensitive Mutation, EGFR H773L, in a Chinese Patient With NSCLC.
J Thorac Oncol. 2020;15:e46-e48.
PubMed

WANG L, Yao S, Teng L, Zhang W, et al
Melanoregulin-Anaplastic Lymphoma Kinase (ALK), a Novel ALK Rearrangement That Responds to Crizotinib in Lung Adenocarcinoma.
J Thorac Oncol. 2020;15:e44-e46.
PubMed

FUKUDO M, Sasaki T, Ohsaki Y
PD-1 Blockers: Staying Long in the Body and Delayed Toxicity Risks.
J Thorac Oncol. 2020;15:e42-e44.
PubMed

KANEMURA H, Hayashi H, Hagiwara S, Otani T, et al
Severe Immune-Related Hepatitis Treated With Plasma Exchange.
J Thorac Oncol. 2020;15:e39-e42.
PubMed

MAO W, Chen R, Zhang J, Zheng M, et al
TMED2-ALK, a Novel ALK Fusion Gene Identified in a Patient With Lung Adenocarcinoma.
J Thorac Oncol. 2020;15:e37-e39.
PubMed

FANG W, Huang Y, Gan J, Zheng Q, et al
Emergence of EGFR G724S After Progression on Osimertinib Responded to Afatinib Monotherapy.
J Thorac Oncol. 2020;15:e36-e37.
PubMed

FANG W, Huang Y, Gan J, He B, et al
Nintedanib Effect in Osimertinib-Induced Interstitial Pneumonia.
J Thorac Oncol. 2020;15:e34-e35.
PubMed

OH S, Lim JH, Park N, Choi S, et al
Dual Inhibition of EGFR and BRAF Can Be Harmful in Patients Harboring an EGFR-Activating Mutation.
J Thorac Oncol. 2020;15:e32-e34.
PubMed

WANG H, Tian R, Gao P, Wang Q, et al
Tocilizumab for Fulminant Programmed Death 1 Inhibitor-Associated Myocarditis.
J Thorac Oncol. 2020;15:e31-e32.
PubMed

MOLINA-VILA MA, Stahel RA, Dafni U, Jordana-Ariza N, et al
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.
J Thorac Oncol. 2020;15:416-425.
PubMed Abstract available

PELOSI G, Sabella G, Cannone M, Balladore E, et al
Parietal Pleura-Based Malignant Perivascular Epithelioid Cell Neoplasm Protruding Into Serous Cavity: A Hitherto Unrecognized Occurrence.
J Thorac Oncol. 2020;15:462-466.
PubMed

OSAROGIAGBON RU, Faris NR, Stevens W, Fehnel C, et al
Beyond Margin Status: Population-Based Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification Recategorization.
J Thorac Oncol. 2020;15:371-382.
PubMed Abstract available

RUFFINI E, Fang W, Guerrera F, Huang J, et al
The International Association for the Study of Lung Cancer Thymic Tumors Staging Project: The Impact of the Eighth Edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors.
J Thorac Oncol. 2020;15:436-447.
PubMed Abstract available

MIAN I, Abdullaev Z, Morrow B, Kaplan RN, et al
Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma.
J Thorac Oncol. 2020;15:457-461.
PubMed Abstract available

LIU H, Gu Z, Qiu B, Detterbeck FC, et al
A Recurrence Predictive Model for Thymic Tumors and Its Implication for Postoperative Management: a Chinese Alliance for Research in Thymomas Database Study.
J Thorac Oncol. 2020;15:448-456.
PubMed Abstract available

February 2020

TIAN S, Hu W, Niu L, Liu H, et al
Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer.
J Thorac Oncol. 2020 Feb 27. pii: S1556-0864(20)30132.
PubMed Abstract available

CAO P, Jeon J, Levy DT, Jayasekera J, et al
Potential Impact of Cessation Interventions at the Point of Lung Cancer Screening on Lung Cancer and Overall Mortality in the United States.
J Thorac Oncol. 2020 Feb 27. pii: S1556-0864(20)30130.
PubMed Abstract available

ZHANG Y, Zeng L, Zhou C, Li Y, et al
Detection of non-reciprocal/reciprocal ALK translocation as poor predictive marker in first-line crizotinib-treated ALK-rearranged non-small cell lung cancer patients.
J Thorac Oncol. 2020 Feb 26. pii: S1556-0864(20)30129.
PubMed Abstract available

GAO S, Li N, Gao S, Xue Q, et al
Neoadjuvant PD-1 inhibitor (Sintilimab) in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2020 Feb 6. pii: S1556-0864(20)30057.
PubMed Abstract available

BACKMAN M, La Fleur L, Kurppa P, Djureinovic D, et al
Characterization of patterns of immune cell infiltration in non-small cell lung cancer (NSCLC).
J Thorac Oncol. 2020 Feb 3. pii: S1556-0864(20)30015.
PubMed Abstract available

POIRIER JT, George J, Owonikoko TK, Berns A, et al
New approaches to small cell lung cancer therapy : from the laboratory to the clinic.
J Thorac Oncol. 2020 Feb 1. pii: S1556-0864(20)30056.
PubMed Abstract available

JIANG H, Xiao M, Qi C, Cai S, et al
A Novel Oncogenic RET Fusion Variant in Non-Small Cell Lung Cancer: RELCH-RET.
J Thorac Oncol. 2020;15:e27-e28.
PubMed

MATHIAS C, Prado GF, Mascarenhas E, Ugalde PA, et al
Lung Cancer in Brazil.
J Thorac Oncol. 2020;15:170-175.
PubMed

HENDRIKS LEL, Menis J, De Ruysscher DKM, Reck M, et al
Combination of Immunotherapy and Radiotherapy-The Next Magic Step in the Management of Lung Cancer?
J Thorac Oncol. 2020;15:166-169.
PubMed

PUJOL JL, Roch B
Is Darbepoietin Alfa Linked to Mortality During Non-Small Cell Lung Cancer Chemotherapy?
J Thorac Oncol. 2020;15:159-162.
PubMed

SANDS JM, Milan MSD, Oxnard GR
Blood-Based Disease Assessment in SCLC: A Perpetual Proof of Concept or a Clinically Important Tool?
J Thorac Oncol. 2020;15:163-165.
PubMed

JOHKOH T
Take a Look at Clinical Data in Detail, Analyze Them, and Develop a New Diagnostic Method.
J Thorac Oncol. 2020;15:158.
PubMed

LE TALLEC E, Lescoat A, Ballerie A, Cador B, et al
Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus.
J Thorac Oncol. 2020;15:e29-e30.
PubMed

KABBASH MS, Edmund J, Ghafoor A, Hassan R, et al
Intracardiac Involvement by Primary Malignant Mesothelioma: A Report of Two Cases.
J Thorac Oncol. 2020;15:e25-e27.
PubMed

LU R, Qi C, Xiao M, Cai S, et al
STRN3-NTRK1: A Novel NTRK1 Oncogenic Fusion in a Patient with Lung Adenocarcinoma.
J Thorac Oncol. 2020;15:e23-e24.
PubMed

REKHTMAN N, Montecalvo J, Chang JC, Alex D, et al
SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas.
J Thorac Oncol. 2020;15:231-247.
PubMed Abstract available

SUH YJ, Lee HJ, Sung P, Yoen H, et al
A Novel Algorithm to Differentiate Between Multiple Primary Lung Cancers and Intrapulmonary Metastasis in Multiple Lung Cancers With Multiple Pulmonary Sites of Involvement.
J Thorac Oncol. 2020;15:203-215.
PubMed Abstract available

GRAY JE, Villegas A, Daniel D, Vicente D, et al
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.
J Thorac Oncol. 2020;15:288-293.
PubMed Abstract available

January 2020

COHEN D, Hondelink LM, Solleveld-Westerink N, Uljee SM, et al
Optimizing mutation and fusion detection in Non-Small Cell Lung Cancer by sequential DNA and RNA sequencing.
J Thorac Oncol. 2020 Jan 31. pii: S1556-0864(20)30093.
PubMed Abstract available

TRAVIS WD, Dacic S, Wistuba I, Sholl L, et al
IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY.
J Thorac Oncol. 2020 Jan 28. pii: S1556-0864(20)30026.
PubMed Abstract available

DAGOGO-JACK I, Schrock AB, Kem M, Jessop N, et al
Clinicopathologic Characteristics of BRG1-Deficient Non-Small Cell Lung Cancer.
J Thorac Oncol. 2020 Jan 24. pii: S1556-0864(20)30023.
PubMed Abstract available

ARAI S, Takeuchi S, Fukuda K, Taniguchi H, et al
Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer.
J Thorac Oncol. 2020 Jan 20. pii: S1556-0864(20)30022.
PubMed Abstract available

GUISIER F, Dubos-Arvis C, Vinas F, Doubre H, et al
Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced Non Small Cell Lung Cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018.
J Thorac Oncol. 2020 Jan 13. pii: S1556-0864(20)30020.
PubMed Abstract available

CHIH-HSIN YANG J, Schuler M, Popat S, Miura S, et al
Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Database of 693 Cases.
J Thorac Oncol. 2020 Jan 10. pii: S1556-0864(20)30014.
PubMed Abstract available

GAINOR JF, Stevens SE, Willers H, Shih HA, et al
Intracranial Activity of Gefitinib and Capmatinib in a Patient with Previously Treated Non-Small Cell Lung Cancer Harboring a Concurrent EGFR Mutation and MET Amplification.
J Thorac Oncol. 2020;15:e8-e10.
PubMed

WANG X, Lai Y, Dai W, He J, et al
Mutation Profile of Tibetan Lung Cancer Revealed by Whole Exome Sequencing.
J Thorac Oncol. 2020;15:e10-e13.
PubMed

VAN EEDEN R, Tunmer M, Geldenhuys A, Nayler S, et al
Lung Cancer in South Africa.
J Thorac Oncol. 2020;15:22-28.
PubMed

DAVIES KD, Merrick DT
Skipping Expected Mechanisms of MET-Mediated Oncogenesis.
J Thorac Oncol. 2020;15:9-11.
PubMed

SCHOENFELD AJ, Yu HA
The Evolving Landscape of Resistance to Osimertinib.
J Thorac Oncol. 2020;15:18-21.
PubMed

NESTLE U, Adebahr S, van Herk M
Retrospective Analyses of Registry Data for Technical Radiation Oncology Questions: Apples Versus Pears or Solid Evidence?
J Thorac Oncol. 2020;15:15-17.
PubMed

ARULANANDA S, John T
Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush?
J Thorac Oncol. 2020;15:12-14.
PubMed

PENG Y, Zhang L, Zeng T, Liu L, et al
Characterization of Hyperprogression After Immunotherapy in a Lung Adenocarcinoma Patient With Strong Expression of Programmed Death Ligand 1.
J Thorac Oncol. 2020;15:e4-e8.
PubMed

HIRANO S, Hayama N, Tabeta H, Kuroki T, et al
Drastic Response of Rechallenge of Nivolumab in a Patient with NSCLC Who Progressed on the First Nivolumab Treatment.
J Thorac Oncol. 2020;15:e20-e22.
PubMed

VAN TURENHOUT ST, Berghuis M, Snaebjornsson P, Wilgenhof S, et al
Cytomegalovirus in Steroid-Refractory Immune Checkpoint Inhibition-Related Colitis.
J Thorac Oncol. 2020;15:e15-e20.
PubMed

GAUTSCHI O, Menon R, Bertrand M, Murer C, et al
Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma.
J Thorac Oncol. 2020;15:e13-e15.
PubMed

WANG Z, Jia Q, Tang X, Yan L, et al
Transformation to Lung Adenocarcinoma From Complete Remission-Experienced SCLC.
J Thorac Oncol. 2020;15:e1-e3.
PubMed

SCAGLIOTTI G, Moro-Sibilot D, Kollmeier J, Favaretto A, et al
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients.
J Thorac Oncol. 2020;15:80-90.
PubMed Abstract available

BALDACCI S, Figeac M, Antoine M, Descarpentries C, et al
High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study.
J Thorac Oncol. 2020;15:120-124.
PubMed Abstract available

MIKUBO M, Seto K, Kitamura A, Nakaguro M, et al
Calculating the Tumor Nuclei Content for Comprehensive Cancer Panel Testing.
J Thorac Oncol. 2020;15:130-137.
PubMed Abstract available

TAN VS, Correa RJM, Rodrigues GB, Palma DA, et al
Intraluminal Superior Vena Cava Invasion.
J Thorac Oncol. 2020;15:144-145.
PubMed

SCHENK EL, Mandrekar SJ, Dy GK, Aubry MC, et al
A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer
J Thorac Oncol. 2020;15:110-119.
PubMed Abstract available

NICHOLSON AG, Sauter JL, Nowak AK, Kindler HL, et al
EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach.
J Thorac Oncol. 2020;15:29-49.
PubMed Abstract available

December 2019

CHUNG HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, et al
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.
J Thorac Oncol. 2019 Dec 20. pii: S1556-0864(19)33850.
PubMed Abstract available

LANTUEJOUL S, Tsao MS, Cooper WA, Girard N, et al
PD-L1 Testing for Lung Cancer in 2019: Perspective from the IASLC Pathology Committee.
J Thorac Oncol. 2019 Dec 20. pii: S1556-0864(19)33847.
PubMed Abstract available

HWANG JK, Page BJ, Flynn D, Passmore L, et al
Validation of the eighth edition TNM lung cancer staging system; a brief report.
J Thorac Oncol. 2019 Dec 18. pii: S1556-0864(19)33846.
PubMed Abstract available

ALDEA M, Hendriks L, Mezquita L, Jovelet C, et al
Circulating tumor DNA analysis for oncogene-addicted non-small cell lung cancer patients with isolated central nervous system progression.
J Thorac Oncol. 2019 Dec 13. pii: S1556-0864(19)33716.
PubMed Abstract available

WANG Z, Duan J, Wang G, Zhao J, et al
Allele frequency-adjusted blood-based tumor mutational burden as a predictor of overall survival for non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors.
J Thorac Oncol. 2019 Dec 12. pii: S1556-0864(19)33720.
PubMed Abstract available

PARK S, Lee SH, Park K
In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing.
J Thorac Oncol. 2019;14:e279-e280.
PubMed

LUO P, Lin A, Li K, Wei T, et al
DDR Pathway Alteration, Tumor Mutation Burden, and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole Exome and Targeted Gene Sequencing.
J Thorac Oncol. 2019;14:e276-e279.
PubMed

PASSIGLIA F, Calandri M, Guerrera F, Malapelle U, et al
Lung Cancer in Italy.
J Thorac Oncol. 2019;14:2046-2052.
PubMed

PASTORINO U, Tagliabue E
Non-Human Determinants of Lung Cancer Outcome: A Target for Inhibition of Pro-Metastatic Effect of Surgery, Triggered by Postoperative Bacterial Pneumonia.
J Thorac Oncol. 2019;14:2039-2041.
PubMed

November 2019

WILLIAMS GH, Nicholson AG, Snead DRJ, Thunnissen E, et al
Inter-observer Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2019 Nov 25. pii: S1556-0864(19)33664.
PubMed Abstract available

NISHIO M, Felip E, Orlov S, Park K, et al
Final Overall Survival, Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged Non-Small-Cell Lung Cancer.
J Thorac Oncol. 2019 Nov 25. pii: S1556-0864(19)33660.
PubMed Abstract available

LIN SH, Lin Y, Yao L, Kalhor N, et al
Phase II trial of concurrent atezolizumab with chemoradiation in unresectable non-small cell lung cancer.
J Thorac Oncol. 2019 Nov 25. pii: S1556-0864(19)33659.
PubMed Abstract available

HUBER RM, Hansen KH, Paz-Ares Rodriguez L, West HL, et al
Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
J Thorac Oncol. 2019 Nov 19. pii: S1556-0864(19)33645.
PubMed Abstract available

TAN WL, Chua KLM, Lin CC, Lee VHF, et al
Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer.
J Thorac Oncol. 2019 Nov 13. pii: S1556-0864(19)33640.
PubMed Abstract available

EDWARDS JG, Chansky K, van Schil P, Nicholson AG, et al
The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer.
J Thorac Oncol. 2019 Nov 12. pii: S1556-0864(19)33637.
PubMed Abstract available

BROOKS ED, Verma V, Senan S, De Baere T, et al
Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
J Thorac Oncol. 2019 Nov 8. pii: S1556-0864(19)33634.
PubMed Abstract available

SHARMA GG, Cortinovis D, Agustoni F, Arosio G, et al
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.
J Thorac Oncol. 2019;14:e257-e259.
PubMed

LI J, Li C, Cheng B, He J, et al
The Relative Impact of Family History of Different Cancers on Lung Cancer Risk.
J Thorac Oncol. 2019;14:e248-e249.
PubMed

JAZIEH AR, Algwaiz G, Errihani H, Elghissassi I, et al
Lung Cancer in the Middle East and North Africa Region.
J Thorac Oncol. 2019;14:1884-1891.
PubMed

October 2019

LIN JJ, Schoenfeld AJ, Zhu VW, Yeap BY, et al
Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive non-small cell lung cancer refractory to second-generation ALK inhibitors.
J Thorac Oncol. 2019 Oct 26. pii: S1556-0864(19)33573.
PubMed Abstract available

OWONIKOKO TK, Niu H, Nackaerts K, Csoszi T, et al
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for Small-Cell Lung Cancer: Primary and Correlative Biomarker Analyses.
J Thorac Oncol. 2019 Oct 23. pii: S1556-0864(19)33572.
PubMed Abstract available

CAIOLA E, Iezzi A, Tomanelli M, Bonaldi E, et al
LKB1 deficiency renders non-small-cell lung cancer cells sensitive to ERK inhibitors.: ERK inhibitors in LKB1 mutated NSCLC.
J Thorac Oncol. 2019 Oct 18. pii: S1556-0864(19)33568.
PubMed Abstract available

FELIP E, de Braud FG, Maur M, Loong HH, et al
Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small-cell lung cancer: results of an open-label, multicenter, phase 1B study: Ceritinib plus nivolumab in ALK-rearranged NSCLC.
J Thorac Oncol. 2019 Oct 18. pii: S1556-0864(19)33564.
PubMed Abstract available

READY NE, Ott PA, Hellmann MD, Zugazagoitia J, et al
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.
J Thorac Oncol. 2019 Oct 17. pii: S1556-0864(19)33531.
PubMed Abstract available

MOHAN S, Foy V, Ayub M, Leong HS, et al
Profiling of circulating free DNA using targeted and genome wide sequencing in patients with Small Cell Lung Cancer.
J Thorac Oncol. 2019 Oct 16. pii: S1556-0864(19)33566.
PubMed Abstract available

GASCON P, Nagarkar R, Smakal M, Syrigos KN, et al
A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin alfa for Chemotherapy-Induced Anemia in Patients With Advanced Non-Small Cell Lung Cancer.
J Thorac Oncol. 2019 Oct 16. pii: S1556-0864(19)33563.
PubMed Abstract available

HAN D, Heuvelmans MA, van der Aalst CM, van Smoorenburg LH, et al
New Fissure-attached Nodules in Lung Cancer Screening: A Brief Report from The NELSON Study.
J Thorac Oncol. 2019 Oct 10. pii: S1556-0864(19)33521.
PubMed Abstract available

ALMOTLAK AA, Farooqui M, Siegfried JM
Inhibiting pathways predicted from a steroid hormone gene signature yields synergistic anti-tumor effects in non-small cell lung cancer.
J Thorac Oncol. 2019 Oct 10. pii: S1556-0864(19)33523.
PubMed Abstract available

CHIH-HSIN YANG J, Cheng Y, Murakami H, Yang PC, et al
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutation: Final Overall Survival and Biomarker Analysis.
J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33332.
PubMed

ZUGAZAGOITIA J, Liu Y, Toki M, McGuire J, et al
Quantitative assessment of CMTM6 in the tumor microenvironment and association with response to PD-1 pathway blockade in advanced-stage non-small-cell lung cancer.
J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33342.
PubMed Abstract available

WELSH JW, Heymach JV, Chen D, Verma V, et al
Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer.
J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33525.
PubMed Abstract available

BROWN H, Vansteenkiste J, Nakagawa K, Cobo M, et al
Brief Report: Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced Non-Small Cell Lung Cancer and Response to Osimertinib versus Comparator in FLAURA.
J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33334.
PubMed Abstract available

SANCHIS-BORJA M, Parrot A, Sroussi D, Rivin Del Campo E, et al
Dramatic Radiation Recall Pneumonitis Induced by Osimertinib after Palliative Thoracic Radiotherapy for Lung Cancer.
J Thorac Oncol. 2019;14:e224-e226.
PubMed

GUAN R, Lin A, Luo P, Zhang J, et al
Association between Circulating Inflammatory Proteins and Clinical Prognosis in Chinese Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer.
J Thorac Oncol. 2019;14:e222-e224.
PubMed

ARRIETA O, Zatarain-Barron ZL, Aldaco F, Barron F, et al
Lung Cancer in Mexico.
J Thorac Oncol. 2019;14:1695-1700.
PubMed

GRANNIS FW JR
Lung Cancer Incidence and Mortality with Extended Follow-up during Screening.
J Thorac Oncol. 2019;14:1692-1694.
PubMed

September 2019

HSU CC, Liao BC, Liao WY, Markovets A, et al
Exon-16-skipping HER2 as a novel mechanism of osimertinib-resistance in EGFR L858R/T790M-positive non-small-cell lung cancer.
J Thorac Oncol. 2019 Sep 23. pii: S1556-0864(19)33307.
PubMed Abstract available

GAGNE A, Wang E, Bastien N, Orain M, et al
Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Guidelines.
J Thorac Oncol. 2019 Sep 5. pii: S1556-0864(19)33186.
PubMed Abstract available

FANG W, Huang Y, Gan J, Hong S, et al
A Patient with EGFR Exon 20 Insertion-Mutant Non-Small Cell Lung Cancer Responded to Osimertinib plus Cetuximab Combination Therapy.
J Thorac Oncol. 2019;14:e201-e202.
PubMed

BUROTTO M, Aren O, Renner A, Samtani S, et al
Lung Cancer in Chile.
J Thorac Oncol. 2019;14:1504-1509.
PubMed

ARENBERG D
Micronodules Detected on Lung Cancer Screening CT Scans.
J Thorac Oncol. 2019;14:1501-1503.
PubMed

August 2019

MORENO AC, Fellman B, Hobbs BP, Liao Z, et al
Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients with Early-Stage Non-Small Cell Lung Cancer.
J Thorac Oncol. 2019 Aug 31. pii: S1556-0864(19)33191.
PubMed Abstract available

GILL RR, Tsao AS, Kindler HL, Richards WG, et al
Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Me
J Thorac Oncol. 2019 Aug 27. pii: S1556-0864(19)30695.
PubMed Abstract available

SEN T, Della Corte CM, Milutinovic S, Cardnell RJ, et al
Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer.
J Thorac Oncol. 2019 Aug 27. pii: S1556-0864(19)30692.
PubMed Abstract available

OHUE Y, Kurose K, Karasaki T, Isobe M, et al
Serum Antibody against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-PD-1 Therapy in Non-Small-Cell Lung Cancer.
J Thorac Oncol. 2019 Aug 23. pii: S1556-0864(19)30691.
PubMed Abstract available

HORN L, Whisenant JG, Wakelee H, Reckamp KL, et al
Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer.
J Thorac Oncol. 2019 Aug 22. pii: S1556-0864(19)30665.
PubMed Abstract available

PARK BJ, Kim TH, Shin S, Kim HK, et al
Recommended change in the N descriptor proposed by the International Association for the Study of Lung Cancer: a validation study.
J Thorac Oncol. 2019 Aug 20. pii: S1556-0864(19)30670.
PubMed Abstract available

SPAGGIARI L, Sedda G, Maisonneuve P, Tessitore A, et al
A brief report on survival after robotic lobectomy for early-stage lung cancer.
J Thorac Oncol. 2019 Aug 19. pii: S1556-0864(19)30666.
PubMed Abstract available

FU F, Zhang Y, Wen Z, Zheng D, et al
Distinct prognostic factors in patients with stage I non-small cell lung cancer with radiologic part solid or solid lesions.
J Thorac Oncol. 2019 Aug 19. pii: S1556-0864(19)30664.
PubMed Abstract available

DINGEMANS AC, Hendriks LEL, Berghmans T, Levy A, et al
Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report.
J Thorac Oncol. 2019 Aug 6. pii: S1556-0864(19)30655.
PubMed Abstract available

GOWING SD, Chow SC, Cools-Lartigue JJ, Chen CB, et al
Gram-Negative Pneumonia Augments Non-Small Cell Lung Cancer Metastasis Through Host Toll-like Receptor 4 Activation.
J Thorac Oncol. 2019 Aug 2. pii: S1556-0864(19)30653.
PubMed Abstract available

STIRLING R, Zalcberg J
Peeling the Onion of Health Care Disparity in Lung Cancer.
J Thorac Oncol. 2019;14:e167-e168.
PubMed

JAIN A, Fujioka N, Patel M
Immune Checkpoint Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer: A Report of Two Cases.
J Thorac Oncol. 2019;14:e165-e167.
PubMed

WATANABE Y, Kikuchi R, Iwai Y, Ito M, et al
Varicella Zoster Virus Encephalitis Mimicking Nivolumab-Induced Autoimmune Neuropathy in a Patient with Lung Cancer.
J Thorac Oncol. 2019;14:e163-e165.
PubMed

ZHOU H, Liu J, Zhang Y, Huang Y, et al
Autoimmune Diseases and Lung Cancer: A Mendelian Randomization Study.
J Thorac Oncol. 2019;14:e161-e163.
PubMed

ZWITTER M, Cufer T, Vrankar M, Kern I, et al
Lung Cancer in Slovenia.
J Thorac Oncol. 2019;14:1327-1331.
PubMed

BERNICKER EH, Quigley EMM
The Gut Microbiome Influences Responses to Programmed Death 1 Therapy in Chinese Lung Cancer Patients - the Benefits of Diversity.
J Thorac Oncol. 2019;14:1319-1322.
PubMed

GAY CM, Byers LA
PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?
J Thorac Oncol. 2019;14:1323-1326.
PubMed

July 2019

MAKIMOTO G, Ohashi K, Tomida S, Nishii K, et al
Brief Report: Rapid Acquisition of Alectinib Resistance in ALK-positive Lung Cancer with High Tumor Mutation Burden.
J Thorac Oncol. 2019 Jul 30. pii: S1556-0864(19)30602.
PubMed Abstract available

YANG SC, Kuo CW, Lai WW, Lin CC, et al
Dynamic Changes of Health Utility in Lung Cancer Patients Receiving Different Treatments: A 7-Year Follow-up.
J Thorac Oncol. 2019 Jul 25. pii: S1556-0864(19)30588.
PubMed Abstract available

CONDE E, Hernandez S, Martinez R, Angulo B, et al
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study.
J Thorac Oncol. 2019 Jul 23. pii: S1556-0864(19)30562.
PubMed Abstract available

EDELMAN MJ, Redman MW, Albain KS, McGary EC, et al
Brief Report: SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study).
J Thorac Oncol. 2019 Jul 11. pii: S1556-0864(19)30557.
PubMed Abstract available

BENITEZ JC, Mezquita L, Colle R, Tselikas KL, et al
Hepatic Intra-Arterial Chemotherapy with Immunotherapy in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2019 Jul 11. pii: S1556-0864(19)30556.
PubMed

FUJINO T, Kobayashi Y, Suda K, Koga T, et al
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.
J Thorac Oncol. 2019 Jul 3. pii: S1556-0864(19)30551.
PubMed Abstract available

CANEPA M, Patel NR, Griffith RC, Ng TT, et al
KRAS Mutation for Staging Resected Non-Small Cell Lung Cancer.
J Thorac Oncol. 2019;14:e153-e155.
PubMed

WANG H, Zhang L, Liu W
Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer.
J Thorac Oncol. 2019;14:e141-e143.
PubMed

HO C, Lefresne S, Liberman M, McGuire A, et al
Lung Cancer in Canada.
J Thorac Oncol. 2019;14:1128-1133.
PubMed

FOSTER CC, Pitroda SP, Weichselbaum RR
Beyond Palliation: The Rationale for Metastasis-Directed Therapy for Metastatic Non-Small Cell Lung Cancer.
J Thorac Oncol. 2019 Jul 1. pii: S1556-0864(19)30410.
PubMed

REKHTMAN N, Travis WD
Large No More: The Journey of Pulmonary Large Cell Carcinoma from Common to Rare Entity.
J Thorac Oncol. 2019;14:1125-1127.
PubMed

LAI WV, Rudin CM
Analyzing the Thin Tail: Searching for Biomarkers of Exceptional Survival in SCLC.
J Thorac Oncol. 2019;14:1122-1124.
PubMed

KOUNO S, Atagi S
Immunotherapy for NSCLC With Brain Metastases: What Can We Learn From Real-World Data?
J Thorac Oncol. 2019;14:1119-1121.
PubMed

June 2019

BAUER TM, Besse B, Martinez-Marti A, Trigo JM, et al
Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer.
J Thorac Oncol. 2019 Jun 28. pii: S1556-0864(19)30503.
PubMed Abstract available

NAITO T, Udagawa H, Sato J, Horinouchi H, et al
A minimum of 100 tumor cells in a single biopsy sample is required to assess programmed cell death ligand 1 expression in predicting patient response to nivolumab treatment in non-squamous non-small cell lung carcinoma.
J Thorac Oncol. 2019 Jun 28. pii: S1556-0864(19)30501.
PubMed Abstract available

CHAE YK, Viveiros P, Lopes G, Sukhadia B, et al
Clinical and immunological implications of frameshift mutations in lung cancer.
J Thorac Oncol. 2019 Jun 22. pii: S1556-0864(19)30496.
PubMed Abstract available

MUNDEN RF, Chiles C, Boiselle PM, Sicks JD, et al
Micronodules Detected on CT during the NLST: Prevalence and Relation to Positive Studies and Lung Cancer.
J Thorac Oncol. 2019 Jun 20. pii: S1556-0864(19)30481.
PubMed Abstract available

GUO R, Berry LD, Aisner DL, Sheren J, et al
MET IHC is a Poor Screen for MET Amplification or MET exon 14 mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
J Thorac Oncol. 2019 Jun 19. pii: S1556-0864(19)30474.
PubMed Abstract available

BALATA H, Fong KM, Hendriks LE, Lam S, et al
Prevention and Early Detection for Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
J Thorac Oncol. 2019 Jun 19. pii: S1556-0864(19)30476.
PubMed Abstract available

BLACK WC, Chiles C, Church TR, Gareen IF, et al
Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial National Lung Screening Trial Writing Team (1).
J Thorac Oncol. 2019 Jun 13. pii: S1556-0864(19)30473.
PubMed Abstract available

IAMS WT, Shiuan E, Meador CB, Roth M, et al
Improved prognosis and increased tumor infiltrating lymphocytes in small cell lung cancer patients with neurologic paraneoplastic syndromes.
J Thorac Oncol. 2019 Jun 12. pii: S1556-0864(19)30463.
PubMed Abstract available

AGGARWAL C, Redman MW, Lara PN Jr, Borghaei H, et al
Brief Report: SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously-treated Patients with Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30462.
PubMed Abstract available

KIM Y, Kim CH, Lee HY, Lee SH, et al
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor.
J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30454.
PubMed Abstract available

LAIRD J, Lok BH, Carney B, Kossatz S, et al
PET Imaging of a [(18)F]-radiolabeled PARP Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in Small Cell Lung Cancer Patient-Derived Xenografts.
J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30453.
PubMed Abstract available

GIAJLEVRA N, Levra MG, Durieux V, Novello S, et al
Defining synchronous oligometastatic non-small cell lung cancer: a systematic review.
J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30458.
PubMed Abstract available

GONG L, Qin J, Xie F, Han N, et al
The Evolutionary Difference Between Extracranial Lesions and Leptomeningeal Metastasis in a Patient With Afatinib-Resistant Lung Cancer.
J Thorac Oncol. 2019;14:e120-e123.
PubMed

JAZIEH AR, Algwaiz G, Alshehri SM, Alkattan K, et al
Lung Cancer in Saudi Arabia.
J Thorac Oncol. 2019;14:957-962.
PubMed

ADJEI AA
Lung Cancer Worldwide.
J Thorac Oncol. 2019;14:956.
PubMed

MILLER AB
Improving Surveillance following Treatment for Lung Cancer.
J Thorac Oncol. 2019;14:955.
PubMed

RUTKOWSKI J, Saad ED, Burzykowski T, Buyse M, et al
Chronological Trends in Progression-free, Overall and Post-progression Survival in First-line Therapy for Advanced Non-small-cell Lung Cancer.
J Thorac Oncol. 2019 Jun 1. pii: S1556-0864(19)30415.
PubMed Abstract available

SHEPSHELOVICH D, Xu W, Lu L, Fares A, et al
Body mass index (BMI), BMI change, and overall survival in small cell and non-small cell lung cancer patients: a pooled analysis of the International Lung Cancer Consortium.
J Thorac Oncol. 2019 Jun 1. pii: S1556-0864(19)30416.
PubMed Abstract available

HANDRA-LUCA A
Alveolar Septa Muscle: Subclinical Pulmonary Hypertension-Related Change or Malformation?
J Thorac Oncol. 2019;14:e124-e125.
PubMed

ROTHSCHILD SI
KRAS and Immune Checkpoint Inhibitors-Serendipity Raising Expectations.
J Thorac Oncol. 2019;14:951-954.
PubMed

May 2019

LANGER CJ, Redman MW, Wade JL 3rd, Aggarwal C, et al
Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
J Thorac Oncol. 2019 May 31. pii: S1556-0864(19)30414.
PubMed Abstract available

PARK S, Lee H, Lee B, Lee SH, et al
DNA Damage Response and Repair Pathway Alteration and Its Association with Tumor Mutation Burden and Platinum-Based Chemotherapy in Small Cell Lung Cancer.
J Thorac Oncol. 2019 May 21. pii: S1556-0864(19)30381.
PubMed Abstract available

GOMEZ DR, Rimner A, Simone CB 2nd, Cho BCJ, et al
The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applie
J Thorac Oncol. 2019 May 21. pii: S1556-0864(19)30380.
PubMed Abstract available

SPIGEL DR, McCleod M, Jotte RM, Einhorn L, et al
Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged >/=70 Years or with Poor Performance Status (CheckMate 153).
J Thorac Oncol. 2019 May 20. pii: S1556-0864(19)30376.
PubMed Abstract available

LEE Y, Kim TM, Kim DW, Kim S, et al
Pre-clinical Modeling of Osimertinib for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
J Thorac Oncol. 2019 May 17. pii: S1556-0864(19)30369.
PubMed Abstract available

FLIPPOT R, Biondani P, Auclin E, Xiao D, et al
Activity of epidermal growth factor tyrosine kinase inhibitors in non-small cell lung carcinoma with refractory leptomeningeal metastases.
J Thorac Oncol. 2019 May 17. pii: S1556-0864(19)30370.
PubMed Abstract available

MURPHY SJ, Harris FR, Kosari F, Terra S, et al
Using genomics to differentiate multiple primaries from metastatic lung cancer.
J Thorac Oncol. 2019 May 16. pii: S1556-0864(19)30374.
PubMed Abstract available

MUPPA P, Parrilha Terra SB, Sharma A, Mansfield AS, et al
Immune Cell Infiltration May be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer.
J Thorac Oncol. 2019 May 9. pii: S1556-0864(19)30356.
PubMed Abstract available

TREMBLAY A, Taghizadeh N, Huang J, Kasowski D, et al
A Randomized Controlled Study of Integrated Smoking Cessation in a Lung Cancer Screening Program.
J Thorac Oncol. 2019 May 8. pii: S1556-0864(19)30359.
PubMed Abstract available

CANNON-ALBRIGHT LA, Carr SR, Akerley W
Population-based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer.
J Thorac Oncol. 2019 May 7. pii: S1556-0864(19)30316.
PubMed Abstract available

VARGHESE C, Rajagopalan S, Karwoski RA, Bartholmai BJ, et al
Computed Tomography based Score Indicative of Lung Cancer Aggression (SILA) Predicts the Degree of Histological Tissue Invasion and Patient Survival in Lung Adenocarcinoma Spectrum.
J Thorac Oncol. 2019 May 4. pii: S1556-0864(19)30355.
PubMed Abstract available

THOMAS A, Vilimas R, Trindade C, Erwin-Cohen R, et al
Durvalumab in Combination with Olaparib in Patients with Relapsed Small Cell Lung Cancer: Results from a Phase II Study.
J Thorac Oncol. 2019 May 4. pii: S1556-0864(19)30361.
PubMed Abstract available

KATSUMATA S, Aokage K, Ishii G, Nakasone S, et al
Prognostic impact of the number of metastatic lymph nodes on the eighth edition of the TNM classification of non-small cell lung cancer.
J Thorac Oncol. 2019 May 2. pii: S1556-0864(19)30313.
PubMed Abstract available

MEHLMAN C, Chaabane N, Lacave R, Kerrou K, et al
Ceritinib ALK T1151R Resistance Mutation in Lung Cancer With Initial Response to Brigatinib.
J Thorac Oncol. 2019;14:e95-e96.
PubMed

ZHANG J, Wang J, Qian Z, Han Y, et al
CCR5 is Associated With Immune Cell Infiltration and Prognosis of Lung Cancer.
J Thorac Oncol. 2019;14:e102-e103.
PubMed

AHN MJ
Combination of Osimertinib with Durvalumab in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: Is There Room for Reinvestigation?
J Thorac Oncol. 2019;14:766-767.
PubMed

CHIAPPETTA M, Petracca Ciavarella L, Margaritora S
Can Pemetrexed Also Have a Potential Role Preoperatively in the Management of Advanced Thymic Epithelial Tumors?
J Thorac Oncol. 2019;14:e89.
PubMed

MITSUDOMI T
BRAF Fusion - Another Mechanism of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors.
J Thorac Oncol. 2019;14:764-765.
PubMed

GROEN HJM, Hiltermann TJN
Air Pollution and Adenocarcinoma in Never-Smokers.
J Thorac Oncol. 2019;14:761-763.
PubMed

DAVIES KD, Villalobos VM, Aisner DL
Ready or Not, Here I Come: Inflammatory Myofibroblastic Tumors With Kinase Alterations Revealed Through Molecular Hide and Seek.
J Thorac Oncol. 2019;14:758-760.
PubMed

April 2019

JIN Y, Dong H, Xia L, Yang Y, et al
The diversity of gut microbiome is associated with favorable responses to anti-PD-1 immunotherapy in Chinese non-small cell lung cancer patients.
J Thorac Oncol. 2019 Apr 23. pii: S1556-0864(19)30286.
PubMed Abstract available

REMON J, Reguart N, Auclin E, Besse B, et al
Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy?
J Thorac Oncol. 2019 Apr 23. pii: S1556-0864(19)30202.
PubMed

HUNG RJ, Spitz MR, Houlston RS, Schwartz AG, et al
Lung Cancer Risk in Never Smokers of European Descent is Associated with Genetic Variation in the 5P15.33 TERT-CLPTM1L Region.
J Thorac Oncol. 2019 Apr 19. pii: S1556-0864(19)30289.
PubMed Abstract available

DAI J, Liu M, Yang Y, Li Q, et al
Optimal Lymph Nodes Examination and Adjuvant Chemotherapy for Stage I Lung Cancer.
J Thorac Oncol. 2019 Apr 19. pii: S1556-0864(19)30290.
PubMed Abstract available

MANOHARAN P, Salem A, Mistry H, Gornall M, et al
[18F]fludeoxyglucose PET/CT in small-cell lung cancer: Analysis of the CONVERT randomized controlled trial.
J Thorac Oncol. 2019 Apr 16. pii: S1556-0864(19)30282.
PubMed Abstract available

REMON J, Ahn MJ, Girard N, Johnson M, et al
Advanced Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
J Thorac Oncol. 2019 Apr 16. pii: S1556-0864(19)30280.
PubMed Abstract available

SORICH MJ, Rowland A, Karapetis CS, Hopkins AM, et al
Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for non-small cell lung cancer: pooled analysis of clinical trials.
J Thorac Oncol. 2019 Apr 15. pii: S1556-0864(19)30285.
PubMed Abstract available

MICHELS S, Massuti B, Schildhaus HU, Franklin J, et al
Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial.
J Thorac Oncol. 2019 Apr 9. pii: S1556-0864(19)30276.
PubMed Abstract available

KRATZ JR, Haro GJ, Cook NR, He J, et al
Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.
J Thorac Oncol. 2019 Apr 5. pii: S1556-0864(19)30270.
PubMed Abstract available

MEANEY C, Mitchell KA, Zingone A, Brown D, et al
Circulating Inflammation Proteins Associated with Lung Cancer in African Americans.
J Thorac Oncol. 2019 Apr 3. pii: S1556-0864(19)30269.
PubMed Abstract available

LI C, Liang H, Zhong N, He J, et al
Optimal Starting Age for Lung Cancer Screening With Low-Dose Computed Tomography: A Population Level Analysis.
J Thorac Oncol. 2019;14:e82-e84.
PubMed

QIN J, Wang J, Lin X, Wang J, et al
Erlotinib Resistance with EGFR L858R/Y891D Double Mutation in a Patient with Non-Small Cell Lung Cancer.
J Thorac Oncol. 2019;14:e65-e68.
PubMed

ARJYAL L
Concurrent Chemoradiation in Elderly Patients with Limited-Stage Small Cell Lung Cancer.
J Thorac Oncol. 2019;14:e63.
PubMed

LU S, Li Z
Rethinking Our Approach of Combining Novel Agents With Standard Chemotherapy in Small Cell Lung Cancer.
J Thorac Oncol. 2019;14:580-582.
PubMed

WANG Z, Wu YL
Re-emerging C797S In Trans and Rechallenge of Osimertinib With Erlotinib.
J Thorac Oncol. 2019;14:e81-e82.
PubMed

CHRISTODOULOU M, Faivre-Finn C
Author's Reply to the: Letter to the Editor.
J Thorac Oncol. 2019;14:e63-e64.
PubMed

MACKINTOSH JA, Marshall HM, Fong KM
A Targeted Approach to the Complications of Targeted Therapy.
J Thorac Oncol. 2019;14:577-579.
PubMed

MOLNAR TF, Szipocs A, Szalai Z
Neoadjuvant Crizotinib for ALK Re-arranged NSCLC?
J Thorac Oncol. 2019;14:574-576.
PubMed

March 2019

BOUSEMA JE, van Dorp M, Noyez VJJM, Dijkgraaf MGW, et al
Unforeseen N2 disease following negative endosonography with or without confirmatory mediastinoscopy in resectable non-small cell lung cancer: a systematic review and meta-analysis.
J Thorac Oncol. 2019 Mar 21. pii: S1556-0864(19)30211.
PubMed

CAMIDGE DR, Dziadziuszko R, Peters S, Mok T, et al
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study.
J Thorac Oncol. 2019 Mar 19. pii: S1556-0864(19)30210.
PubMed Abstract available

OSAROGIAGBON RU, Veronesi G, Fang W, Ekman S, et al
Early Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
J Thorac Oncol. 2019 Mar 6. pii: S1556-0864(19)30199.
PubMed Abstract available

LEE J, Maeng CH, Song JU
The Role of Prophylactic Cranial Irradiation in Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
J Thorac Oncol. 2019;14:e60-e61.
PubMed

KOGURE Y, Ishii Y, Oki M
Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.
J Thorac Oncol. 2019;14:e55-e57.
PubMed

LAM S
Lung Cancer Screening in Never-Smokers.
J Thorac Oncol. 2019;14:336-337.
PubMed

FERRARA R, Caramella C, Besse B, Champiat S, et al
Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?
J Thorac Oncol. 2019;14:328-331.
PubMed

RAMAEKERS B, De Ruysscher D
Quality of Life After Stereotactic Radiotherapy for Early-Stage Lung Cancer: Mission Accomplished?
J Thorac Oncol. 2019;14:326-327.
PubMed

BUCKNELL NW, Ball D
PCI in Small Cell-Review the Cohorts.
J Thorac Oncol. 2019;14:e59-e60.
PubMed

RIHAWI K, Giannarelli D, Galetta D, Delmonte A, et al
BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience.
J Thorac Oncol. 2019;14:e57-e59.
PubMed

LE T, Minna JD, Gerber DE
Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?
J Thorac Oncol. 2019;14:332-335.
PubMed

February 2019

DZIADZIUSZKO R, Smit EF, Dafni U, Wolf J, et al
Afatinib in non-small cell lung cancer with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP).
J Thorac Oncol. 2019 Feb 27. pii: S1556-0864(19)30148.
PubMed Abstract available

SHUKUYA T, Yamada T, Koenig MJ, Xu J, et al
The effect of LKB1 activity on the sensitivity to PI3K/mTOR inhibition in non-small cell lung cancer.
J Thorac Oncol. 2019 Feb 27. pii: S1556-0864(19)30150.
PubMed Abstract available

CAMIDGE DR, Kim EE, Usari T, Polli A, et al
Renal Effects of Crizotinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer.
J Thorac Oncol. 2019 Feb 26. pii: S1556-0864(19)30146.
PubMed Abstract available

HENDRIKS LEL, Henon C, Auclin E, Mezquita L, et al
Outcome of non-small cell lung cancer patients with brain metastases treated with checkpoint inhibitors.
J Thorac Oncol. 2019 Feb 16. pii: S1556-0864(19)30117.
PubMed Abstract available

NEGRAO MV, Lam VK, Reuben A, Rubin ML, et al
PD-L1 expression, tumor mutational burden and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer.
J Thorac Oncol. 2019 Feb 16. pii: S1556-0864(19)30116.
PubMed Abstract available

LIZEE T, Basch E, Tremolieres P, Voog E, et al
Cost-effectiveness of web-based patient-reported outcome surveillance in lung cancer patients.
J Thorac Oncol. 2019 Feb 15. pii: S1556-0864(19)30113.
PubMed Abstract available

AGGARWAL R, Lam AC, McGregor M, Menezes R, et al
Outcomes of Long-term Interval Rescreening with Low-Dose CT for Lung Cancer in Different Risk Cohorts.
J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30112.
PubMed Abstract available

HSU WH, Zhao X, Zhu J, Kim IK, et al
Chk1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in small cell lung cancer by promoting mitotic cell death.
J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30108.
PubMed Abstract available

LEE JW, Zhang Y, Eoh KJ, Sharma R, et al
The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30111.
PubMed Abstract available

ZIMMERMAN S, Das A, Wang S, Julian R, et al
2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer.
J Thorac Oncol. 2019 Feb 11. pii: S1556-0864(19)30099.
PubMed Abstract available

JEANSON A, Tomasini P, Souquet-Bressand M, Brandone N, et al
Brief report: efficacy of immune checkpoint inhibitors in KRAS-mutant Non-small cell lung cancer (NSCLC).
J Thorac Oncol. 2019 Feb 6. pii: S1556-0864(19)30040.
PubMed Abstract available

EL OSTA B, Behera M, Kim S, Berry LD, et al
Characteristics and outcomes of patients with metastatic KRAS mutant lung adenocarcinomas: The Lung Cancer Mutation Consortium experience.
J Thorac Oncol. 2019 Feb 5. pii: S1556-0864(19)30097.
PubMed Abstract available

ZHAO X, Kallakury B, Chahine JJ, Hartmann D, et al
Surgical resection of small cell lung carcinoma: prognostic factors and the tumor microenvironment.
J Thorac Oncol. 2019 Feb 5. pii: S1556-0864(19)30096.
PubMed Abstract available

IJSSELDIJK MA, Shoni M, Siegert C, Wiering BM, et al
Survival after SBRT for Clinically diagnosed or Biopsy-proven Early-stage Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
J Thorac Oncol. 2019 Feb 2. pii: S1556-0864(19)30094.
PubMed Abstract available

TABBO F, D'Aveni A, Tota D, Pignataro D, et al
Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase-Positive Lung Cancer Patient: Adverse Event or Disease Spread?
J Thorac Oncol. 2019;14:e38-e40.
PubMed

VARKARIS A, Sehgal K, Rangachari D, Costa DB, et al
Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer.
J Thorac Oncol. 2019;14:e34-e36.
PubMed

WATANABE K, Kage H, Shinozaki-Ushiku A, Kohsaka S, et al
Spontaneous Transdifferentiation from Small Cell Lung Carcinoma to Squamous Cell Carcinoma.
J Thorac Oncol. 2019;14:e31-e34.
PubMed

BOGART JA, Mix M
Management of the Brain in Small Cell Lung Cancer: Are Patients Paying a Lot Now Instead of a Little Later?
J Thorac Oncol. 2019;14:153-156.
PubMed

TSOU TC, Gowen K, Ali SM, Miller VA, et al
Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion.
J Thorac Oncol. 2019;14:e29-e30.
PubMed

GOLDMAN JW, Garon EB
Nivolumab in Previously Treated SCLC: Encouraging, but Still Awaiting the Complete Story.
J Thorac Oncol. 2019;14:160-162.
PubMed

CARBONE M, Yang H, Gaudino G
Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?
J Thorac Oncol. 2019;14:157-159.
PubMed

January 2019

KIM ES, Roy UB, Ersek JL, King J, et al
Updates Regarding Biomarker Testing for Non-Small Cell Lung Cancer: Considerations from the National Lung Cancer Roundtable.
J Thorac Oncol. 2019 Jan 29. pii: S1556-0864(19)30003.
PubMed

RECK M, Horn L, Novello S, Barlesi F, et al
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small-Cell Lung Cancer.
J Thorac Oncol. 2019 Jan 21. pii: S1556-0864(19)30029.
PubMed Abstract available

TSENG CH, Tsuang BJ, Chiang CJ, Ku KC, et al
The relationship between air pollution and lung cancer in non-smokers in Taiwan.
J Thorac Oncol. 2019 Jan 18. pii: S1556-0864(19)30026.
PubMed Abstract available

DAGOGO-JACK I, Rooney M, Nagy RJ, Lin JJ, et al
Molecular Analysis of Plasma from Patients with ROS1-Positive Non-Small Cell Lung Cancer.
J Thorac Oncol. 2019 Jan 18. pii: S1556-0864(19)30027.
PubMed Abstract available

PUJOL JL, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al
A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT-1603 Trial.
J Thorac Oncol. 2019 Jan 18. pii: S1556-0864(19)30025.
PubMed Abstract available

DAGOGO-JACK I, Robinson H, Mino-Kenudson M, Farago AF, et al
Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients with Minimal Smoking History.
J Thorac Oncol. 2019 Jan 17. pii: S1556-0864(19)30024.
PubMed Abstract available

WU YL, Lu S, Cheng Y, Zhou C, et al
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer: CheckMate 078 Randomized Phase III Clinical Trial.
J Thorac Oncol. 2019 Jan 16. pii: S1556-0864(19)30020.
PubMed Abstract available

QUINTANAL-VILLALONGA A, Molina-Pinelo S, Cirauqui C, Ojeda-Marquez L, et al
FGFR1 cooperates with EGFR in lung cancer oncogenesis, and their combined inhibition shows improved efficacy.
J Thorac Oncol. 2019 Jan 9. pii: S1556-0864(19)30008.
PubMed Abstract available

DAVIES KD, Lomboy A, Lawrence CA, Yourshaw M, et al
Brief Report: DNA-based versus RNA-based detection of MET exon 14 skipping events in lung cancer.
J Thorac Oncol. 2019 Jan 9. pii: S1556-0864(19)30007.
PubMed Abstract available

LU S, Yu Y, Li Z, Yu R, et al
Brief Report: EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer.
J Thorac Oncol. 2019 Jan 2. pii: S1556-0864(18)33515.
PubMed Abstract available

LEE YL, Hsu JF, Yang CJ
Tracheoesophageal Fistula in a Patient with Advanced Non-Small Cell Lung Cancer Who Received Chemoradiotherapy and Ramucirumab.
J Thorac Oncol. 2019;14:e17-e18.
PubMed

VAN LOON J, Dingemans AC
Is Concurrent Chemoradiotherapy Also the Best Treatment for Elderly Patients with Limited-Stage Small Cell Lung Cancer? - What the CONVERT Data Can Tell Us.
J Thorac Oncol. 2019;14:13-15.
PubMed

ABADA PB
Tracheoesophageal Fistula in a Patient With Advanced NSCLC Who Received Chemoradiotherapy and Ramucirumab.
J Thorac Oncol. 2019;14:e19.
PubMed

DRESLER C, Warren GW, Arenberg D, Yang P, et al
Indeed, Nuance Matters.
J Thorac Oncol. 2019;14:e16-e17.
PubMed

STIEFEL F, Bourquin C
Nuance Matters.
J Thorac Oncol. 2019;14:e15.
PubMed

MCCOACH CE
A Cautionary Analysis of Immunotherapy Prior to Targeted Therapy.
J Thorac Oncol. 2019;14:8-10.
PubMed

DAVID EA, Atay SM, McFadden PM, Kim AW, et al
Sublobar or Suboptimal: Does Tumor Spread through Air Spaces Signify the End of Sublobar Resections for T1N0 Adenocarcinomas?
J Thorac Oncol. 2019;14:11-12.
PubMed

December 2018

PACHECO JM, Gao D, Smith D, Purcell WT, et al
Natural history and factors associated with overall survival in stage IV ALK rearranged non-small-cell lung cancer.
J Thorac Oncol. 2018 Dec 29. pii: S1556-0864(18)33533.
PubMed Abstract available

YATABE Y, Dacic S, Borczuk AC, Warth A, et al
Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.
J Thorac Oncol. 2018 Dec 17. pii: S1556-0864(18)33514.
PubMed Abstract available

IAMS WT, Beckermann KE, Almodovar K, Hernandez J, et al
Small cell lung cancer transformation as a mechanism of resistance to PD-1 therapy in KRAS mutant lung adenocarcinoma: A report of two cases.
J Thorac Oncol. 2018 Dec 10. pii: S1556-0864(18)33511.
PubMed

SEIJO LM, Peled N, Ajona D, Boeri M, et al
Biomarkers in lung cancer screening: achievements, promises and challenges.
J Thorac Oncol. 2018 Dec 4. pii: S1556-0864(18)33501.
PubMed Abstract available

YANG JC, Gadgeel SM, Sequist LVD, Wu CL, et al
Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Sensitizing EGFR Mutation.
J Thorac Oncol. 2018 Dec 4. pii: S1556-0864(18)33506.
PubMed Abstract available

November 2018

HECHTNER M, Eichler M, Wehler B, Buhl R, et al
Quality of life in Non-Small Cell Lung Cancer survivors - a multicenter cross-sectional study.
J Thorac Oncol. 2018 Nov 30. pii: S1556-0864(18)33497.
PubMed Abstract available

SURESH K, Psoter KJ, Voong KR, Shankar B, et al
Impact of Checkpoint Inhibitor Pneumonitis on Survival in Non-Small Cell Lung Cancer Patients receiving Immune Checkpoint Immunotherapy.
J Thorac Oncol. 2018 Nov 29. pii: S1556-0864(18)33493.
PubMed Abstract available

ERNANI V, Appiah AK, Marr A, Zhang C, et al
Adjuvant Systemic Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer (NSCLC) Treated with Stereotactic Body Radiation Therapy (SBRT).
J Thorac Oncol. 2018 Nov 29. pii: S1556-0864(18)33495.
PubMed Abstract available

QU Y, Emoto K, Eguchi T, Aly RG, et al
Pathologic assessment after neoadjuvant chemotherapy for non-small cell lung cancer: Importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma.
J Thorac Oncol. 2018 Nov 29. pii: S1556-0864(18)33494.
PubMed Abstract available

LICHTENSTEIN M, Nipp RD, Muzikansky A, Goodwin K, et al
Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC).
J Thorac Oncol. 2018 Nov 23. pii: S1556-0864(18)33454.
PubMed Abstract available

KARACHALIOU N, Bracht JWP, Bruno MF, Drozdowskyj A, et al
BRIEF REPORT: Association of PALB2 Messenger RNA Expression with platinum-docetaxel efficacy in advanced non-small cell lung cancer.
J Thorac Oncol. 2018 Nov 22. pii: S1556-0864(18)33450.
PubMed Abstract available

FUJIMOTO D, Yoshioka H, Kataoka Y, Morimoto T, et al
Pseudoprogression in previously treated patients with non-small cell lung cancer who received nivolumab monotherapy: A multicenter retrospective cohort study.
J Thorac Oncol. 2018 Nov 20. pii: S1556-0864(18)33418.
PubMed Abstract available

KANG HR, Cho JY, Lee SH, Lee YJ, et al
Role of low-dose computerized tomography in lung cancer screening among never-smokers.
J Thorac Oncol. 2018 Nov 13. pii: S1556-0864(18)33417.
PubMed Abstract available

ZHANG C, Li SL, Nie Q, Dong S, et al
Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small-Cell Lung Cancer with ALK-rearrangement: A Brief Report.
J Thorac Oncol. 2018 Nov 5. pii: S1556-0864(18)33410.
PubMed Abstract available

SINICROPI-YAO SL, Amann JM, Lopez DLY, Cerciello F, et al
Co-expression analysis reveals mechanisms underlying the varied roles of NOTCH1 in non-small cell lung cancer.
J Thorac Oncol. 2018 Nov 5. pii: S1556-0864(18)33411.
PubMed Abstract available

BLAAUWGEERS H, Damhuis R, Lissenberg-Witte B, de Langen AJ, et al
A population-based study of outcomes in surgically resected T3N0 non-small cell lung cancer in the Netherlands, defined using TNM-7 and TNM-8; justification of changes and an argument to incorporate histology in the staging algorithm?
J Thorac Oncol. 2018 Nov 5. pii: S1556-0864(18)33413.
PubMed Abstract available

SHIN DW, Cho J, Noh JM, Han H, et al
Disparities in the diagnosis and treatment of lung cancer among people with disabilities.
J Thorac Oncol. 2018 Nov 2. pii: S1556-0864(18)33407.
PubMed Abstract available

RICCIUTI B, Marcomigni L, Metro G, Bellezza G, et al
Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib.
J Thorac Oncol. 2018;13:e220-e222.
PubMed

YOSHIDA H, Ooi M, Kim YH
Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis.
J Thorac Oncol. 2018;13:e219-e220.
PubMed

October 2018

KIM Y, Lee B, Shim JH, Lee SH, et al
Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced non-small cell lung cancer.
J Thorac Oncol. 2018 Oct 31. pii: S1556-0864(18)33383.
PubMed Abstract available

GELSOMINO F, Facchini G, Barbera MA, Lamberti G, et al
Complete recalcification following arterial embolization of massive osteolytic bone metastasis from non-small cell lung cancer (NSCLC).
J Thorac Oncol. 2018 Oct 31. pii: S1556-0864(18)33384.
PubMed

SCHROCK AB, Welsh A, Chung JH, Pavlick D, et al
Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced non-small cell lung cancer.
J Thorac Oncol. 2018 Oct 24. pii: S1556-0864(18)33205.
PubMed Abstract available

BASU ROY U, King-Kallimanis BL, Kluetz PG, Selig W, et al
Learning from Patients: Reflections on Use of Patient-Reported Outcomes in Lung Cancer Trials.
J Thorac Oncol. 2018 Oct 15. pii: S1556-0864(18)33052.
PubMed

LAMMERS A, Slatore CG, Fromme EK, Vranas K, et al
Association of Early Palliative Care with Chemotherapy Intensity in Patients with Advanced Stage Lung Cancer : A National Cohort Study.
J Thorac Oncol. 2018 Oct 15. pii: S1556-0864(18)33184.
PubMed

OKAMI J, Shintani Y, Okumura M, Ito H, et al
Demographics, safety and quality, and prognostic information in both the seventh and eighth editions of the TNM classification in 18,973 surgical cases of the Japanese Joint committee of Lung Cancer Registry database in 2010.
J Thorac Oncol. 2018 Oct 10. pii: S1556-0864(18)33180.
PubMed Abstract available

READY N, Farago AF, de Braud F, Atmaca A, et al
Third-Line Nivolumab Monotherapy in Recurrent Small Cell Lung Cancer: CheckMate 032.
J Thorac Oncol. 2018 Oct 10. pii: S1556-0864(18)33181.
PubMed Abstract available

CHAE YK, Oh MS
Detection of minimal residual disease using ctDNA in lung cancer: current evidence and future directions.
J Thorac Oncol. 2018 Oct 5. pii: S1556-0864(18)33174.
PubMed Abstract available

SCHILD SE, Fan W, Stinchcombe TE, Vokes EE, et al
Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018 Oct 4. pii: S1556-0864(18)33173.
PubMed Abstract available

LEVY A, Le Pechoux C, Mistry H, Martel-Lafay I, et al
Prophylactic cranial irradiation for limited-stage small-cell lung cancer patients: secondary findings from the prospective randomized phase 3 CONVERT trial.
J Thorac Oncol. 2018 Oct 4. pii: S1556-0864(18)33171.
PubMed Abstract available

CHU X, Li Y, Zhu Z
A Case of Small Cell Lung Cancer Transformation from EGFR-Mutant Lung Adenocarcinoma with Primary Resistance to Gefitinib.
J Thorac Oncol. 2018;13:e211-e214.
PubMed

TAKIGAWA N
How Should We Treat Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer?
J Thorac Oncol. 2018;13:1438-1440.
PubMed

SHOLL LM
Recognizing the Challenges of Oncogene Fusion Detection: A Critical Step toward Optimal Selection of Lung Cancer Patients for Targeted Therapies.
J Thorac Oncol. 2018;13:1433-1435.
PubMed

September 2018

BLUMENTHAL GM, Bunn PA Jr, Chaft JE, McCoach CE, et al
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.
J Thorac Oncol. 2018 Sep 27. pii: S1556-0864(18)33129.
PubMed

SURESH K, Voong KR, Shankar B, Forde PM, et al
Pneumonitis in Non-Small Cell Lung Cancer patients receiving Immune Checkpoint Immunotherapy: incidence and risk factors.
J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33118.
PubMed Abstract available

QIN N, Li N, Wang C, Pu Z, et al
Association of mosaic loss of chromosome Y with lung cancer risk and prognosis in a Chinese population.
J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33125.
PubMed Abstract available

TOKI MI, Mani N, Smithy JW, Liu Y, et al
Immune marker profiling and PD-L1 expression across Non-Small Cell Lung Cancer mutations.
J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33124.
PubMed Abstract available

QIN A, Johnson A, Ross JS, Miller VA, et al
Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling.
J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33126.
PubMed Abstract available

FRUH M M, Betticher DC, Stupp R, Xyrafas A, et al
Multimodal Treatment in Operable Stage III Non-Small Cell Lung Cancer: A Pooled Analysis on Long Term Results of three SAKK trials (SAKK 16/96, 16/00, 16/01).
J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33123.
PubMed Abstract available

TSAO AS, Lindwasser OW, Adjei AA, Adusumilli PS, et al
Current and Future Management of Malignant Mesothelioma : A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer and Mesothelioma Applied Research Foundation
J Thorac Oncol. 2018 Sep 25. pii: S1556-0864(18)33121.
PubMed Abstract available

DE RUYSSCHER D, Wanders R, Hendriks LE, van Baardwijk A, et al
Progression-Free-Survival and Overall Survival beyond 5 years of non-small cell lung cancer patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450).
J Thorac Oncol. 2018 Sep 22. pii: S1556-0864(18)30935.
PubMed Abstract available

YU H, Chen Z, Ballman K, Watson MA, et al
Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early stage squamous cell lung carcinoma.
J Thorac Oncol. 2018 Sep 22. pii: S1556-0864(18)33116.
PubMed Abstract available

RAMALINGAM S, Dinan MA, Crawford J
Survival comparison in patients with Stage IV lung cancer in Academic versus Community Centers in the United States.
J Thorac Oncol. 2018 Sep 22. pii: S1556-0864(18)33117.
PubMed Abstract available

GANDARA DR, von Pawel J, Mazieres J, Sullivan R, et al
Atezolizumab Treatment Beyond Progression in Advanced Non-Small Cell Lung Cancer: Results From the Randomized, Phase III OAK Study.
J Thorac Oncol. 2018 Sep 11. pii: S1556-0864(18)33043.
PubMed Abstract available

SUN TY, Niu X, Chakraborty A, Neal JW, et al
Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small-cell lung cancer.
J Thorac Oncol. 2018 Sep 11. pii: S1556-0864(18)33046.
PubMed

FERRER L, Giaj Levra M, Brevet M, Antoine M, et al
A brief report of transformation from Non-small cell to small cell lung cancer: Molecular and therapeutic characteristics.
J Thorac Oncol. 2018 Sep 11. pii: S1556-0864(18)33044.
PubMed Abstract available

LIN JJ, Chin E, Yeap BY, Ferris LA, et al
Brief Report: Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small-Cell Lung Cancer.
J Thorac Oncol. 2018 Sep 8. pii: S1556-0864(18)33040.
PubMed Abstract available

DESCARPENTRIES C, Lepretre F, Escande F, Kherrouche Z, et al
Optimization of routine testing for MET exon 14 splice site mutations in non-small cell lung cancer patients.
J Thorac Oncol. 2018 Sep 6. pii: S1556-0864(18)33038.
PubMed Abstract available

DENG W, Xu T, Wang Y, Xu Y, et al
Survival Patterns for Patients with Resected N2 Non-Small Cell Lung Cancer and Postoperative Radiotherapy: A Prognostic Scoring Model and Heat Map Approach.
J Thorac Oncol. 2018 Sep 4. pii: S1556-0864(18)33036.
PubMed Abstract available

LE-RADEMACHER J, Dahlberg S, Lee JJ, Adjei AA, et al
Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations.
J Thorac Oncol. 2018 Sep 4. pii: S1556-0864(18)33034.
PubMed Abstract available

SWAMI U, Smith M, Zhang J
Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.
J Thorac Oncol. 2018;13:e183-e184.
PubMed

MO X, Xu-Welliver M
Response to the Letter to Editor re: The Additional Prognostic Value of Tumor Volume Changes during Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018;13:e182-e183.
PubMed

WALRAVEN I, Kwint M, Belderbos J
The Additional Prognostic Value of Tumor Volume Changes during Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018;13:e181-e182.
PubMed

JIN B, Chuang X, Liu Y
Remarkable Long-Term Efficacy of Nivolumab Immunotherapy in a Chinese Patient with Extensive-Disease Small Cell Lung Cancer.
J Thorac Oncol. 2018;13:e174-e177.
PubMed

DENG L, Kiedrowski LA, Ravera E, Cheng H, et al
Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition.
J Thorac Oncol. 2018;13:e169-e172.
PubMed

XU YJ, Shi ZL, Wang Z, Du L, et al
Gefitinib in the Treatment of a Pulmonary Sequestration Patient Complicated by Large Cell Lung Carcinoma.
J Thorac Oncol. 2018;13:e165-e168.
PubMed

MARINO M, Visca P, Ottaviano M
PD-L1 Testing in Lung Cancer: An International Pathologist's Initiative in an Unknown "Middle Earth".
J Thorac Oncol. 2018;13:1239-1241.
PubMed

August 2018

MORO M, Caiola E, Ganzinelli M, Zulato E, et al
Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS/LKB1 Non-Small Cell Lung Cancer (NSCLC).
J Thorac Oncol. 2018 Aug 24. pii: S1556-0864(18)32988.
PubMed Abstract available

BORGHAEI H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, et al
24-Month Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab As First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
J Thorac Oncol. 2018 Aug 20. pii: S1556-0864(18)30942.
PubMed Abstract available

LAUFER-GEVA S, Rozenblum AB, Twito T, Grinberg R, et al
The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer.
J Thorac Oncol. 2018 Aug 16. pii: S1556-0864(18)30940.
PubMed Abstract available

GUAITOLI G, Baldessari C, Tomasello C, Barbieri F, et al
Late Gastrointestinal Toxicity During Nivolumab Therapy in Non-Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease.
J Thorac Oncol. 2018;13:e152-e153.
PubMed

FUJIOKA S, Kitajima T, Itotani R
Myositis in a Patient with Advanced Lung Cancer Treated with Osimertinib.
J Thorac Oncol. 2018;13:e137-e139.
PubMed

GARCIA CA, Dacic S, Villaruz LC
Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018;13:e135-e136.
PubMed

HAMANN HA, Pujol JL
Introduction to the Special Section: The Experience and Impact of Lung Cancer Stigma.
J Thorac Oncol. 2018;13:1053-1054.
PubMed

July 2018

SU S, Dong ZY, Xie Z, Yan LX, et al
Strong PD-L1 expression predicts poor response and de novo resistance to EGFR TKIs among non-small cell lung cancer patients with EGFR mutation.
J Thorac Oncol. 2018 Jul 26. pii: S1556-0864(18)30811.
PubMed Abstract available

ROACH MC, Robinson CG, DeWees TA, Ganachaud J, et al
Stereotactic body radiation therapy (SBRT) for central early stage non-small cell lung cancer: results of a prospective phase I/II trial.
J Thorac Oncol. 2018 Jul 26. pii: S1556-0864(18)30812.
PubMed Abstract available

ZHANG M, Wang Q, Ding Y, Wang G, et al
Brief Report: CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer.
J Thorac Oncol. 2018 Jul 13. pii: S1556-0864(18)30785.
PubMed Abstract available

KATO R, Hayashi H, Sano K, Handa K, et al
Nivolumab-induced hemophilia A presenting as gastric ulcer bleeding in a patient with non-small cell lung cancer.
J Thorac Oncol. 2018 Jul 11. pii: S1556-0864(18)30779.
PubMed

OCCHIPINTI S, Dunn J, O'Connell DL, Garvey G, et al
Lung Cancer Stigma Across the Social Network: Patients' and Caregivers' Perspectives.
J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30766.
PubMed Abstract available

RIESS JW, Gandara DR, Frampton GM, Madison R, et al
Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30770.
PubMed Abstract available

WILLIAMSON TJ, Choi AK, Kim JC, Garon EB, et al
A longitudinal investigation of internalized stigma, constrained disclosure, and quality of life across 12 weeks in lung cancer patients on active oncologic treatment.
J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30769.
PubMed Abstract available

PATIL T, Smith DE, Bunn PA, Aisner DL, et al
The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib.
J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30772.
PubMed Abstract available

SEHGAL K, Peters MLB, VanderLaan PA, Rangachari D, et al
Activity of brigatinib in the setting of alectinib resistance mediated by ALK-I1171S in ALK rearranged lung cancer.
J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30771.
PubMed

KINSEY E, Ajazi E, Wang X, Johnston MAM, et al
Predictors of physical and functional loss in advanced stage lung cancer patients receiving platinum chemotherapy.
J Thorac Oncol. 2018 Jul 4. pii: S1556-0864(18)30676.
PubMed Abstract available

LIU Y, Lusk CM, Cho MH, Silverman EK, et al
Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer.
J Thorac Oncol. 2018 Jul 4. pii: S1556-0864(18)30767.
PubMed Abstract available

VELCHETI V, Madison R, Ali SM, Schrock AB, et al
WAC/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.
J Thorac Oncol. 2018;13:e122-e123.
PubMed

ASSALLUM H, Harris K
The Impact of the Eighth TNM Classification for Lung Cancer on the Endobronchial Ultrasound Procedure.
J Thorac Oncol. 2018;13:e119-e120.
PubMed

NAVARRO A, Martinez-Marti A, Felip E
HIV-Positive Patients with Lung Cancer: Is Immunotherapy a Safe and Active Option for Them?
J Thorac Oncol. 2018;13:874-876.
PubMed

June 2018

WU YL, Lu S, Lu Y, Zhou J, et al
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018 Jun 29. pii: S1556-0864(18)30721.
PubMed Abstract available

SHIUE K, Cerra-Franco A, Shapiro R, Estabrook N, et al
Histology, tumor volume, and radiation dose predict outcomes in non-small cell lung cancer patients after stereotactic ablative radiotherapy.
J Thorac Oncol. 2018 Jun 26. pii: S1556-0864(18)30716.
PubMed Abstract available

LIN JJ, Zhu VW, Schoenfeld AJ, Yeap BY, et al
Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study.
J Thorac Oncol. 2018 Jun 20. pii: S1556-0864(18)30714.
PubMed Abstract available

WANG S, Yang L, Ci B, Maclean M, et al
Development and Validation of a Nomogram Prognostic Model for Small-Cell Lung Cancer Patients.
J Thorac Oncol. 2018 Jun 11. pii: S1556-0864(18)30687.
PubMed Abstract available

HARATAKE N, Tagawa T, Hirai F, Toyokawa G, et al
Stevens-Johnson syndrome induced by pembrolizumab in a lung cancer patient.
J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30681.
PubMed

JONES CC, Mercaldo SF, Blume JD, Wenzlaff AS, et al
Racial disparities in lung cancer survival: The contribution of stage, treatment, and ancestry.
J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30682.
PubMed Abstract available

ROLFO C, Mack PC, Scagliotti GV, Baas P, et al
IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC).
J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30680.
PubMed Abstract available

GERAUD A, Mezquita L, Bigot F, Caramella C, et al
Long leptomeningeal responses with brigatinib in two heavily pre-treated ALK-rearranged non-small cell lung cancer patients.
J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30683.
PubMed

PARK S, Ahn BC, Lim SW, Sun JM, et al
Characteristics and outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
J Thorac Oncol. 2018 Jun 5. pii: S1556-0864(18)30673.
PubMed Abstract available

YEGYA-RAMAN N, Wang K, Kim S, Reyhan M, et al
Dosimetric Predictors of Symptomatic Cardiac Events after Conventional-Dose Chemoradiation Therapy for Inoperable Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018 Jun 5. pii: S1556-0864(18)30675.
PubMed Abstract available

WOZNIAK AJ, Schwartz AG
Risk of Second Lung Cancer in Patients With Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results Data.
J Thorac Oncol. 2018;13:e106-e107.
PubMed

MASCALCHI M, Sali L
Risk of Second Lung Cancer in ITALUNG LDCT Screening.
J Thorac Oncol. 2018;13:e105-e106.
PubMed

WU CK, Kao SJ, Lai HC
Targeted Therapy and Immunotherapy Lead to Rapid Regression of Advanced Non-Small Cell Lung Cancer with Multiple Driver Mutations.
J Thorac Oncol. 2018;13:e103-e105.
PubMed

BONOMI P, Blumenthal G, Ferris AS, Stewart DJ, et al
Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria.
J Thorac Oncol. 2018;13:748-751.
PubMed

TSENG D, Padda SK, Wakelee HA
Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018;13:741-744.
PubMed

May 2018

GETTINGER S, Hellmann MD, Chow LQM, Borghaei H, et al
Nivolumab Plus Erlotinib in Patients with Epidermal Growth Factor Receptor-Mutant Advanced Non-Squamous Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018 May 23. pii: S1556-0864(18)30628.
PubMed Abstract available

HAMANN HA, Ver Hoeve ES, Carter-Harris L, Studts JL, et al
Multilevel Opportunities to Address Lung Cancer Stigma across the Cancer Control Continuum.
J Thorac Oncol. 2018 May 22. pii: S1556-0864(18)30627.
PubMed Abstract available

FEHRENBACHER L, von Pawel J, Park K, Rittmeyer A, et al
Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab vs docetaxel in patients with previously treated advanced non-small cell lung cancer.
J Thorac Oncol. 2018 May 16. pii: S1556-0864(18)30611.
PubMed Abstract available

GADGEEL SM, Pennell NA, Fidler MJ, Halmos B, et al
Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC).
J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30600.
PubMed Abstract available

SPIGEL DR, Chaft JE, Gettinger S, Chao BH, et al
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients with Non-Small-Cell Lung Cancer.
J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30603.
PubMed Abstract available

WALTER JE, Heuvelmans MA, Yousaf-Khan U, Dorrius MD, et al
New subsolid pulmonary nodules in lung cancer screening: a brief report of the NELSON trial.
J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30605.
PubMed Abstract available

KARANTH S, Rajan SS, Sharma G, Yamal JM, et al
Racial-Ethnic Disparities in End-of-Life Care Quality among Lung Cancer Patients: A SEER-Medicare-Based Study.
J Thorac Oncol. 2018 May 10. pii: S1556-0864(18)30540.
PubMed Abstract available

CODONY-SERVAT J, Garcia-Roman S, Molina-Vila MA, Bertran-Alamillo J, et al
Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.
J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30592.
PubMed Abstract available

SMYTH RJ, Toomey SM, Sartori A, Hanrahan EO, et al
Brief report on the detection of the EGFR-T790M mutation in exhaled breath condensate from lung cancer patients.
J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30595.
PubMed Abstract available

NAKAMURA R, Inage Y, Tobita R, Yoneyama S, et al
Sarcopenia in resected non-small cell lung cancer: Effect on postoperative outcomes.
J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30597.
PubMed Abstract available

KATZ SI, Hammer M, Bagley S, Aggarwal C, et al
Radiologic pseudoprogression during anti-PD1 therapy for advanced non-small cell lung cancer.
J Thorac Oncol. 2018 May 5. pii: S1556-0864(18)30536.
PubMed Abstract available

VOKES EE, Govindan R, Iscoe N, Hossain AM, et al
The Impact of Staging by Positron Emission Tomography on Overall Survival and Progression-free Survival in Patients with Locally Advanced Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018 May 4. pii: S1556-0864(18)30589.
PubMed Abstract available

GARASSINO MC, Gelibter AJ, Grossi F, Chiari R, et al
Italian nivolumab expanded access program in nonsquamous non-small-cell lung cancer patients: results in never-smokers and EGFR-mutant patients.
J Thorac Oncol. 2018 May 3. pii: S1556-0864(18)30553.
PubMed Abstract available

TAMURA T, Akimoto E, Matsumoto C, Mori S, et al
Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small-Cell Lung Cancer.
J Thorac Oncol. 2018 May 3. pii: S1556-0864(18)30554.
PubMed

SAFIRI S, Ashrafi-Asgarabad A
Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab: Methodological Issues.
J Thorac Oncol. 2018;13:e85-e86.
PubMed

WU B
Response: Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR Tyrosine Kinase Inhibitor Therapy.
J Thorac Oncol. 2018;13:e84-e85.
PubMed

HOYLE C, Dyer M
Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer after Progression during First-Line EGFR Tyrosine Kinase Inhibitor Therapy.
J Thorac Oncol. 2018;13:e83-e84.
PubMed

MARTINEZ VILA C, Garcia Garcia Y, Carcereny Costa E
Prolonged Partial Response to Osimertinib after Disease Progression to Rociletinib in Metastasic EGFR T790M-Positive Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018;13:e77-e79.
PubMed

DRESLER C, Warren GW, Arenberg D, Yang P, et al
"Teachable Moment" Interventions in Lung Cancer: Why Action Matters.
J Thorac Oncol. 2018;13:603-605.
PubMed

HERMAN M, Warkentin MT, Shepshelovich D, Latifovic L, et al
Heritable Germline Variation and Lung Cancer Susceptibility: One Size Does not Fit All.
J Thorac Oncol. 2018;13:601-602.
PubMed

TANIZAKI J, Chiba Y, Haratani K, Hayashi H, et al
In Reply.
J Thorac Oncol. 2018;13:e86-e87.
PubMed

RANGACHARI D, VanderLaan PA, Costa DB
Updated Correlation of 22C3-PD-L1 >/=50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting.
J Thorac Oncol. 2018;13:e81-e83.
PubMed

MIYAWAKI E, Murakami H, Takahashi T
Correlation between 22C3-PD-L1 Expression and EGFR Mutations in Japanese Patients with Advanced Lung Adenocarcinoma.
J Thorac Oncol. 2018;13:e79-e81.
PubMed

ROSSI A, Novello S
The Tradition of the Rising Sun: When Geography Counts.
J Thorac Oncol. 2018;13:598-600.
PubMed

HO C
Anticipating the Next Step in the Management of ALK-Positive NSCLC.
J Thorac Oncol. 2018;13:595-597.
PubMed

April 2018

DUDNIK E, Peled N, Nechushtan H, Wollner M, et al
BRAF mutant lung cancer: PD-L1 expression, tumor mutational burden, microsatellite instability status and response to immune check-point inhibitors.
J Thorac Oncol. 2018 Apr 30. pii: S1556-0864(18)30552.
PubMed Abstract available

ANDREANO A, Peake MD, Janes SM, Valsecchi MG, et al
The Care and Outcomes of Older Persons with Lung Cancer in England and the United States, 2008-2012.
J Thorac Oncol. 2018 Apr 26. pii: S1556-0864(18)30550.
PubMed Abstract available

VAN KEMPEN LC, Wang H, Aguirre ML, Spatz A, et al
Afatinib in Osimertinib-Resistant EGFR ex19del / T790M / P794L mutated Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30548.
PubMed

LI Z, Shen L, Ding D, Huang J, et al
Efficacy of Crizotinib Among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-small-cell Lung Cancer.
J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30542.
PubMed Abstract available

MUNARI E, Zamboni G, Lunardi G, Marchionni L, et al
PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsies and whole sections.
J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30543.
PubMed Abstract available

VAN VEGGEL B, de Langen AJ, Hashemi S, Monkhorst K, et al
Brief report: Afatinib and cetuximab in four patients with EGFR exon 20 insertion positive advanced non-small-cell lung cancer.
J Thorac Oncol. 2018 Apr 24. pii: S1556-0864(18)30538.
PubMed Abstract available

SCHILD SE, Fan W, Stinchcombe TE, Vokes EE, et al
Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018 Apr 21. pii: S1556-0864(18)30537.
PubMed Abstract available

WADE S, Weber M, Caruana M, Kang YJ, et al
Estimating the cost-effectiveness of lung cancer screening with low dose computed tomography for high risk smokers in Australia.
J Thorac Oncol. 2018 Apr 21. pii: S1556-0864(18)30531.
PubMed Abstract available

DONINGTON JS, Kim YT, Tong B, Moreira AL, et al
Progress in the management of Early Stage Non-Small Cell Lung Cancer in 2017.
J Thorac Oncol. 2018 Apr 11. pii: S1556-0864(18)30508.
PubMed Abstract available

OWADA-OZAKI Y, Muto S, Takagi H, Inoue T, et al
Prognostic Impact of Tumor Mutation Burden in Patients with Completely Resected Non-Small Cell Lung Cancer: Brief Report.
J Thorac Oncol. 2018 Apr 11. pii: S1556-0864(18)30509.
PubMed Abstract available

OSTIOS-GARCIA L, Faig J, Leonardi GC, Adeni AE, et al
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients with Non-Small-Cell Lung Cancer.
J Thorac Oncol. 2018 Apr 6. pii: S1556-0864(18)30270.
PubMed Abstract available

SANDBERG Y, den Bakker MA
Small cell lung cancer presenting as carcinocythemia.
J Thorac Oncol. 2018 Apr 6. pii: S1556-0864(18)30269.
PubMed

MA Y, Zheng X, Zhao H, Fang W, et al
First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.
J Thorac Oncol. 2018 Apr 4. pii: S1556-0864(18)30264.
PubMed Abstract available

CARR SR, Akerley W, Cannon-Albright L
Genetic Contribution to Non-Squamous, Non-Small Cell Lung Cancer in Non-Smokers.
J Thorac Oncol. 2018 Apr 4. pii: S1556-0864(18)30263.
PubMed Abstract available

WATANABE J, Furuya N, Fujiwara Y
Appearance of a BRAF Mutation Conferring Resistance to Crizotinib in Non-Small Cell Lung Cancer Harboring Oncogenic ROS1 Fusion.
J Thorac Oncol. 2018;13:e66-e69.
PubMed

MORMILE R
Metformin and Lung Cancer: The Final Blow to the Obesity Paradox?
J Thorac Oncol. 2018;13:e65-e66.
PubMed

SAFIRI S
Comments on Comorbidity in Lung Cancer: A Prospective Cohort Study of Self-Reported versus Register-Based Comorbidity.
J Thorac Oncol. 2018;13:e61.
PubMed

SANDFELD-PAULSEN B, Aggerholm-Pedersen N
Response to Safri: "Comments on Comorbidity in Lung Cancer: A Prospective Cohort Study of Self-Reported versus Register-Based Comorbidity".
J Thorac Oncol. 2018;13:e61-e62.
PubMed

MASAI K, Motoi N
Response to Letter to the Editor Titled "Comments on Prognostic Impact of Margin Distance and Tumor Spread through Air Spaces in Limited Resection for Primary Lung Cancer".
J Thorac Oncol. 2018;13:e58-e59.
PubMed

MANSORI K, Ayubi E, Safiri S
Comments on Prognostic Impact of Margin Distance and Tumor Spread through Air Spaces in Limited Resection for Primary Lung Cancer.
J Thorac Oncol. 2018;13:e57-e58.
PubMed

SUN JM
Response to Costantini et al. "Comments on Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer".
J Thorac Oncol. 2018;13:e56-e57.
PubMed

COSTANTINI A, Cadranel J
Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018;13:e55-e56.
PubMed

LEVY A, Hendriks LE, Faivre-Finn C
Are We Ready to Safely Combine Anti-PD-1/PD-L1 with Cranial Irradiation in Non-Small Cell Lung Cancer Patients?
J Thorac Oncol. 2018;13:475-477.
PubMed

SENAN S, Rusthoven CG, Slotman BJ, Siva S, et al
Progress in Radiotherapy for Regional and Oligometastatic Disease in 2017.
J Thorac Oncol. 2018;13:488-496.
PubMed Abstract available

March 2018

GAJRA A, Zemla TJ, Jatoi A, Feliciano JL, et al
Time-to-Treatment-Failure and Related Outcomes among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients.
J Thorac Oncol. 2018 Mar 30. pii: S1556-0864(18)30254.
PubMed Abstract available

LI Y, Liu B, Connolly ID, Kakusa BW, et al
Brief Report: Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases.
J Thorac Oncol. 2018 Mar 28. pii: S1556-0864(18)30222.
PubMed Abstract available

SHIBAHARA D, Tanaka K, Iwama E, Kubo N, et al
Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018 Mar 26. pii: S1556-0864(18)30215.
PubMed Abstract available

LEE CK, Lord S, Marschner I, Wu YL, et al
The value of early depth of response in predicting long-term outcome in EGFR-mutant lung cancer.
J Thorac Oncol. 2018 Mar 23. pii: S1556-0864(18)30212.
PubMed Abstract available

FLORES R, Taioli E, Yankelevitz DF, Becker BJ, et al
Initiative for Early Lung Cancer Research on Treatment: Development of Study Design and Pilot Implementation.
J Thorac Oncol. 2018 Mar 22. pii: S1556-0864(18)30211.
PubMed Abstract available

GETTINGER SN, Wurtz A, Goldberg SB, Rimm D, et al
Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in Twenty-Six Patients with Advanced Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018 Mar 22. pii: S1556-0864(18)30210.
PubMed Abstract available

MAENG CH, Song JU, Shim SR, Lee J, et al
The Role of Prophylactic Cranial Irradiation in Patients with Extensive Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
J Thorac Oncol. 2018 Mar 8. pii: S1556-0864(18)30180.
PubMed Abstract available

PARRA ER, Villalobos P, Zhang J, Behrens C, et al
Immunohistochemical and Image Analysis-based Study Demonstrate that Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors.
J Thorac Oncol. 2018 Mar 8. pii: S1556-0864(18)30182.
PubMed Abstract available

ROCCO G, Pennazza G, Santonico M, Longo F, et al
Breathprinting and early diagnosis of lung cancer.
J Thorac Oncol. 2018 Mar 8. pii: S1556-0864(18)30183.
PubMed Abstract available

SPIGEL DR, Reynolds C, Waterhouse D, Garon EB, et al
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-line Treatment of ALK Translocation-Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).
J Thorac Oncol. 2018 Mar 5. pii: S1556-0864(18)30176.
PubMed Abstract available

TOYOOKA S, Okumura N, Nakamura H, Nakata M, et al
A multi-center randomized controlled study of paclitaxel plus carboplatin versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer.
J Thorac Oncol. 2018 Mar 2. pii: S1556-0864(18)30168.
PubMed Abstract available

YASUDA Y, Ozasa H, Kim YH
PD-L1 Expression in Small Cell Lung Cancer.
J Thorac Oncol. 2018;13:e40-e41.
PubMed

CHO JH, Sun JM, Lee SH, Ahn JS, et al
Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018;13:e34-e36.
PubMed

RANDHAWA S, Moore RF, DiSesa V, Kaiser L, et al
Role of Thoracic Surgeons in Lung Cancer Screening: Opportune Time for Involvement.
J Thorac Oncol. 2018;13:298-300.
PubMed

FAN J, Dai X, Nie X
Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas.
J Thorac Oncol. 2018;13:e45-e48.
PubMed

YIN J, Zhang Y, Zhang Y, Peng F, et al
Reporting on Two Novel Fusions, DYSF-ALK and ITGAV-ALK, Coexisting in One Patient with Adenocarcinoma of Lung, Sensitive to Crizotinib.
J Thorac Oncol. 2018;13:e43-e45.
PubMed

RIHAWI K, Cinausero M, Fiorentino M, Salvagni S, et al
Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins.
J Thorac Oncol. 2018;13:e41-e43.
PubMed

RAEZ LE, Pinto JA, Schrock AB, Ali SM, et al
EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?
J Thorac Oncol. 2018;13:e33-e34.
PubMed

February 2018

GIROUX DJ, Van Schil P, Asamura H, Rami-Porta R, et al
The IASLC Lung Cancer Staging Project: A Renewed Call to Participation.
J Thorac Oncol. 2018 Feb 21. pii: S1556-0864(18)30131.
PubMed Abstract available

WEN J, Liu H, Wang L, Wang X, et al
Potentially Functional variants of ATG16L2 predict radiation pneumonitis and outcomes in patients with non-small cell lung cancer after definitive radiotherapy.
J Thorac Oncol. 2018 Feb 15. pii: S1556-0864(18)30103.
PubMed Abstract available

VAN DE GOOR R, van Hooren M, Dingemans AM, Kremer B, et al
Training and validating a portable electronic nose for lung cancer screening.
J Thorac Oncol. 2018 Feb 6. pii: S1556-0864(18)30093.
PubMed Abstract available

EATON KD, Romine PE, Goodman GE, Thornquist MD, et al
Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility.
J Thorac Oncol. 2018 Feb 2. pii: S1556-0864(18)30090.
PubMed Abstract available

MORGENSZTERN D, Samson P, Waqar SN, Devarakonda S, et al
Early mortality in patients undergoing adjuvant chemotherapy for non-small-cell lung cancer.
J Thorac Oncol. 2018 Feb 1. pii: S1556-0864(18)30036.
PubMed Abstract available

ASHRAFI-ASGARABAD A, Safiri S
Prognostic Value of Primary Tumor Volume Changes on Kilovoltage Onboard Cone Beam Computed Tomography during Definitive Chemoradiotherapy for stage III Non-Small Cell Lung Cancer: Methodological Issues.
J Thorac Oncol. 2018;13:e26-e27.
PubMed

LEONE A
C797S and T790M EGFR Mutations in Non-Small Cell Lung Cancer: In Trans or in Separate Clones?
J Thorac Oncol. 2018;13:e21-e22.
PubMed

GAZDAR AF
Morphologic and Other Forms of Heterogeneity in Small Cell Lung Cancer: What Can We Learn from Them?
J Thorac Oncol. 2018;13:148-150.
PubMed

January 2018

KATZMAN D, Wu S, Sterman DH
Immunological Aspects of Cryoablation of Non-Small Cell Lung Cancer: A Comprehensive Review.
J Thorac Oncol. 2018 Jan 29. pii: S1556-0864(18)30079.
PubMed Abstract available

WOLFF HB, Alberts L, Kastelijn EA, Lissenberg-Witte BI, et al
Differences in longitudinal health utility between stereotactic body radiation therapy and surgery in stage I non-small cell lung cancer.
J Thorac Oncol. 2018 Jan 29. pii: S1556-0864(18)30083.
PubMed Abstract available

HUBBELING HG, Schapira EF, Horick NK, Goodwin KEH, et al
Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018 Jan 26. pii: S1556-0864(18)30039.
PubMed Abstract available

STONE E, Jett J, Warren G, Cummings KM, et al
Cannabis Use, Lung Cancer, and Related Issues.
J Thorac Oncol. 2018 Jan 24. pii: S1556-0864(18)30038.
PubMed Abstract available

LINDEMAN NI, Cagle PT, Aisner DL, Arcila ME, et al
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and
J Thorac Oncol. 2018 Jan 23. pii: S1556-0864(17)33071.
PubMed Abstract available

HOUSTON KA, Mitchell KA, King J, White A, et al
Histologic Lung Cancer Incidence Rates and Trends vary by Race/Ethnicity and Residential County.
J Thorac Oncol. 2018 Jan 19. pii: S1556-0864(18)30003.
PubMed Abstract available

NYGARD L, Vogelius IR, Fischer BM, Kjaer A, et al
A competing risk model of first failure site after definitive (chemo) radiation therapy for locally advanced non-small cell lung cancer.
J Thorac Oncol. 2018 Jan 18. pii: S1556-0864(18)30006.
PubMed Abstract available

MAROM EM, Ofek E, Bekker E, Onn A, et al
Tattoo Induced False Positive FDG PET-CT Interpretation while Staging for Lung Cancer.
J Thorac Oncol. 2018 Jan 17. pii: S1556-0864(18)30005.
PubMed

RICCIUTI B, Metro G, Brambilla M, Ludovini V, et al
Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma.
J Thorac Oncol. 2018;13:e9-e12.
PubMed

MCCANN B, Clark B
Four-Year Complete Remission in a Patient with Metastatic Epidermal Growth Factor Receptor-Mutated Lung Cancer Treated with Two Cycles of Erlotinib.
J Thorac Oncol. 2018;13:e7-e8.
PubMed

ZHANG X, Zheng X
Reply to "Obesity Paradox in Lung Cancer Prognosis: Is MiR-26b the Achilles Heel?"
J Thorac Oncol. 2018;13:e16.
PubMed

MORMILE R
Obesity Paradox in Lung Cancer Prognosis: Is MiR-26b the Achilles Heel?
J Thorac Oncol. 2018;13:e15.
PubMed

DONG ZY, Zhang C, Li YF, Su J, et al
Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.
J Thorac Oncol. 2018;13:85-96.
PubMed Abstract available

BUCCIARELLI PR, Tan KS, Chudgar NP, Brandt W, et al
BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis.
J Thorac Oncol. 2018;13:73-84.
PubMed Abstract available

PATIL NS, Righi L, Koeppen H, Zou W, et al
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
J Thorac Oncol. 2018;13:124-133.
PubMed Abstract available

NOONAN SA, Patil T, Gao D, King GG, et al
Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.
J Thorac Oncol. 2018;13:134-138.
PubMed Abstract available

SALVI S, Ravetti JL, Arena G, Musso C, et al
Evaluation of RET Gene Rearrangement by Fluorescence In Situ Hybridization in Malignant Mesothelioma.
J Thorac Oncol. 2018;13:e12-e14.
PubMed

AHN MJ
Cell-free DNA Analysis in SCLC: Ready for Clinical Practice?
J Thorac Oncol. 2018;13:10-11.
PubMed

December 2017

PILOTTO S, Sperduti I, Leuzzi G, Chiappetta M, et al
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment.
J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33101.
PubMed Abstract available

WU SP, Liao RQ, Tu HY, Wang WJ, et al
Stromal PD-L1+regulatory T cells and PD-1+CD8+ T cells define the response of different subsets of non-small-cell lung cancer to PD-1/PD-L1 blockade immunotherapy.
J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33102.
PubMed Abstract available

ROBIN TP, Camidge DR, Stuhr K, Nath SK, et al
Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in Oncogene-Addicted Non-Small-Cell Lung Cancer.
J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33107.
PubMed Abstract available

MILLER ED, Fisher JL, Haglund KE, Grecula JC, et al
The addition of chemotherapy to radiation therapy improves survival in elderly patients with stage III non-small cell lung cancer.
J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33108.
PubMed Abstract available

FELIP E, Barlesi F, Besse B, Chu Q, et al
Brief Report: Phase 2 Study of the HSP-90 inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.
J Thorac Oncol. 2017 Dec 13. pii: S1556-0864(17)33083.
PubMed Abstract available

TSENG YH, Ho HL, Lai CR, Luo YH, et al
Brief Report: PD-L1 expression of tumor cells, macrophages, and immune cells in non-small cell lung cancer patients with malignant pleural effusion.
J Thorac Oncol. 2017 Dec 12. pii: S1556-0864(17)33079.
PubMed Abstract available

AOKAGE K, Miyoshi T, Ishii G, Kusumoto M, et al
Influence of Ground-Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non-Small Cell Lung Cancer.
J Thorac Oncol. 2017 Dec 12. pii: S1556-0864(17)33080.
PubMed Abstract available

STIEFEL F, Bourquin C
Adverse Effects of "Teachable Moment" Interventions in Lung Cancer: Why Prudence Matters.
J Thorac Oncol. 2017 Dec 11. pii: S1556-0864(17)32862.
PubMed

STABILE LP, Farooqui M, Kanterewicz B, Abberbock S, et al
Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer.
J Thorac Oncol. 2017 Dec 9. pii: S1556-0864(17)33076.
PubMed Abstract available

FUJIMOTO D, Sato Y, Uehara K, Ishida K, et al
Predictive performance of four programmed cell death ligand 1 assay systems on nivolumab response in previously treated patients with non-small cell lung cancer.
J Thorac Oncol. 2017 Dec 9. pii: S1556-0864(17)33072.
PubMed Abstract available

HOTTA K, Aoe K, Kozuki T, Ohashi K, et al
A Phase II Study of Trastuzumab Emtansine in HER2-positive Non-Small-Cell Lung Cancer.
J Thorac Oncol. 2017 Dec 4. pii: S1556-0864(17)33065.
PubMed Abstract available

BOLZACCHINI E, Tuzi A, Gobba S, Pinotti G, et al
Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer.
J Thorac Oncol. 2017;12:e208-e210.
PubMed

GU F, Cheung L, Katki H, Caporaso N, et al
Response to Safiri et al. "Comments on Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever-Smokers for Lung Cancer Screening".
J Thorac Oncol. 2017;12:e208.
PubMed

SAFIRI S, Mansourpour H, Ayubi E
Comments on Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever-Smokers For Lung Cancer Screening.
J Thorac Oncol. 2017;12:e207.
PubMed

NAKANISHI Y, Masuda S, Iida Y, Takahashi N, et al
Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib.
J Thorac Oncol. 2017;12:e202-e204.
PubMed

Erratum to: Pyo KH, Lim SM, Kim HR, Sung YH, Yun MR, Kim S-M, et al. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Postive Human Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(3):491-500.
J Thorac Oncol. 2017;12:1859.
PubMed

WATZA D, Schwartz AG
Addressing Underrepresented Populations in Lung Cancer Research: The Hispanic/Latino Lung Cancer Registry Identifies Distinct Mutation Profiles for NSCLC.
J Thorac Oncol. 2017;12:1744-1745.
PubMed

November 2017

SOCINSKI MA, Obasaju C, Gandara D, Hirsch FR, et al
Current and Emergent Therapy Options for Advanced Squamous-Cell Lung Cancer.
J Thorac Oncol. 2017 Nov 23. pii: S1556-0864(17)33053.
PubMed Abstract available

HENDRY S, Byrne DJ, Wright GM, Young RJ, et al
Comparison of four PD-L1 immunohistochemical assays in lung cancer.
J Thorac Oncol. 2017 Nov 23. pii: S1556-0864(17)33054.
PubMed Abstract available

TANIZAKI J, Haratani K, Hayashi H, Chiba Y, et al
Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab.
J Thorac Oncol. 2017 Nov 20. pii: S1556-0864(17)33008.
PubMed Abstract available

YANKELEVITZ DF
CT Screening for Lung Cancer: Successful Trial, but Failed Understanding.
J Thorac Oncol. 2017 Nov 18. pii: S1556-0864(17)32767.
PubMed

RECK M, Taylor F, Penrod JR, DeRosa M, et al
Impact of Nivolumab Versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients With Advanced Squamous Non-Small Cell Lung Cancer: Results From the CheckMate 017 Study.
J Thorac Oncol. 2017 Nov 9. pii: S1556-0864(17)32878.
PubMed Abstract available

FERRARA R, Auger N, Auclin E, Besse B, et al
Clinical and translational implications of RET rearrangements in non-small cell lung cancer.
J Thorac Oncol. 2017 Nov 8. pii: S1556-0864(17)32866.
PubMed Abstract available

RICORDEL C, Llamas-Gutierrez F, Chiforeanu D, Lena H, et al
Large Cell Neuroendocrine Lung Carcinoma Transformation as an Acquired Resistance Mechanism to Osimertinib.
J Thorac Oncol. 2017;12:e184-e186.
PubMed

LEE JS, Hur JY, Kim HJ, Lee KY, et al
A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non-Small Cell Lung Cancer Patient.
J Thorac Oncol. 2017;12:e179-e181.
PubMed

HENNINGFIELD MF, Adjei AA
Lung Cancer Awareness Month-A Lot of Progress, But More Work Needs to Be Done.
J Thorac Oncol. 2017;12:1603-1605.
PubMed

October 2017

PARK SE, Lee SH, Ahn JS, Ahn MJ, et al
Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
J Thorac Oncol. 2017 Oct 31. pii: S1556-0864(17)32850.
PubMed Abstract available

WU B, Gu X, Zhang Q
Cost-effectiveness of osimertinib for EGFR-mutation-positive non-small-cell lung cancer after progression of first-line EGFR TKI therapy.
J Thorac Oncol. 2017 Oct 31. pii: S1556-0864(17)32851.
PubMed Abstract available

SANDFELD-PAULSEN B, Meldgaard P, Aggerholm-Pedersen N
Comorbidity in lung cancer: A prospective cohort study of self-reported versus register-based comorbidity.
J Thorac Oncol. 2017 Oct 19. pii: S1556-0864(17)32788.
PubMed Abstract available

PINATO DJ, Newsom-Davis T
Regression of para-neoplastic rash following lung cancer chemotherapy.
J Thorac Oncol. 2017 Oct 14. pii: S1556-0864(17)32786.
PubMed

TOKACA N, Barth S, O'Brien M, Bhosle J, et al
Molecular adequacy of image-guided rebiopsies for molecular retesting in advanced non-small cell lung cancer: a single centre experience.
J Thorac Oncol. 2017 Oct 5. pii: S1556-0864(17)32760.
PubMed Abstract available

THAKUR MK, Ruterbusch JJ, Schwartz AG, Gadgeel SM, et al
Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology and End Results (SEER) Data.
J Thorac Oncol. 2017 Oct 5. pii: S1556-0864(17)32766.
PubMed Abstract available

SHUKUYA T, Patel S, Shane-Carson K, He K, et al
Lung Cancer Patients with Germline Mutations detected by next generation sequencing and/or liquid biopsy.
J Thorac Oncol. 2017 Oct 5. pii: S1556-0864(17)32764.
PubMed

SHOLL LM
Next-Generation Sequencing from Liquid Biopsies in Lung Cancer Patients: Advances in Comprehensive Biomarker Testing.
J Thorac Oncol. 2017;12:1464-1466.
PubMed

September 2017

SUN JM, Noh JM, Oh D, Kim HK, et al
Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer.
J Thorac Oncol. 2017 Sep 26. pii: S1556-0864(17)32708.
PubMed Abstract available

MEYER M, Vliegenthart R, Henzler T, Buergy D, et al
Management of progressive pulmonary nodules found during and outside of CT lung cancer screening studies.
J Thorac Oncol. 2017 Sep 26. pii: S1556-0864(17)32713.
PubMed Abstract available

BOYER MJ, Williams CD, Harpole DH, Onaitis MW, et al
Improved Survival of Stage I Non-Small Cell Lung Cancer: A VA Central Cancer Registry Analysis.
J Thorac Oncol. 2017 Sep 23. pii: S1556-0864(17)32706.
PubMed Abstract available

ALMODOVAR K, Iams WT, Meador CB, Zhao Z, et al
Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse.
J Thorac Oncol. 2017 Sep 22. pii: S1556-0864(17)32705.
PubMed Abstract available

TERAOKA S, Fujimoto D, Morimoto T, Kawachi H, et al
Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study.
J Thorac Oncol. 2017 Sep 19. pii: S1556-0864(17)30825.
PubMed Abstract available

HIGGINS KA, Pillai RN, Chen Z, Tian S, et al
Concomitant chemotherapy and radiotherapy with SBRT Boost for Unresectable, Stage III Non-small Cell Lung Cancer: A phase I Study.
J Thorac Oncol. 2017 Sep 12. pii: S1556-0864(17)30734.
PubMed Abstract available

GIMBRONE NT, Sarcar B, Gordian ER, Rivera JI, et al
Brief Report: Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients.
J Thorac Oncol. 2017 Sep 11. pii: S1556-0864(17)30731.
PubMed Abstract available

MASAI K, Sakurai H, Sukeda A, Suzuki S, et al
Prognostic Impact of Margin Distance and Tumor Spread Through Air Spaces in Limited Resection for Primary Lung Cancer.
J Thorac Oncol. 2017 Sep 4. pii: S1556-0864(17)30727.
PubMed Abstract available

RUSTHOVEN CG, Kavanagh BD
Prophylactic Cranial Irradiation (PCI) vs Active MRI Surveillance for Small-Cell Lung Cancer: The Case for Equipoise.
J Thorac Oncol. 2017 Sep 4. pii: S1556-0864(17)30728.
PubMed Abstract available

SEPESI B, Correa AM, Dmitrovsky E, Liu X, et al
Reply to "Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer: Methodological Issues".
J Thorac Oncol. 2017;12:e150-e151.
PubMed

SAFIRI S, Khazaei S, Ayubi E
The Influence of Body Mass Index on Overall Survival following Surgical Resection of Non-Small Cell Lung Cancer: Methodological Issues.
J Thorac Oncol. 2017;12:e149-e150.
PubMed

KHUNGER M, Calabrese C, Kontzias A, Velcheti V, et al
To Treat or Not to Treat: Role of Immunotherapy in Patients with Concomitant Diagnosis of Advanced-Stage Non-Small Cell Lung Cancer and Psoriasis.
J Thorac Oncol. 2017;12:e147-e149.
PubMed

KOMATSU T, Nakamura K, Kawase A
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer.
J Thorac Oncol. 2017;12:e143-e144.
PubMed

FUNAZO T, Nomizo T, Kim YH
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.
J Thorac Oncol. 2017;12:e140-e141.
PubMed

GORTAIS H, Daniel C, Bidard FC, Jeannot E, et al
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis.
J Thorac Oncol. 2017;12:e138-e139.
PubMed

EZE C, Roengvoraphoj O, Manapov F
Prophylactic Cranial Irradiation in Resected Small Cell Lung Cancer: Comprehensive Staging, Adjuvant Chemotherapy, and Strict Stratification of Pathological Stage Play a Role.
J Thorac Oncol. 2017;12:e137-e138.
PubMed

VAN SCHIL PE
Optimal Treatment of Stage IIIA-N2 Non-Small Cell Lung Cancer: A Neverending Story?
J Thorac Oncol. 2017;12:1338-1340.
PubMed

August 2017

WALD P, Mo X, Barney C, Gunderson D, et al
Prognostic value of primary tumor volume changes on kV-CBCT during definitive chemoradiotherapy for stage III non-small cell lung cancer.
J Thorac Oncol. 2017 Aug 23. pii: S1556-0864(17)30685.
PubMed Abstract available

ARULANANDA S, Do H, Musafer A, Mitchell P, et al
Combination osimertinib and gefitinib in C797S and T790M EGFR mutated non-small-cell lung cancer.
J Thorac Oncol. 2017 Aug 23. pii: S1556-0864(17)30681.
PubMed Abstract available

DAVID EA, Clark JM, Cooke DT, Melnikow J, et al
The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non-small Cell Lung Cancer.
J Thorac Oncol. 2017 Aug 23. pii: S1556-0864(17)30683.
PubMed Abstract available

GU F, Cheung LC, Freedman ND, Katki HA, et al
Potential impact of including Time to First Cigarette into risk models for selecting ever-smokers for lung-cancer screening.
J Thorac Oncol. 2017 Aug 14. pii: S1556-0864(17)30664.
PubMed Abstract available

LIN JJ, Shaw AT
Recent Advances in Targeting ROS1 in Lung Cancer.
J Thorac Oncol. 2017 Aug 14. pii: S1556-0864(17)30668.
PubMed Abstract available

KONO M, Allen PK, Lin SH, Wei X, et al
Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival.
J Thorac Oncol. 2017 Aug 10. pii: S1556-0864(17)30661.
PubMed Abstract available

XIZHAO S, Wei J, Haiqing C, Fan Y, et al
Validation of the stage groupings in the 8th edition of the TNM classification for lung cancer.
J Thorac Oncol. 2017 Aug 3. pii: S1556-0864(17)30659.
PubMed Abstract available

SAFIRI S, Ayubi E
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer: Methodological Issues.
J Thorac Oncol. 2017;12:e130-e131.
PubMed

KIMURA H, Tounai Y, Nagato K, Morimoto JI, et al
A Case of Heart Failure after Treatment with Anti-PD-1 Antibody Followed by Adoptive Transfer of Cytokine-Activated Killer Cells in a Recurrent Lung Cancer Patient.
J Thorac Oncol. 2017;12:e128-e130.
PubMed

YANAGISAWA S, Miyauchi E, Ichinose M
Numb Chin Syndrome: An Ominous Sign of Lung Cancer.
J Thorac Oncol. 2017;12:e114-e116.
PubMed

SHOJAEE S, Vachani A, Nana-Sinkam P
The Financial Implications of Lung Cancer Screening: Is It Worth It?
J Thorac Oncol. 2017;12:1177-1179.
PubMed

STONE E, Slatore CG
The Obesity Paradox-What Does It Mean for Lung Cancer Surgery?
J Thorac Oncol. 2017;12:1174-1176.
PubMed

July 2017

FURUTA H, Yoshida T, Shimizu J, Tomita N, et al
Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non-small Cell Lung Cancer.
J Thorac Oncol. 2017 Jul 31. pii: S1556-0864(17)30656.
PubMed

ZHANG X, Liu Y, Shao H, Zheng X, et al
Obesity paradox in lung cancer prognosis: evolving biological insights and clinical implications.
J Thorac Oncol. 2017 Jul 27. pii: S1556-0864(17)30619.
PubMed Abstract available

LI C, Huang C, Mok TS, Zhuang W, et al
Comparison of 22C3-PD-L1 expression between surgically resected specimens and paired tissue microarrays in non-small cell lung cancer.
J Thorac Oncol. 2017 Jul 24. pii: S1556-0864(17)30612.
PubMed Abstract available

NORSKOV MS, Dahl M, Tybjaerg-Hansen A
Genetic variation in GSTP1, lung function, risk of lung cancer and mortality in 66,000 individuals.
J Thorac Oncol. 2017 Jul 21. pii: S1556-0864(17)30605.
PubMed Abstract available

LOGANADANE G, Hendriks L, Le Pechoux C, Levy A, et al
The current role of whole brain radiation therapy in non-small cell lung cancer patients.
J Thorac Oncol. 2017 Jul 18. pii: S1556-0864(17)30585.
PubMed Abstract available

CHO BC, Kim DW, Bearz A, Laurie SA, et al
ASCEND-8: A Randomized Phase 1 Study of Ceritinib 450 mg or 600 mg Taken With a Low-Fat Meal Versus 750 mg in Fasted State in Patients With Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
J Thorac Oncol. 2017 Jul 17. pii: S1556-0864(17)30578.
PubMed Abstract available

SHLOMI D, Abud M, Liran O, Bar J, et al
Detection of Lung Cancer and EGFR Mutation by Electronic Nose System.
J Thorac Oncol. 2017 Jul 11. pii: S1556-0864(17)30573.
PubMed Abstract available

YANG JC, Ou SI, De Petris L, Gadgeel S, et al
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small-Cell Lung Cancer.
J Thorac Oncol. 2017 Jul 5. pii: S1556-0864(17)30570.
PubMed Abstract available

YOSHIDA R, Sasaki T, Ohsaki Y
EGFR and KRAS Mutations in Triple-Mutated Lung Cancer.
J Thorac Oncol. 2017;12:e92-e93.
PubMed

June 2017

GORE EM, Hu C, Sun AY, Grimm DF, et al
Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone To Prophylactic Cranial Irradiation And Consolidative Extra-Cranial Irradiation For Extensive Disease Small Cell Lung Cancer (ED-SCLC): NRG Oncology RTOG 0937.
J Thorac Oncol. 2017 Jun 22. pii: S1556-0864(17)30468.
PubMed Abstract available

GUPTA A, Saltarski JM, White MA, Scaglioni PP, et al
Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer.
J Thorac Oncol. 2017 Jun 21. pii: S1556-0864(17)30466.
PubMed Abstract available

BARON AE, Kako S, Feser WJ, Malinowski H, et al
Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer.
J Thorac Oncol. 2017 Jun 17. pii: S1556-0864(17)30461.
PubMed Abstract available

EDELMAN MJ, Hu C, Le QT, Donington JS, et al
Randomized Phase II Study of Preoperative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-small Cell Lung Cancer: NRG Oncology RTOG 0839.
J Thorac Oncol. 2017 Jun 16. pii: S1556-0864(17)30459.
PubMed Abstract available

EVISON M, Clive A, Castle L, Powell H, et al
Resectable clinical N2 non-small cell lung cancer; what is the optimal treatment strategy? An update by the British Thoracic Society Lung Cancer Specialist Advisory Group.
J Thorac Oncol. 2017 Jun 14. pii: S1556-0864(17)30448.
PubMed Abstract available

AOKAGE K, Miyoshi T, Ishii G, Kusumoto M, et al
Clinical and Pathological Staging Validation in the Eighth Edition of TNM Classification for Lung Cancer: Correlation Between Solid Size on Thin-section Computed Tomography and Invasive Size in Pathological Findings in the New T Classification.
J Thorac Oncol. 2017 Jun 13. pii: S1556-0864(17)30444.
PubMed Abstract available

SACHER AG, Komatsubara KM, Oxnard GR
Application of plasma genotyping technologies in non-small cell lung cancer: a practical review.
J Thorac Oncol. 2017 Jun 10. pii: S1556-0864(17)30441.
PubMed Abstract available

RANGACHARI D, Le X, Shea M, Huberman MS, et al
Cases of ALK-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy.
J Thorac Oncol. 2017 Jun 10. pii: S1556-0864(17)30440.
PubMed

LEVENTAKOS K, Peikert T, Midthun D, Molina JR, et al
Management of multifocal lung cancer: Results of a survey.
J Thorac Oncol. 2017 Jun 2. pii: S1556-0864(17)30421.
PubMed Abstract available

CHIC N, Mayo-de-Las-Casas C, Reguart N
Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.
J Thorac Oncol. 2017;12:e78-e80.
PubMed

HSU CL, Chen KY, Kuo SW, Chang YL, et al
Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
J Thorac Oncol. 2017;12:e75-e76.
PubMed

CHEN CW, Kuo CW, Chen YL, Ho CL, et al
Successful AZD9291 Therapy in Advanced Non-Small Cell Lung Cancer after Failure of HM61713.
J Thorac Oncol. 2017;12:e72-e74.
PubMed

UGUEN A, Schick U, Quere G
A Rare Case of ROS1 and ALK Double Rearranged Non-Small Cell Lung Cancer.
J Thorac Oncol. 2017;12:e71-e72.
PubMed

THUNNISSEN E, Witte BI, Noguchi M, Yatabe Y, et al
Reply to Letter "The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases."
J Thorac Oncol. 2017;12:e70-e71.
PubMed

SABOUR S
Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer; Statistical Issue on Reproducibility Analysis.
J Thorac Oncol. 2017;12:e69.
PubMed

GREEN S, Dawe DE, Banerji S
Immune Signatures of Non-Small Cell Lung Cancer.
J Thorac Oncol. 2017;12:913-915.
PubMed

FARUKI H, Mayhew GM, Serody JS, Hayes DN, et al
Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
J Thorac Oncol. 2017;12:943-953.
PubMed Abstract available

SHAIKH F, Zauderer MG, von Reibnitz D, Wu AJ, et al
Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
J Thorac Oncol. 2017;12:993-1000.
PubMed Abstract available

SCHROCK AB, Li SD, Frampton GM, Suh J, et al
Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
J Thorac Oncol. 2017;12:932-942.
PubMed Abstract available

VERRI C, Borzi C, Holscher T, Dugo M, et al
Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers.
J Thorac Oncol. 2017;12:922-931.
PubMed Abstract available

May 2017

SEPESI B, Gold KA, Correa AM, Heymach JV, et al
The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer.
J Thorac Oncol. 2017 May 25. pii: S1556-0864(17)30390.
PubMed Abstract available

WAN R, Wang Z, Lee JJ, Wang S, et al
Comprehensive analysis of the discordance of EGFR mutation status between tumor tissues and matched circulating tumor DNA in advanced non-small-cell lung cancer.
J Thorac Oncol. 2017 May 25. pii: S1556-0864(17)30391.
PubMed Abstract available

KARLSSON A, Brunnstrom H, Micke P, Veerla S, et al
Gene expression profiling of large cell lung cancer links transcriptional phenotypes to the new histological WHO2015 classification.
J Thorac Oncol. 2017 May 20. pii: S1556-0864(17)30388.
PubMed Abstract available

FELLER-KOPMAN D, Liu S, Geisler BP, DeCamp MM, et al
Cost-Effectiveness of a Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer.
J Thorac Oncol. 2017 May 9. pii: S1556-0864(17)30364.
PubMed Abstract available

CRESSMAN S, Peacock SJ, Tammemagi MC, Evans WK, et al
The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency.
J Thorac Oncol. 2017 May 9. pii: S1556-0864(17)30354.
PubMed Abstract available

ADAMS MN, Burgess JT, He Y, Gately K, et al
Expression of CDCA3 is a prognostic biomarker and potential therapeutic target in non-small cell lung cancer.
J Thorac Oncol. 2017 May 6. pii: S1556-0864(17)30351.
PubMed Abstract available

GONG X, Li X, Jiang T, Xie H, et al
Combined Radiotherapy and anti-PD-L1 antibody Synergistically Enhances Anti-tumor Effect in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2017 May 3. pii: S1556-0864(17)30343.
PubMed Abstract available

MIYAUCHI E, Ichinose M, Inoue A
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease.
J Thorac Oncol. 2017;12:e59-e61.
PubMed

DAHELE M, Damhuis R
The Relationship between Histology, Stage, and Type of Treatment in Patients with Early-Stage Lung Cancer.
J Thorac Oncol. 2017;12:e58-e59.
PubMed

RICCIUTI B, Metro G, Baglivo S, Colabrese D, et al
Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient.
J Thorac Oncol. 2017;12:e51-e55.
PubMed

OGATA H, Yamamoto Y, Harada T, Nakanishi Y, et al
Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.
J Thorac Oncol. 2017;12:e46-e47.
PubMed

ABDUL KARIM L, Wang P, Chahine J, Kallakury B, et al
Harmonization of PD-L1 Immunohistochemistry Assays for Lung Cancer: A Working Progress.
J Thorac Oncol. 2017;12:e45.
PubMed

THORNE-NUZZO T, Williams C, Catallini A, Clements J, et al
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib.
J Thorac Oncol. 2017;12:804-813.
PubMed Abstract available

ZHAO ZR, Situ DR, Lau RWH, Mok TSK, et al
Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas.
J Thorac Oncol. 2017;12:890-896.
PubMed Abstract available

RANGACHARI D, VanderLaan PA, Shea M, Le X, et al
Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 >/=50% Expression in Lung Adenocarcinoma.
J Thorac Oncol. 2017;12:878-883.
PubMed Abstract available

SAXON JA, Sholl LM, Janne PA
EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
J Thorac Oncol. 2017;12:884-889.
PubMed Abstract available

REULING EMBP, Dickhoff C, Daniels JMA
Treatment of Bronchial Carcinoid Tumors: Is Surgery Really Necessary?
J Thorac Oncol. 2017;12:e57-e58.
PubMed

LANTUEJOUL S, Le Stang N, Damiola F, Scherpereel A, et al
PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?
J Thorac Oncol. 2017;12:778-781.
PubMed

SAVIC S, Rothschild S, Bubendorf L
Lonely Driver ROS1.
J Thorac Oncol. 2017;12:776-777.
PubMed

BOTLING J, Sandelin M
Immune Biomarkers on the Radar-Comprehensive "Immunograms" for Multimodal Treatment Prediction.
J Thorac Oncol. 2017;12:770-772.
PubMed

April 2017

CHANSKY K, Detterbeck FC, Nicholson AG, Rusch VW, et al
The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer.
J Thorac Oncol. 2017 Apr 28. pii: S1556-0864(17)30340.
PubMed Abstract available

RECK M, Blais N, Juhasz E, Gorbunova V, et al
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-small Cell Lung Cancer.
J Thorac Oncol. 2017 Apr 28. pii: S1556-0864(17)30338.
PubMed Abstract available

JENKINS S, C-H Yang J, Ramalingam SS, Yu K, et al
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced non-small Cell Lung Cancer.
J Thorac Oncol. 2017 Apr 17. pii: S1556-0864(17)30280.
PubMed Abstract available

SOO RA, Adjei AA
Predicting Clinical Outcomes Using Proteomics in Non-Small Cell Lung Cancer-The Past, Present, and Future.
J Thorac Oncol. 2017;12:602-606.
PubMed

GARDNER EE, Poirier JT, Rudin CM
Histone Code Aberrancies in Small Cell Lung Cancer.
J Thorac Oncol. 2017;12:599-601.
PubMed

PETERS MLB, Costa DB, Rangachari D
Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies.
J Thorac Oncol. 2017;12:e35-e36.
PubMed

LAINE A, Choy H
Single-Fraction Carbon Ion Radiotherapy for Early-Stage NSCLC-The Future Is Now.
J Thorac Oncol. 2017;12:610-611.
PubMed

JOHN T, Russell PA, Thapa B
Is Mesothelioma in China Rare or Misdiagnosed?
J Thorac Oncol. 2017;12:607-609.
PubMed

March 2017

SENAN S, Louie AV
Correlation, Causation and Confounding-What Is the True Risk of Lung Cancer following Breast Cancer Radiotherapy?
J Thorac Oncol. 2017 Mar 22. pii: S1556-0864(17)30127.
PubMed

YANAGAWA N
The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma: Author's Reply.
J Thorac Oncol. 2017;12:e25-e26.
PubMed

MAO R, Chen C, Fei K
The Clinical Implications and Thoughts on Different Patterns in Resected Lung Adenocarcinoma.
J Thorac Oncol. 2017;12:e24-e25.
PubMed

February 2017

WARTH A, Beasley MB, Mino-Kenudson M
Breaking New Ground: The Evolving Concept of Spread through Air Spaces (STAS).
J Thorac Oncol. 2017;12:176-178.
PubMed

HEIGENER DF, Reck M
PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?
J Thorac Oncol. 2017;12:171-172.
PubMed

January 2017

BASSE C, Merveilleux du Vignaux C, Girard N
Postoperative Radiotherapy in Completely Resected Stage II and III Thymoma: How to Translate the Potential Survival Benefit in the Setting of the Future Adoption of the IASLC-ITMIG TNM-Based Staging System.
J Thorac Oncol. 2017;12:e8-e9.
PubMed

RUSSO A, Franchina T, Ricciardi GRR, Adamo V, et al
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation.
J Thorac Oncol. 2017;12:e6-e8.
PubMed

LI YS, Jiang BY, Yang JJ, Tu HY, et al
Little Influence of Bevacizumab in Diagnosis of Leptomeningeal Metastases in Current Study.
J Thorac Oncol. 2017;12:e5-e6.
PubMed

VENNIYOOR A
False-Negative MRI Findings for Leptomeningeal Metastases with Use of Bevacizumab.
J Thorac Oncol. 2017;12:e5.
PubMed

SOLOMON B
Trials and Tribulations of EGFR and MET Inhibitor Combination Therapy in NSCLC.
J Thorac Oncol. 2017;12:9-11.
PubMed

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: